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Abstract 
Cancer, which is characterised by aggressiveness and increased capacity for 
metastatic spread still requires basic researchers and clinicians to direct 
enormous efforts toward the development of novel therapeutic targets. Potential 
novel targets can be identified and exploited in combination with currently existing 
therapeutic approaches to improve their efficacy and overcome treatment 
resistance of tumour cells, protecting the patient from recurrence. To achieve this, 
different strategies and techniques can be proposed to identify the most 
promising candidate molecules for further exploitation as therapeutic targets. 
Human epidermal growth factor receptors (HERs) and NF-E2-related factor 2 
(NRF2) are regulators of cellular proliferation and determinants of cancer initiation 
and progression.  NRF2 and HERs confer cancers with resistance to several 
therapeutic agents. Nevertheless, there is limited understanding of the regulation 
of HER expression and activation, and the link between NRF2 and HER 
signalling pathways. This research has demonstrated that pharmacological 
activation of NRF2 by tert-butyl hydroquinone (tBHQ) upregulates the expression 
of HER family receptors, HER1 and HER4, elevates phospho protein kinase B 
(pAKT) levels, and enhances the proliferation of ovarian cancer cells. 
Pharmacological inhibition using retinoic acid (RA) and bexarotene and genetic 
inhibition using small interfering RNA (siRNA), did the opposite. Further, tBHQ 
caused transcriptional induction of HER1 and HER4 with different levels of 
expression, while siRNA-mediated knockdown of NRF2 prevented this and 
further caused transcriptional repression. A panel of potent NRF2 inhibitors were 
screened with the hope of finding the most potent for further investigation. 
Bexarotene was found to be the most potent and was used either alone, or in 
combination with lapatinib or erlotinib. The use of these drugs in combination with 
bexarotene resulted in the repression of HER1, HER2, HER3 and HER4 
expression, inhibition of NRF2, elevation of ROS, depletion of glutathione and 
enhanced cytotoxicity in PEO1, OVCAR3, SKOV3 and MCF7-AREc32 cell lines. 
This explained the crosstalk mechanism between HER receptor family and NRF2 
and the role of NRF2 in drug resistance and as a relevant anti-cancer target 
which opens up novel avenues of targeting HER receptor kinase family and 
NRF2 pathways for improving cancer therapy. 
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Structure of the Thesis 
This thesis is designed into seven chapters and sections of references and 
appendices, chapter one is a general introduction and literature review and 
chapter two is the materials and methods. Chapters three, four, five and six are in 
line with the research aims and objectives of the thesis. Chapter seven is the 
discussion and conclusion while the other sections are references and 
appendices respectively. The following are the brief description of each chapter: 
Chapter One: Provides the general introduction of cancer, then ovarian cancer 
specifically, followed by the deep review of what has been done, what needs to 
be done by the research in the area of this study. This chapter provides a 
background of this research which gives an insight that paved a way of 
developing hypothesis and aims and objectives of this study. 
Chapter Two: Provides material and methods followed for the successful 
completion of this research which involves small portion of bioinformatics and all 
the rest are laboratory based. It gives a complete description of the materials 
used and methods followed during the data collection and analysis.  
Chapter Three: Is the first research chapter and it explains how the first objective 
is achieved. This section of the study reported on cloning of promoter regions of 
human HER1 and HER4 genes which subsequently provides an insight into the 
study in the next research chapter. 
Chapter Four: Is the second research chapter and it explains how the second 
objective is achieved. It provides the molecular basis for regulation of the 
expression of these genes by NRF2. It explains the regulation of HER1 and 
HER4 upon NRF2 activation with tBHQ and inhibition with RA and knocking down 
with siRNA, there by highlighting the possibility of direct linkage between ROS, 
HER family and NRF2 signalling pathways. 
Chapter Five: Is the third research chapter and it explains how panels of 
compounds expected to be the potent NRF2-ARE inhibitors were screened to 
uncover the most potent compound for the next research chapter in this study.  
Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page xxvi 
 
Chapter Six: Is the fourth and the last research chapter which explains how the 
last objective of this research is achieved. In this section, all the HER receptor 
family were investigated following treatments with either bexarotene or in 
combination with lapatinib or erlotinib. A series of experiments such as 
cytotoxicity assays, immunoblotting, ROS level detection as well as total 
glutathione were performed. 
Chapter Seven: Discusses and provides key findings and concludes this 
research. It also gives recommendations for future studies. 
References section: Contains all the references cited in this research in 
alphabetical order and in Harvard referencing style recommended by Abertay 
University. 
Appendices section: Provides the information of the materials, equipment, 
reagents, chemicals used in this study as well as their nature, source and the 
company they are purchased or name of the donor. 
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1.1.    Cancer 
Cancer is a complex disorder characterised by abnormal growth and alterations 
in cells, reduced cell death and increased cellular energy metabolism (Ivey et al., 
2016, Hojjat-Farsangi et al., 2014, Hojjat-Farsangi et al., 2017, Hanahan and 
Weinberg, 2011). Cell division and apoptosis are considered the two most 
common physiological processes that regulate normal tissue homoeostasis, and 
their disruption could lead to the pathogenesis of cancer, a fatal disease that 
consists of immortal cells (Hojjat-Farsangi et al., 2014, Nwabo Kamdje et al., 
2014, Hojjat-Farsangi et al., 2017). Cancer is initiated by repeated cell attrition 
and repopulation involving two concepts of cancer initiation. Firstly, cancer is the 
result of a series of genetic changes that subsequently transform normal cells into 
malignant ones. Secondly, deregulation of specific biological processes during 
tumour development helps and sustains cancer initiation and progression (Labi 
and Erlacher, 2015). Cancer is considered one of the leading causes of death 
worldwide, with reported cases in 2012 of approximately 14 million (Torre et al., 
2015, Ferlay et al., 2013, WHO, 2017, Ferlay et al., 2015). In the next 20 years, 
the number of cases of cancer is expected to rise by 70% to 25 million (WHO, 
2017). Possible causes of cancer include tobacco smoking, obesity, poor diet, 
infections such as hepatitis B, hepatitis C and human papillomavirus (HPV), 
exposure to ionising radiation and environmental pollutants (WHO, 2017). 
Different cancers may have dissimilar signs and symptoms depending on the 
organ affected and gender of the sufferer. For example, bladder and kidney 
cancer is associated with blood in urine, have pain increased urination and 
urinary tract infection and interstitial cystitis. Breast cancer has symptoms such 
as lump or thickening of lumps (not all lumps are cancerous), itching, redness or 
soreness of the nipples. Ovarian cancer often has no symptoms until in the later 
stages of development, symptoms include weight loss, fatigue, bloating, and 
abdominal pain (WHO, 2017). Cancer can be detected by physical examinations, 
screenings such as blood tests, scanning or medical biopsy (WHO, 2017).   
Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 3 
 
1.2.     Ovarian Cancer 
Ovarian cancer is a fatal type of cancer affecting the female reproductive tract 
and is the leading cause of death from gynaecological malignancies (Permuth-
Wey and Sellers, 2009, Merino and Jaffe, 1993, Barber, 2012, Barber, 1986, 
Colombo et al., 2006, Jacobs et al., 2016). It is estimated that every year up to 
eight out of 100,000 women die of ovarian cancer (Permuth-Wey and Sellers, 
2009, Merino and Jaffe, 1993, Barber, 2012, Barber, 1986, Colombo et al., 2006, 
Jacobs et al., 2016). About 50% of ovarian cancers are diagnosed in women over 
the age of 65, and this proportion is expected to increase in coming years as 
populations and life expectancies increase. This is why ovarian cancer cases 
tend to worsen as the age of a patient rises (Edwards et al., 2002, Oberaigner et 
al., 2012, Tew, 2016). Decreased survival in older women with ovarian cancer is 
as a result of cancer being more aggressive with advanced age, an inherent 
resistance to chemotherapy, and individual patient factors such as multiple 
concurrent medical problems, cognitive impairment, depression, frailty, poor 
nutrition and limited social support leading to greater toxicity of the therapy. 
Others factors can also include physician and health care bias towards the elderly 
which can result in inadequate surgery, suboptimal chemotherapy and poor 
enrolment in clinical trials (Tew, 2016, Tew et al., 2014).  
1.2.1 Types of Ovarian Cancer  
Ovarian cancer is classified according to the type of cell from which it starts. 
Below are descriptions of different types of ovarian cancer. 
1.2.1.1 Epithelial tumours 
Epithelial tumours of the ovary constitute almost 90% of all malignant ovarian 
tumours. This form of ovarian cancer generally occurs in postmenopausal 
women. Epithelial tumours are thought to derive from the surface epithelium 
(coelomic epithelium or mesothelium) covering the ovary and the underlying 
stroma. Although the ovary is not of Müllerian origin, the source of these 
neoplasms, namely the surface epithelium, is derived from the coelomic 
epithelium, which in the embryo gives rise to the Müllerian ducts. The latter form 
the fallopian tubes, uterine body, cervix and possibly the upper part of the vagina 
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with their large variety of epithelia (Seidman et al., 2011). It is generally agreed 
that a large subpopulation of epithelia ovarian cancers arise from fallopian tube 
mucosal epithelium. However, there is still some debate as to whether the 
cancers originate from secretory or ciliate cell lineage (Rohozinski et al., 2017). 
The fallopian tube and associated infundibulum epithelium primarily contain two 
different cell types, ciliated and secretory, that can give rise to epithelial ovarian 
cancers. Whilst the ciliated cells have motile cilia that help in the movement of the 
egg released from the ovary to the uterus, the secretory cells have non-motile 
primary cilia that are thought to act as sensory structures (Rohozinski et al., 2017, 
Hagiwara et al., 2008). Therefore, tracing the patterns of gene and protein 
expression in ovarian tumours may help to determine the cell type that 
contributes to the cancer’s origin. This type of approach was reported by Cheng 
et al., (2005) when they noted that HOX gene expression can be used to clearly 
and successfully identify the region of origin of tissue within the female 
reproductive tract (Cheng et al., 2005). 
Surgery is often the initial treatment of choice for ovarian cancer including 
epithelial types, provided that patients are medically fit. Patients who are not 
candidates for optimal debulking should be considered for neo-adjuvant 
chemotherapy followed by interval debulking surgery and then further 
chemotherapy. Patients who are not fit for surgery may be given chemotherapy 
and considered for surgery later, or treated solely with chemotherapy 
(Holschneider and Berek, 2017). 
1.2.1.2 Germ cell carcinoma tumours 
Germ cell carcinoma tumours make up approximately 5% of ovarian cancer 
cases. In disparity with epithelial ovarian cancers that arise from the surface 
coelomic epithelium, ovarian germ cell tumours are believed to originate from 
primordial germ cells that migrate into the gonadal ridge at six weeks of 
embryonic life. This type of tumour might exhibit a spectrum of histologic 
differentiation that impersonates a primitive developing embryo. The concept of 
germ cell tumours as a specific group of gonadal neoplasms has emerged over 
recent decades. The concept is based on the common histogenesis of these 
neoplasms, the relatively frequent presence of histologically different neoplastic 
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elements within the same tumour, the presence of histologically similar 
neoplasms in extragonadal locations along the line of migration of the primitive 
germ cells from the wall of the yolk sac to the gonadal ridge and the remarkable 
homology between the various tumours in the male and female (Talerman and 
Vang, 2011a, Talerman and Vang, 2011b). For instance, dysgerminoma appears 
to be descended from relatively undifferentiated cells, whereas yolk sac tumours 
show malignant change in a cell line committed to extraembryonic differentiation. 
The immature teratomas are derived from cells predisposed to somatic 
differentiation and recapitulate tissue from all three primitive germ cell layers, 
namely ectoderm, endoderm and mesoderm. Taken together, the dysgerminoma, 
yolk sac tumour, immature teratoma and their hybrid mixed germ cell tumour 
comprise more than 90% of malignant germ cell tumours. Although germ cell 
carcinoma tumours account for less than 5% of ovarian cancers, their importance 
is greater than their numerical incidence implies because they occur in children 
and women in their early 20s (Talerman and Vang, 2011a, Gershenson, 1994, 
Lee-Jones, 2003). 
The preferred initial approach for patients with suspected germ cell tumours for 
both diagnostic and therapeutic intent is surgery, and the safety of such an 
approach has been well established. In the past, radiation therapy was the 
traditional approach for patients with germ cell malignancies and dysgerminomas 
in particular, because dysgerminomas are sensitive to radiation therapy with 
overall survival rates of between 70% and 100%. However, recent advances 
have paved the way for success in combination chemotherapy. The excellent 
response of germ cell malignancies to adjuvant chemotherapy has allowed a 
tailored approach to the surgical management of this disease in women who 
desire fertility preservation (Emily R. Penick and Charlotte S. Marcus, 2018).  
1.2.1.3 Stromal carcinoma tumours 
Stromal carcinoma tumours are the category of ovarian tumours that includes all 
those containing granulosa cells, theca cells and luteinized derivatives, Sertoli 
cells, Leydig cells and fibroblasts of gonadal stromal origin. These types of 
tumours originate from the ovarian matrix, and consist of cells from the embryonic 
sex cord and mesenchyme. About 90% of hormonally active ovarian tumours 
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belong to this category, and are associated with physiologic and pathologic signs 
of estrogen or androgen excess (or both) including isosexual precocity, hirsutism, 
abnormal bleeding, endometrial hyperplasia or carcinoma and increased breast 
cancer risk. Amongst all types of ovarian cancers, 5% to 10% belong in the 
stromal carcinoma tumour group. Most of these (70%) are granulosa cell 
tumours, which are low-grade malignancies with a relapse rate of 10% to 33% 
(Emily R. Penick and Charlotte S. Marcus, 2018).  
Because the majority of stromal carcinoma tumours are benign or low malignant 
potential tumours, surgical therapy is the preferred approach for treating this type 
of cancer. Furthermore, for patients who wish to retain fertility, unilateral salpingo-
oophorectomy with preservation of the uterus, contralateral ovary and full surgical 
staging, is an appropriate therapy for patients with stage IA disease. Advanced-
stage disease and disease in older women should be managed with complete 
staging and hysterectomy with bilateral salpingo-oophorectomy. Patients with 
early-stage disease can be treated with surgical therapy alone and can expect an 
excellent prognosis. However, those with stage IC or greater should be 
counselled about adjuvant therapy. The most common chemotherapy regimen is 
bleomycin, etoposide and cisplatin (Emily R. Penick and Charlotte S. Marcus, 
2018).  
1.2.1.4 Small cell carcinoma of the ovary 
Small cell carcinoma of the ovary is a very rare tumour that affects mainly women 
in their early 20s. Approximately two-thirds of patients with ovarian small cell 
carcinoma have hypercalcemia. Small cell ovarian cancer is very aggressive, 
grows very quickly and is a highly malignant tumour with a poor prognosis. 
Although small cell carcinoma was briefly mentioned in a 1979 monograph by 
Scully (Scully, 1979), its entity was first fully described by (Richard Dickersin et 
al., 1982). Presently, there are around 300 cases of this type of tumour reported 
in the literature (Kapoun et al., 2015). Tumour markers, which are useful in 
epithelial ovarian cancers, are non-informative for this type of tumour. The 
histological diagnosis of small cell carcinoma of the ovary is based on the finding 
of a small cell population with high nuclear atypia, numerous mitoses and 
frequent necrosis. The growth pattern is usually solid and trabecular, with typical 
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and almost pathognomic follicle-like spaces. In addition, some unusual findings 
have been described such as mucinous glands, mucinous signet ring cells, 
spindle cell sarcomatoid change, large cells and rhabdoid cytomorphology 
(Witkowski et al., 2016, Kascak et al., 2016).  
Treatment of this type of ovarian tumour is stage dependent. For example, in 
early stages, surgery (as with ovarian cancers) is preferred, followed by adjuvant 
chemotherapy with cisplatin and etoposide. Most patients with this type of tumour 
respond to chemotherapy treatment employing a combination of agents such as 
cisplatin, etoposide, doxorubicin and bleomycin, or cyclophosphamide and 
vinblastine (Witkowski et al., 2016, Kascak et al., 2016). There are different 
opinions on approaches in the early stages of this type of ovarian tumour. Some 
reports recommend fertility-sparing surgery followed by adjuvant chemotherapy, 
others suggest radical staging surgery with pelvic and paraaortic 
lymphadenectomy (Powell et al., 1998, Pautier et al., 2007). For late stages, it is 
recommended that neoadjuvant chemotherapy followed by radical staging 
surgery should be considered (Harrison et al., 2006). Due to the highly 
aggressive nature of this tumour, prognosis is very poor and despite various 
approaches, one-year survival of patients with this type of tumour is only around 
50% (Witkowski et al., 2016, Richard Dickersin et al., 1982).  
Despite approaches such as surgical and chemotherapeutic treatment 
approaches, metastatic ovarian cancer is still incurable mainly as a result of a 
lack of effective therapeutic strategies. Because of this, intense efforts are being 
made to define potential molecular targets that may augment the survival of 
patients with ovarian cancer (Williams et al., 2007). In this respect, several 
reports have identified potential therapeutic targets, with the efficacy of 
treatments against such targets being analysed in clinical trials in various phases 
of development. Amongst such experimental treatments, agents acting on 
inhibiting tyrosine kinases have received particular attention (Alečković and Kang, 
2015, Goltsov et al., 2014a, Jeong et al., 2013, Lee et al., 2016b, Præstegaard et 
al., 2016).  
Many reports have implicated the HER receptor tyrosine kinase (RTK) family as 
an alternative target in cancer treatment, including ovarian cancer (Gschwind et 
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al., 2004, Mendelsohn and Baselga, 2000, de Bono and Rowinsky, 2002, 
Normanno et al., 2003, Reese and Slamon, 1997). Up to 70% of ovarian cancers 
have HER1 overexpression and most of the drugs targeting this receptor are 
already in clinical use. HER2 overexpression has also been reported in ovarian 
cancer and most of the drugs used in targeting the receptor, especially in breast 
cancer, are in clinical use and being given to patients. A study by Sheng and 
colleagues also reported the involvement of HER3 as a potential target in ovarian 
cancer (Montero et al., 2015). Similarly, high incidences of HER4 expression in 
ovarian cancer have also been reported (Davies et al., 2014). Because of the 
relevance of tyrosine kinases in ovarian cancer, the use of HER family-targeting 
monoclonal antibodies and drugs such as trastuzumab, pertuzumab lapatinib and 
erlotinib are increasingly attractive (White et al., 2014, Khalil et al., 2016b, 
Montero et al., 2015, Mullen et al., 2007, Langdon et al., 2010). 
In contrast, NRF2 has been implicated in cancer development and progression as 
causing resistance to chemotherapy. NRF2 has now become a molecular target 
to overcome chemoresistance in cancers including ovarian cancer (Khalil et al., 
2016a, Khalil and Deeni, 2015, Wang et al., 2008, Ren, 2011, Olayanju et al., 
2015, Chian et al., 2014b, Tang et al., 2011, Wu et al., 2014).  NRF2 inhibitors 
such as bexarotene and RA, whose mechanism of action involves blocking NRF2 
nuclear import and its subsequent binding to deoxyribonucleic acid (DNA) (Wang 
et al., 2007, Wu et al., 2014, Wang et al., 2013), trigonelline and ascorbic acid 
that block NRF2 from translocating to the nucleus (Arlt et al., 2013, Sirota et al., 
2015, Tarumoto et al., 2004) have been identified. Other inhibitors identified 
include brusatol that down-regulates NRF2 levels by affecting NRF2 translation 
and post-translational regulation (Ren, 2011, Olayanju et al., 2015) and luteolin, 
which degrades NRF2 at the messenger ribonucleic acid (mRNA) level (Chian et 
al., 2014b, Tang et al., 2011). In addition, Chrysin, which down-regulates 
phosphoinositide 3-kinase /protein inase B (PI3K/Akt) and extracellular signal-
related kinase (ERK) pathway leading to NRF2 repression (Gao et al., 2013a), 
and apigenin, which inhibits NRF2 via suppressing PI3K/Akt pathways (Gao et 
al., 2013b), are amongst the inhibitors reported. The discovery of additional 
inhibitors that would inhibit the over-activation of NRF2 in such a way as to 
sensitise cancer cells to chemotherapy is in progress (Arlt et al., 2013, No et al., 
Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 9 
 
2014). Other methods to improve cancer therapy involve gene therapy using 
small siRNA. Gene therapy involves the insertion of genetic material into the cells 
of a patient, resulting in a therapeutic benefit (Kanninen et al., 2015). siRNA-
based therapy has shown great promise for many diseases and many targets for 
siRNA therapy including oncogenes such as NRF2, which is involved in cancer 
survival and resistance to chemotherapy (Huang et al., 2008). 
Below is a detailed description of the HER receptor family and NRF2, their 
expression and how they are being targeted in cancers, including ovarian cancer. 
1.3.     HER Family 
HER family receptors are one of the families belonging to RTKs that regulate key 
signal transduction pathways. HER family receptors become active when their 
ligands, such as epidermal growth factor (EGF)-like proteins and neuregulins, 
bind to them. It is also reported that there are about 30 ligands and four receptors 
in the HER receptor family in humans that make up the complex signal-
transduction network, and where activated, receptor-ligand complexes vary in 
both the strength and type of cellular responses that they induce (Cook et al., 
2014, Yarden, 2001). The process of transducing extracellular signals occurs 
when growth factor receptors such as HER family receptors, activate intracellular 
messengers or directly use receptor translocation to the nucleus, leading to many 
conformational changes and receptor activations (Wieduwilt, 2008, Cook et al., 
2014, Lee et al., 2016a, Zaczek et al., 2005). This activation subsequently leads 
to the induction of a number of signalling pathways including Ras/ Raf and 
PKI3/Akt MAPK, leading to DNA synthesis cell migration, survival, adhesion and 
proliferation (Cook et al., 2014, Wieduwilt, 2008). The different arrangements that 
the HER family possess to form dimers, either homodimers or heterodimers 
(Figure 1.1), lead to a diversity of distinctive purpose (McCubrey et al., 2015, 
Cook et al., 2014). 
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Figure 1.1: HER family receptors and their respective ligands. The receptors are shown based on their 
ability for homodimerization or heterodimerisation alongside the specific ligands. The figure is retrieved from 
(Cook et al., 2014). 
 
RTK pathways, including the HER receptor family, are frequently impaired in 
cancer and are commonly targeted in cancer treatment, with the treatment 
targeting them being promising (Wieduwilt, 2008, Cook et al., 2014, Lee et al., 
2016a, Zaczek et al., 2005).   
1.3.1   HER1 
HER1 is one of the four members of the HER family receptors. It is a glycoprotein 
with a molecular weight of 175 kDa. This cellular transmembrane protein is 
activated when its ligands such as EGF, transforming growth factor-α (TGFα), 
heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin 
(BTC), epi-regulin (EPR) and epigen bind to it, an event that leads to 
homodimerization of this receptor or heterodimerization with other receptors from 
the family. Following this, activation and autophosphorylation of HER1 initiate a 
series of intracellular signalling pathways that steer important cellular processes 
such as proliferation, adhesion, migration and apoptosis. However, studies have 
reported the over-expression of HER1 protein in a variety of cancers such as 
breast, ovarian head/neck and colorectal cancers (Moulder et al., 2001, Witton et 
al., 2003, Lee et al., 2005, Gordon et al., 2005, Reid et al., 2007, Mullen et al., 
Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 11 
 
2007). This increase in HER1 expression has been associated with poor 
treatment outcomes (Cook et al., 2014, Ilkhani et al., 2015, Schneider, 2009, 
Witton et al., 2003).  
1.3.2.   HER2 
HER2 is a monomeric protein that belongs to the HER family of receptors, and is 
a membrane-bound tyrosine kinase and glycoprotein of 185 kDa. It has three 
different segments including the extracellular amino end segment, which contains 
four domains. These include the hydrophobic transmembrane segment and the 
carboxyl end segment, which also contains another three domains with 
autophosphorylation sites known as the juxtamembrane, the tyrosine kinase and 
the C-terminal tail parts. Amongst all the family members, HER2 is the only one 
that has no known ligand yet heterodimerizes with other members of the HER 
family following ligand binding, which leads to the activation of various 
intracellular signal transduction pathways involved in cellular processes and 
growth (Cook et al., 2014, Wieduwilt, 2008, Mass, 2004, Laughner et al., 2001, 
Rubin and Yarden, 2001, Klapper et al., 1999, Johnston and Leary, 2006). 
HER2 is reported to be amplified and overexpressed in clear cell and mucinous 
tumours of breast and ovarian origin (McAlpine et al., 2009, Tapia et al., 2007, 
Schraml et al., 2003, Lin et al., 2011, Langdon et al., 2010, Mullen et al., 2007). 
Trastuzumab was the first monoclonal antibody used to try and target HER2, and 
a phase II trial indicated a response rate of 7.3%. Following that, another 
humanised antibody targeting HER2 emerged (pertuzumab), and it was given a 
clinical evaluation in ovarian cancer that indicated an improved response of 
14.5%. Numerous approaches have uncovered more effective ways of targeting 
HER2 over-expressing cancers with the use of a combination of trastuzumab with 
pertuzumab having demonstrated much improvement over the use of single 
agents (Omar et al., 2015, Goltsov et al., 2014a, O'Sullivan and Connolly, 2014, 
Limaye et al., 2013, Scheuer et al., 2009, Baselga et al., 2012, Nahta et al., 2004, 
Langdon et al., 2010, Nagumo et al., 2009b, Sims et al., 2012b). In 2016, a study 
by Li et al. reported a safe and effective continuing treatment of trastuzumab 
beyond first line therapy for HER2 positive advanced gastric cancer (Li et al., 
2016). 
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1.3.3.   HER3 
HER3 is a transmembrane glycoprotein with a molecular weight of 180 kDa. It is 
the third member of the HER family and interacts with various ligands such as 
neuregulin NRG-1 and NRG -2. However, HER3 is different from other HER 
family members for two important reasons: firstly, it lacks a functioning kinase 
domain and evidence suggests that even though HER3 can bind ATP, the 
phospho-transfer reaction is catalytically unstable; and secondly, HER3 has the 
ability to induce the PI3K-AKT pathway which in turn induces cancer cell 
proliferation (Cook et al., 2014, Wang et al., 2014). 
Several studies have shown that HER3 is an indispensable chaperone to HER2. 
This is because as HER2 has no known ligand and HER3 has no functional 
kinase activity, they become suitable in making complexes with each other 
(Calderwood et al., 2006, Gajria and Chandarlapaty, 2011, Khalil et al., 2016a, 
Khalil et al., 2016b). The dimerization of HER2 and HER3 has been implicated in 
cancer initiation and progression (Wang et al., 2014). 
1.3.4.   HER4 
HER4 is another member of the HER receptor family. It is a transmembrane 
glycoprotein with a molecular weight of 180 kDa, multiple furin-like cysteine rich 
domains, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site 
and a PDZ domain-binding motif. HER4 is activated following its binding by 
neuregulins (NRG)-2 and -3, a heparin-binding EGF-like growth factor and 
betacellulin. This ligand binding leads to the induction of various cellular 
responses including mitogenesis and differentiation. Overexpression or mutation 
of HER4 has been associated with cancers, including ovarian (Okazaki et al., 
2016, Qiu et al., 2008). Not much is known about the role of HER4 in cancer; 
however, a recent study by Okazaki et al (2016) reported developing a novel 
monoclonal antibody called P6-1 which significantly suppressed NRG-1, one of 
the ligands known to bind to human HER4 protein. The study confirmed that the 
antibody clearly suppresses NRG-1 ligand, which leads to reduced expression of 
HER4 in a number of cell lines used, including T47D and MCF7 cells. This, 
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therefore, suggests that targeting HER4 might be an important strategy for 
treating cancers, especially HER4 expressing ones (Okazaki et al., 2016). 
1.4. Composition and signalling patterns of HER family receptors 
The HER family of four are membrane-bound receptors that protrude into the 
cytoplasm. They have some common extracellular ligand-binding domains and a 
single transmembrane domain (Tanner et al., 2006, Linggi and Carpenter, 2006, 
Maihle et al., 2002). Their intracellular tyrosine kinase domain and C-terminal 
non-catalytic signalling tail are also similar across the HER family. All the HER 
family members have ligand binding domains except HER2, and once the ligand 
binds to the extracellular domain of any corresponding receptor, it induces a 
structural reconfiguration of the receptor leading to dimerization (typically 
homodimerization or heterodimerization) with other family members. This, in turn, 
leads to activation of the receptors resulting in autophosphorylation, 
transphosphorylation and subsequent induction of downstream signalling 
pathways. In another scenario, HER family receptors can be activated without 
any ligand binding, and this involves activation by non-physiological stimuli such 
as oxidative stress, ultraviolet light or γ-irradiation, amongst others (Sheng and 
Liu, 2011). 
HER2 is considered the preferred dimerization partner of all the HER family. It 
has the strongest kinase activity amongst the family members, even though it has 
no known ligand. Hence HER2 can only be activated when it forms a dimer with 
any of the other members. In contrast, HER3 can have a ligand bind to it but has 
no functional kinase activity. It is therefore dependent on other members such as 
HER2 forming heterodimers and phosphorylating its signalling tail, which leads to 
downstream signalling effects. EGF, TGF-α and amphiregulin are HER1 ligands 
that specifically bind to it, whilst HER4 has NRG -3, NRG-4 and tomoregulin as 
ligands. Other ligands such as epiregulin, β-cellulin and heparin-binding EGF-like 
growth factors have dual specificity for both HER1 and HER4. In addition, NRG-1 
and NRG-2 are ligands for both HER3 and HER4 (Sheng and Liu, 2011). 
The activation of HER family members leads to the stimulation and recruitment of 
various adaptors and signalling molecules such as the extracellular signal-
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regulated kinase (ERK) 1/2 via recruitment of growth factor receptor-bound 
protein 2 (Grb2), or SHC-transforming protein 1 (Shc) adaptors and the activation 
of ERK1/2 and phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which have a 
role in cell proliferation and survival. Additionally, phosphorylation and activation 
of HER family and subsequent ERK1/2 and PI3K activation can also lead to the 
activation of a number of transcription factors. These include signal transducers 
and activators of transcription, as well as zinc-finger transcription factor and Fos 
family transcription factors such as (c-Fos), Jun family transcription factors such 
as (c-Jun), Myc family transcription factors (c-Myc) and nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-Κb) (Sheng and Liu, 2011).  
1.4.1.   HER1 expression in ovarian cancer 
A comprehensive review by Siwak et al. (2010) reported on the role of HER1 in 
ovarian cancer and various ways of targeting it. The increased amplification and 
mutation of HER1 in ovarian cancer for up to 4 – 22% and <4% respectively, has 
also been reported (Siwak et al., 2010). Several studies have reported on the use 
of small molecule inhibitors such as gefitinib, lapatinib and erlotinib to block the 
kinase activity of HER1 (Siwak et al., 2010, Burris Iii et al., 2005, Montemurro et 
al., 2007, Kuang et al., 2010, Reid et al., 2007, Mester and Redeuilh, 2008, 
Murphy and Stordal, 2011, Matar et al., 2004, Johnston and Leary, 2006). Most of 
these drugs are already in clinical use and are being used as either single 
treatments or in combination, but most patients using them have reported 
resistance to the drugs (Siwak et al., 2010, Blackwell et al., 2010, Li et al., 
2008b). Monoclonal antibodies such as cetuximab and futuximab targeting the 
HER1 receptor in ovarian cancer have also been reported, though with limited 
activity due to resistance (Sheng and Liu, 2011, Siwak et al., 2010, Yap et al., 
2009, Matar et al., 2004). 
1.4.2.   HER2 expression in ovarian cancer 
Reports have shown HER2 overexpression in ovarian cancer, for example 
SKOV3 cell line that was extracted from an ovarian cancer patient was known to 
have HER2 overexpression (Langdon et al., 1988, Mullen et al., 2007, Meden 
and Kuhn, 1997, Verri et al., 2005, Bookman et al., 2003, Serrano-Olvera et al., 
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2006). Studies have connected a worse prognosis in ovarian cancer as a result of 
overexpression of HER2 (Bookman et al., 2003, Gordon et al., 2006, McAlpine et 
al., 2009, Serrano-Olvera et al., 2006, Berchuck et al., 1990). Although clinically 
HER2-targeted therapies have not shown significant promise as therapeutic 
agents in ovarian cancer, monoclonal antibodies such as trastuzumab and 
pertuzumab have been used to successfully treat HER2-overexpressing breast 
(BarthÉLÉMy et al., 2014, Langdon and Cameron, 2013), and ovarian (Langdon 
et al., 2010, Mullen et al., 2007, Sims et al., 2012b, Goltsov et al., 2014a) 
cancers, though with a low or partial response rate. Lapatinib, which is a dual 
inhibitor of HER1 and HER2 (Johnston and Leary, 2006, Kuang et al., 2010, 
Montemurro et al., 2007), is in clinical use and is used either alone or in 
combination with other anti-cancer drugs such as carboplatin, for treating patients 
with platinum-sensitive recurrent ovarian cancer (Sheng and Liu, 2011, Kimball et 
al., 2008, Lheureux et al., 2012). 
1.4.3.   HER3 expression in ovarian cancer 
HER3 has been reported to be amplified and over-expressed in epithelial ovarian 
cancers (Sheng and Liu, 2011, Tanner et al., 2006, Nagumo et al., 2009b). A 
number of reports have connected the overexpression of HER3 with poor 
prognosis in cancers, including ovarian (Zhang et al., 2009, Reschke et al., 2008, 
Hayashi et al., 2008, Xu et al., 1999, Tanner et al., 2006, Nagumo et al., 2009b). 
Besides the full-length HER3, several segments of HER3 isoforms that consist of 
its extracellular domains have been mentioned and studied in ovarian cancer, 
though their functional significance remains unclear (Sheng and Liu, 2011, Lee 
and Maihle, 1998). HER3 has been reported to contribute towards resistance of 
drugs targeting HER1, HER2 and HER4 (Amin et al., 2010, Campbell et al., 2010, 
Hynes and Lane, 2005, Gala and Chandarlapaty, 2014, Ma et al., 2014). HER3 
activation is increased, potentially through increased localisation of HER3, to the 
cytoplasmic membrane. Also, HER3 activation is reported to overcome resistance 
to gefitinib, especially in HER1-mutant non-small-cell lung cancer cell lines upon 
MET amplification (Engelman and Jänne, 2008, Turke et al., 2010). Not long ago, 
the inhibition of AKT was implicated in up-regulating HER receptors expression 
and phosphorylation, suggesting that HER3 may also have a role in mediating 
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resistance to PI3K/AKT pathway inhibitors (Sheng and Liu, 2011, Chandarlapaty 
et al., 2011, Sergina et al., 2007). 
Several monoclonal antibodies such as pertuzumab and trastuzumab are already 
in clinical use for the treatment of breast and ovarian cancers (Langdon et al., 
2010, Langdon and Cameron, 2013, Khalil et al., 2016b, Khalil et al., 2016a, 
Nahta et al., 2004, Molina et al., 2001, Hudis, 2007, Ajgal et al., 2017, Luen et al., 
2017). These antibodies are used to block the binding sites of the ligands for 
HER2, thereby antagonising the possible homodimerization of HER2 or 
heterodimerization of HER2 with either HER3 or other HER family members. The 
use of the combination of pertuzumab with gemcitabine or of gemcitabine alone 
to treat ovarian cancer has also been reported, though with little improvement 
(Makhija et al., 2010). More recently, signalling through the HER3 receptor 
pathway has been reported to correlate with expression of its natural ligand, 
neuregulin-1 (NRG1), in both ovarian cancer cell lines and in primary human 
ovarian cancer cells (Srinivasan et al., 1999, Gilmour et al., 2002). The 
expression of NRG1 has been observed in 30 – 83% of ovarian carcinomas 
(Gilmour et al., 2002, Sheng et al., 2010).  So far, the potential activity of these 
immunotherapeutics and other drugs as single agents or in combination with 
additional cytotoxic or biological therapies in ovarian and other cancers, is 
currently an area of interest and remains under focus (Sheng and Liu, 2011, 
Sheng et al., 2010, Ciardiello et al., 2000, Vanneman and Dranoff, 2012, Agarwal 
and Kaye, 2003, Gerber and Ferrara, 2005). 
1.4.4.   HER4 expression in ovarian cancer 
HER4 has as yet not been well studied, therefore its full role in cancer is not fully 
understood (Madhusudan and Ganesan, 2004). HER4 is reported to be 
expressed in ovarian cancer (Gilmour et al., 2001), with many cancer cases such 
as melanoma having reported that an increase in the proliferation of cells was as 
a result of the mutation of HER4 (Madhusudan and Ganesan, 2004, Sheng and 
Liu, 2011, Gilmour et al., 2002). This suggests that HER4 has a role in cancer 
initiation and progression (Madhusudan and Ganesan, 2004, Sheng and Liu, 
2011, Gilmour et al., 2002).  
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Despite the unclear role of HER4, most of the known ovarian cancer cell lines 
with high HER4 expression have been derived from platinum-refractory tumours 
(Gilmour et al., 2002, Gilmour et al., 2001), thereby suggesting the possibility that 
platinum resistance is as a result of HER4 overexpression and may be 
associated with the development of platinum resistance. In addition, the HER4 
rate of expression has been implicated in improved ovarian cancer cell survival 
(Gilmour et al., 2002). Moreover, it has been reported that the clone P6-1 
monoclonal antibody blocks HER4 binding to NRG1(Okazaki et al., 2016), and 
that the antibody appeared to show a stimulatory effect in a number ovarian 
cancer cell lines investigated, thereby raising alarm as to the possible role of 
HER4 in cancer cells (Okazaki et al., 2016). It, therefore, appears that HER4 is 
overexpressed in ovarian cancer (Sheng and Liu, 2011). This suggests that 
HER4 could provide alternative and salvage cell signalling and proliferation 
pathway to promote and sustain cancers. Thus, it would be of interest to target 
HER4 as a way to improve ovarian cancer therapy. 
1.5. HER family regulation and expression 
Regulation of HER receptor activation is a complex process (Krähn et al., 2001, 
Wood et al., 2004, Katz et al., 2007, Jorissen et al., 2003). The HER family are 
activated following ligand binding and receptor dimerization. As noted earlier, the 
ligands are specific to their respective receptors, with some having a dual 
specification of binding where they bind to one or more different receptors in the 
family to evoke signal transduction cascades and outcomes (Krähn et al., 2001). 
For example, HER receptors can mediate a signal that activates other 
downstream signalling pathways such as AKT or MAPK, which subsequently 
leads to cell growth, movement, survival, differentiation and death. Some of the 
ligands of these HER family receptors are reported to be overexpressed, with this 
being probably due to mutation of the respective receptors in many cancers 
(Roskoski Jr, 2014, Cell, 2016, Ritter et al., 2007, Rusch et al., 1997, Cuello et 
al., 2001). For example, HER1 has been found to be mutated in gliomas and 
NSCLC due to the gene rearrangements, amplification and subsequent 
overexpression of their aberrant protein products (Schlegel et al., 1994, Nicholas 
et al., 2006). HER2 overexpression is also reported in breast, ovarian, bladder 
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and NSCLC cancers, amongst others (Roskoski Jr, 2014, Cell, 2016, Khalil et al., 
2016b, Shattuck et al., 2008, Mullen et al., 2007). 
HER receptors’ signalling cascade is regulated by both positive and negative 
feed-back and feed-forward loops, including transcription-independent early loops 
and late loops mediated by newly synthesised proteins and microRNAs (review 
reported by (Avraham and Yarden, 2011)). For example, a receptor that has been 
activated can be “switched off” through receptor dephosphorylation, receptor 
ubiquitination or the removal of active receptors from the cell surface through 
endosomal sorting and lysosomal degradation (Cell, 2016, Roskoski Jr, 2014).  
1.6. Targeting the HER receptor family pathway for therapeutic 
intervention in cancer 
Several studies on targeting HER signalling pathways have noted the use of 
small molecules and monoclonal antibodies in cancer chemoprevention and 
tumour suppression (Hynes and Lane, 2005, Fabian et al., 2005, Sequist et al., 
2008, Langdon et al., 2010, Langdon and Cameron, 2013, Huang et al., 2004, 
Sartore-Bianchi et al., 2009, Scartozzi et al., 2004, Xiong et al., 2004, Gonzales 
et al., 2016, Cell, 2016). These drugs are used either in single or combination 
treatments to obtain a desired best result, with a number of suggestions having 
been made both pre-clinically and clinically that targeting more than one receptor 
could display better efficacy than just a single treatment approach (Cell, 2016, 
Gilmour et al., 2001, Zhou et al., 2004).  
Combination therapies are being actively pursued to expand therapeutic options, 
as well as to deal with chemoresistance conferred by cancer. Approaches to 
uncovering effective combination treatments have focused on drugs targeting 
intracellular processes of the cancer cells, and in particular on small molecules 
that target aberrant kinases (Dry et al., 2016). Many clinical drug combination 
successes seem to involve drug pairs with independent effects, rather than 
synergistic activity within the tumour cells. Using combination therapies to target 
different cancer cellular processes such as modulating stromal cells that interact 
with the tumour, strengthening physical barriers that confine tumour growth, 
epigenetic control, boosting the immune system to attack tumour cells and even 
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regulating the microbiome to support antitumor responses, could deal with the 
persistence of cancer chemoresistance (Dry et al., 2016, Klemm and Joyce, 
2015)  
The process and approaches for dealing with inhibitors such as small molecule 
inhibitors, monoclonal antibodies and heat shock protein drugs are under 
constant review to improve cancer treatment. More prodrugs and natural drugs 
are under development in order to achieve production of more blockers of 
receptors from overexpression (Fabbro et al., 2002, Barrera et al., 2012). 
1.6.1.    Small molecule kinase inhibitors 
Small molecules are drugs that are developed to inhibit aberrant RTK signalling 
by selectively interfering with their intrinsic tyrosine kinase activity. This 
consequently blocks receptor autophosphorylation and activation of downstream 
signalling pathways (Levitzki, 1999, Levitzki, 2000, Zwick et al., 2002). Most small 
molecule inhibitors are at present in clinical development for the treatment of 
human cancers (Kim et al., 2009, Workman and Collins, 2014, Paez et al., 2004, 
Kris et al., 2003, Herbst et al., 2002, Harrington et al., 2004). These include 
imatinib, erlotinib, lapatinib, tyrphostin and gefitinib. Inhibitors such as genistein 
and herbimycin A (isolated from fungal extracts) are the beginning stages for the 
generation of many types of synthetic small-molecules, especially for the HER 
family (Noonberg and Benz, 2000). Tyrphostin was the first synthetic RTK 
inhibitor introduced in 1988 (Levitzki and Mishani, 2006, Kim et al., 2009). 
Subsequently, another inhibitor, 2-phenylaminopyrimidine, was identified as a 
lead RTK inhibitor (Kim et al., 2009, Druker et al., 2001, Buchdunger et al., 1996).  
Imatinib was one of the novel anti-cancer drugs reported to inhibit kinase activity 
BCR-ABL fusion protein, which is responsible for constitutive proliferate 
signalling. Imatinib acts by blocking ATP access to its binding sites in the protein, 
thus leading to the inhibition tyrosine phosphorylation of the substrate (Fabbro et 
al., 2002, Manley et al., 2002).  
Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 20 
 
1.6.2.    Monoclonal antibodies  
Monoclonal antibodies work by blocking ligand–receptor interaction, thereby 
inhibiting ligand-induced RTK signalling and increasing RTK down-regulation and 
internalisation. By binding to specific epitopes on cancer cells, monoclonal 
antibodies induce immune-mediated responses leading to cellular cytotoxicity, 
and thus apoptosis and growth inhibition (Cragg et al., 1999, Zwick et al., 2002). 
Monoclonal antibodies such as bevacizumab and cetuximab targeting HER1 
(Herbst et al., 2005, Cunningham et al., 2004) and pertuzumab and trastuzumab 
targeting HER2/HER3 (Goltsov et al., 2014a, Workman and Collins, 2014, Khalil 
et al., 2016a, Langdon et al., 2010, Langdon and Cameron, 2013), are the 
inhibitors of RTKs identified as effective drugs for HER receptor overexpressing 
cancers including ovarian cancer, that suppress dimerization of HER family 
receptors (Goltsov et al., 2014a, Workman and Collins, 2014). Bevacizumab is a 
potent, highly selective and orally available HER1 inhibitor that shows higher 
growth inhibition and promising clinical activity, especially when combined with 
other drugs (Herbst et al., 2005, Hurwitz et al., 2004, Saltz et al., 2008, Giantonio 
et al., 2007) to suggest the targeting of oncogenic Ras. Cetuximab binds to HER1 
with high specificity and with a higher affinity, thus blocking ligand-induced 
phosphorylation of HER1 (Cunningham et al., 2004), and its activity tends to be 
enhanced when combined with other drugs (Cunningham et al., 2004, Van 
Cutsem et al., 2009, Pirker et al., 2009, Bonner et al., 2010). Pertuzumab, which 
inhibits HER2 dimerization, has shown improved clinical activity in ovarian cancer 
(Mullen et al., 2007), and against both breast and ovarian cancer (Langdon et al., 
2010). Trastuzumab has also shown an improved treatment activity in patients 
with HER2 overexpressing cancers (Workman and Collins, 2014).  So far, 
trastuzumab, in combination with pertuzumab, has become part of the routine 
way of treating patients with known HER2 overexpressing cancers, with an 
improved pathologic complete response (pCR) of 39% (Workman and Collins, 
2014, Goltsov et al., 2014a, Maly and Macrae, 2014). A combination of 
pertuzumab and trastuzumab has been shown to provide improved anti-tumour 
activity (Sims et al., 2012a, Baselga et al., 2012, Faratian et al., 2011), thereby 
suggesting that this combination could be an effective way of dealing with HER2-
overexpressing ovarian cancers (Faratian et al., 2011). Monoclonal inhibitors act 
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by antagonising the binding of ligands to the receptors at the extracellular 
compartment, thereby resulting in the internalisation of receptors without 
phosphorylation (Goltsov et al., 2014a, Workman and Collins, 2014). 
1.7. Comparisons between small molecules and monoclonal 
antibodies as RTK inhibitors (RTKi) 
Although small molecule inhibitors and monoclonal antibodies are the antagonists 
of RTK-activated cellular responses, they represent separate drug classes with 
different mechanisms of action and efficiency (Gui and Shen, 2012, Gharwan and 
Groninger, 2016, Dassonville et al., 2017). Monoclonal antibodies are specific to 
RTKs and have a longer half-life than the small molecule RTKi. They act by 
recruiting immune effector cells, leading to the stimulation of antibody- and 
compliment-dependent tumour cell cytotoxicity (Gui and Shen, 2012). Small 
molecule inhibitors are less selective than monoclonal antibodies (Harrington et 
al., 2004), thus offering the potential of a broader spectrum of activity against 
other members of the receptor family, such as HER2 and HER4, but probably 
produce more side effects. Small molecule inhibitors are normally taken orally 
and are relatively smaller in size than monoclonal antibodies; a characteristic that 
increases their possibility of easily intruding large tumours, although they are less 
stable in an in vivo environment (Harrington et al., 2004). The small molecule 
RTKi has also been reported to have more side effects such as diarrhoea, 
nausea and vomiting than monoclonal antibodies. This limits incorporating it 
within standard cancer chemotherapeutic regimes and approaches (Gui and 
Shen, 2012, Cell, 2016, Imai and Takaoka, 2006). It is left therefore to 
researchers and clinicians to investigate and decide whether any of these 
differences between monoclonal antibodies and small molecules are clinically 
meaningful in cancer treatment (Gui and Shen, 2012, Cell, 2016, Imai and 
Takaoka, 2006), despite the combination of small molecule inhibitors and 
monoclonal antibodies being more effective than single treatments with a 
reported reduced relative risk of death (Slamon et al., 2001). 
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1.8. NRF2 
Moi and colleagues (1994) were the first researchers to describe NRF2 as NF-E2 
p45-related factor 2 encoded by NFE2L2, when they identified it as the third 
human cap 'n' collar (CNC) basic-region leucine zipper (bZIP) transcription factor 
(Moi et al., 1994). One year later, Masayuki Yamamoto and colleagues (1995) 
reported an orthologous cDNA from chicken encoding a transcription factor that 
they called erythroid cell-derived protein with CNC homology (ECH) (Hayes et al., 
2016, Itoh, 1997, Itoh et al., 1995). The CNC domain has a unique region located 
amino terminal to the basic DNA-binding region that defines its identity (Andrews 
et al., 1993, Bowerman et al., 1992, Mohler et al., 1991). CNC family basic 
leucine zipper transcription factors play a vital role in the regulation of mammalian 
gene expression and development (Derjuga et al., 2004). The protein is now 
designated NRF2 rather than ECH, and in mammalian species NRF2 
translocates into the nucleus where it forms a heterodimer with small 
musculoaponeurotic fibrosarcoma (sMAF), consisting of a 45 kDa NF-E2 and an 
18 kDa subunits. It then binds to antioxidant response element (ARE) for 
subsequent initiation of expression of approximately 250 genes, including 
cytoprotective and detoxification genes, that contain an ARE with a sequence 5′-
TGACNNNGC-3′ in their promoter regions (Hayes et al., 2016). 
NRF2 is a member of the bZIP family of transcription factors (Mohler et al., 1995). 
While the basic region, just upstream of the leucine zipper region is responsible 
for DNA binding the acidic region is required for transcriptional activation. In 
mammals, the CNC family is composed of four closely related proteins; p45-NF-
E2 (Chan et al., 1993b), NRF1(Chan et al., 1993a),  NRF2 (Moi et al., 1994, Itoh 
et al., 1995)  and NRF3 (Kobayashi et al., 1999). Others are two remotely related 
proteins; BTB and CNC homology 1 (Bach1) (Oyake et al., 1996)  and BTB and 
CNC homology 2 (Bach2) (Muto et al., 1998). The roles of some of the 
mammalian CNC factors have been extensively studied. These proteins (Figure 
1.2), form a heterodimer with other b-ZIP proteins, such as small Mafs (MafK, 
MafG, MafF), to function as transcription factors (Igarashi et al., 1994).  For 
example, the pattern of heterodimeric association between NRF2 and small Mafs, 
is that the small Maf protein provides DNA binding activity to NRF2, while NRF2 
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activates transcription via its transactivation domain (Igarashi et al., 1998). 
Hence, NRF2 cannot bind to the ARE as a monomer, but requires dimerizaton 
with one of the small Maf proteins in order to bring about transactivation (Itoh, 
1997).  
 
Figure 1.2: Structural properties of CNC protein family members. Six Neh domains are conserved 
among vertebrate NRF2, while some of them are included in other CNC proteins. Among them, Neh4 is the 
only domain specific to NRF2. NRF1 also contains a Neh2-like motif, an interaction site for Keap1, but the 
precise function of NRF1–Neh2 is not known. None of the Neh domains exist in the Bach proteins. Retrieved 
from (Kobayashi and Yamamoto, 2006)  
NRF2 contains seven basic domains, namely Neh1-Neh7 (Figure 1.3). The Neh1 
domain is shown to bind to ubiquitin-conjugating enzymes to enhance the stability 
and the transcriptional activity of NRF2. The second domain, known as Neh2, 
possess two essential motifs known as DLG, which have less affinity for Kelch-
like ECH-associated protein 1 (KEAP1), and ETGE, which has a high affinity for 
the interaction between NRF2 and KEAP1 (Hayes et al., 2016, O'Mealey et al., 
2017). The Neh3 domain contains a carboxy-terminal which associates with 
transcription co-activators such as chromodomain helicase DNA binding protein 6 
(CHD6), which is responsible for the transactivation of ARE-dependent genes. 
Both Neh4 and Neh5 domains bind with cAMP response element binding (CREB) 
protein, which facilitates the transactivation of NRF2 target genes. These two 
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transactivation domains are also reported to interact with the nuclear cofactor 
known as receptor-associated coactivator 3/ amplified in breast 1/ steroid 
receptor coactivator-3 (RAC3/AIB1/SRC-3), thereby leading to an improved 
NRF2-ARE gene expression. The Neh5 domain also possesses a redox-sensitive 
nuclear export signal that mediates the cellular localisation of NRF2. The sixth 
domain, known as Neh6, contains a domain that is rich in serine amino acid, and 
it contains two motifs known as DSGIS and DSAPGS. The Neh6 domain is 
involved in the degradation of NRF2 even in stressed cells, where the half-life of 
NRF2 protein is longer than in unstressed conditions. The Neh6 domain also 
offers stability control of NRF2 when NRF2 is in the NRF2-KEAP1 complex 
(Ahmed et al., 2017, Namani et al., 2014, Wang et al., 2007). The Neh7 domain 
is a recent discovery and has been found to specifically interact with RXRα, a 
nuclear receptor that inhibits the NRF2–ARE signalling pathway (Hayes et al., 
2015, Hayes and Dinkova-Kostova, 2014, Hayes et al., 2016, McMahon et al., 
2014, Hayes et al., 2010, Krajka-Kuźniak et al., 2017).  
1.9. KEAP1  
KEAP1, also known as INRF2, is a substrate adaptor that has a MW of a 69-kDa. 
It is a protein that is rich in cysteine, and most notably cysteine 27 amino acid 
residues. KEAP1 is normally complexed with E3 ubiquitin ligase (Cul3), an 
enzyme that under normal basal conditions inhibits the transcriptional activity of 
NRF2 via its ubiquitination and proteasomal degradation in the cytoplasmic 
compartment of a cell (Ahmed et al., 2017; Namani et al., 2014). KEAP1 is 
reported to contain five domains (Figure 1.3): (i) an N-terminal end region; (ii) a 
BTB dimerization domain; (iii) a cysteine-rich intervening region (IVR); (iv) a 
double glycine repeat (DGR) domain which possesses six kelch, and (v) a fifth C-
terminal end region domain. The BTB domain controls the KEAP1 binding with 
the Cul3-based ubiquitin E3 ligase that complexes and ubiquitinates NRF2, and 
also contains a Cys151 residue that plays a vital role in NRF2 stimulation and 
activation (Krajka-Kuźniak et al., 2017, Hayes and Ashford, 2012). The IVR 
domain contains the very reactive cysteine residues Cys273, Cys288 and 
Cys297, which are sensitive to oxidation and are sensors of any agent that 
induces NRF2 (Hayes and Ashford, 2012, Hayes and McMahon, 2009). Amongst 
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these cysteine residues, Cys288 and Cys297 residues are primarily responsible 
as triggers to inhibit the activity of NRF2. The DGR domain, which contains six 
similar structures of Kelch, has the ability to negatively modulate NRF2 by binding 
to its Neh2 domain (Hayes and McMahon, 2009, Hayes and Ashford, 2012, 
Hayes et al., 2016). The DGR and C-terminal region domains, also known as the 
collectively named DC domain, in association with BTB (BTB-DC) together act as 
players leading to NRF2 proteasomal degradation (Hayes and McMahon, 2009, 
Higgins et al., 2009, Hayes and Ashford, 2012, Hayes et al., 2016). 
 
 
Figure 1.3: NRF2 and KEAP1 domain structures: NRF2 contains seven different domains while KEAP1 
has five different domains. Retrieved from  (Krajka-Kuźniak et al., 2017).  
1.10. NRF2 regulation pattern by KEAP1 
NRF2 is maintained in low concentration in the cytoplasm under a normal basal 
condition, due to control by KEAP1 that targets and presents NRF2 for 
ubiquitination and subsequent proteasomal degradation (Hayes et al., 2015, 
Ahmed et al., 2017, Namani et al., 2014). However, since degradation of NRF2 
by the 26 S proteasome requires prior ubiquitination of the substrate molecule, 
recognition and targeting of the NRF2 protein by the ubiquitin ligases may 
represent a critical rate-limiting step. NRF2 activation has been found to be 
promoted by oxidative stress in the cells. An increase in the level of NRF2 in 
response to stress leads to its dissociation from KEAP1, and this being mediated 
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by a post-transcriptional mechanism rather than an increase in NRF2 mRNA 
levels.  Hence activation of NRF2 has an important role in its stability and 
transcriptional activity (Huang et al., 2000, Nguyen et al., 2003, Ma, 2013). 
KEAP1-NRF2 complex is formed in the cytoplasm, where NRF2 is ubiquitinated 
and degraded in the event of normal basal conditions. In the event of stress state, 
NRF2 is dissociated from KEAP1 and translocates into the nucleus (Figure 1.4) 
where it heterodimerise with sMAF and then bind to ARE for initiation of 
expression of cytoprotective and detoxifying genes (Namani et al., 2014). 
 
Figure 1.4: KEAP1–NRF2–ARE complex pathway.  Illustrates how under normal conditions, NRF2 binds 
to KEAP1 at its two motifs ETGE and DLG, up to the level of ubiquitination and degradation. The Figure also 
illustrates the event in the stress state, where NRF2 protected from KEAP1 and obviously protected in the 
cytoplasm, is released, leading to its translocation into the nucleus where it binds with sMAF for subsequent 
initiation of cytoprotective, detoxifying and other ARE gene expression. Figure retrieved from (Namani et al., 
2014). 
Studies have shown that the process where KEAP1 interacts with NRF2 is 
through a mechanism called “hinge and latch” in which two motifs of NRF2 (DLG 
and ETGE) bind with the KEAP1 homodimer. The ETGE motif possesses a 
higher affinity for KEAP1 than the DLG motif and acts as a hinge, whilst DLG acts 
as a latch (Hayes and Ashford, 2012, Hayes et al., 2016). NRF2 first binds with 
KEAP1 at the ETGE site where there is high affinity that is through the hinge, 
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then at the DLG site by the latch. Under normal basal conditions, NRF2 would 
remain attached to KEAP1 through the hinge and latch interaction until activated 
by its inducers throwing it into an oxidative stress state, when it would then 
dissociate from KEAP1 in the cytoplasm. This free NRF2 would then translocate 
to the nucleus, where it would bind with sMAF proteins to form a heterodimer, 
and then transactivate ARE-driven gene expression that would lead to the 
expression of many cytoprotective and detoxifying genes (Hayes, 2000, Hayes et 
al., 2016, Wang et al., 2007). The phosphorylation of NRF2 by a series of protein 
kinases is reported to result in changes in the NRF2–KEAP1 complex and 
subsequent stabilisation of NRF2, which promotes the dissociation of NRF2 from 
KEAP1 and its accumulation in the nucleus (Namani et al., 2014, Ahmed et al., 
2017)  
1.11. The basic canonical and non-canonical NRF2 activation 
pathways 
NRF2 activation involves two basic pathways: canonical and non-canonical. The 
canonical pathway accounts for the primary mechanism of NRF2 activation. This 
is based on the dissociation of NRF2 from KEAP1 in the cytoplasm leading to the 
translocation of NRF2 into the nucleus where it dimerizes with sMAF proteins, 
and then binds to ARE-carrying promoters to subsequently initiate the gene 
expression of cytoprotective and detoxifying enzymes (Krajka-Kuźniak et al., 
2017, Krajka-Kuźniak et al., 2016). The activation of the PI3K/Akt signalling 
pathway and stresses on the endoplasmic reticulum are some of the mechanisms 
that can lead to nuclear accumulation of NRF2 and increased ARE-driven gene 
expression (Xiang et al., 2014, Cullinan and Diehl, 2004, Krajka-Kuźniak et al., 
2017). The non-canonical pathways of NRF2 activation involve numerous 
proteins with motifs similar to the ETGE motif in NRF2 competing with NRF2 for 
KEAP1 binding. Because of this competition, in this process the NRF2 loses out 
in the binding to KEAP1 and therefore becomes free, leading to its accumulation 
in the cytoplasm (Krajka-Kuźniak et al., 2017). This is a harbinger to the eventual 
ease of activation and translocation of NRF2 to the nucleus. Some of these 
proteins that compete with NRF2 include p62, a protein that is known to contain 
Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 28 
 
the STGE motif, dipeptidyl peptidase 3 (DPP3) and a partner and localiser of 
BRCA2 (PALB2) (Krajka-Kuźniak et al., 2017, Krajka-Kuźniak et al., 2016). 
1.12 Early evidence involving NRF2 activation in cancer 
Earlier NRF2 research has pinpointed the roles of NRF2 in preventing cancers 
(Praslicka et al., 2016). For instance, a study by Ramos-Gomez et al (2001) 
reported that NRF2 null mice are more susceptible to carcinogen-induced 
tumours than their NRF2 wild-type counterparts (Ramos-Gomez et al., 2001). 
Moreover, another study by Pearson et al., (2008) in which they compared the 
effects of caloric restriction on NRF2 wild-type and NRF2 null mice, implicated 
NRF2 as playing an important role in preventing cancer in the caloric restricted 
mice (Pearson et al., 2008). 
Studies by Padmanabhan et al., (2006) and Singh et al., (2006) have reported on 
the activation of NRF2 in cancer, following their investigations on mutations and 
polymorphisms in KEAP1 in lung cancer tissues and cell lines (Padmanabhan et 
al., 2006, Singh, 2006). Increased NRF2 activity in cancer was reported to have a 
role in increased cancer cell survival and resistance to chemo- and radiotherapy, 
which could lead to poor prognosis (Solis et al., 2010). Identified differences in 
the clinical manifestation of tumours suggest that those with sustained NRF2 
activation are distinct from those without (Praslicka et al., 2016). Following the 
findings of the role of NRF2 in chemoresistance, researchers have been focusing 
on identifying NRF2 inhibitors to modulate NRF2 to overcome chemoresistance 
(Wu et al., 2014, Chorley et al., 2012, Wang et al., 2007, Khalil et al., 2016b, 
Khalil and Deeni, 2015, Khalil et al., 2016a, Hayes et al., 2016, Hayes and 
McMahon, 2009, Yen et al., 2004a, Yen et al., 2004b, Yen and Lamph, 2006, 
Olayanju et al., 2015, Ren et al., 2011, Chian et al., 2014b, Tang et al., 2011, 
Gao et al., 2013a, Gao et al., 2013b).  
1.13 Chemopreventive and chemoprotective roles of NRF2 
A number of studies have reported on the double-edged role of NRF2. It displays 
a vital role in preventing normal cells from developing tumours and in killing 
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cancers away from normal cells, yet on the other hand it plays a crucial role in 
promoting carcinogenesis, drug resistance and cancer protection (Grossman and 
Ram, 2013, Na et al., 2008, Kim et al., 2008, Li et al., 2008a, Kim et al., 2014, 
Kim and He, 2014).  
The chemopreventive role of NRF2 is reported in many studies, for example, the 
increased expression of NRF2 effectively yielding a positive result (Thimmulappa 
et al., 2002, Kwak et al., 2002, Lee and Surh, 2005, Yu and Kensler, 2005). 
People under treatment with inducers could obtain a high degree of 
chemopreventive efficacy. Health reflects the ability of an organism, including 
humans’ ability to adapt to stress. Hence the activation of NRF2 as a 
chemopreventive measure is an adaptive response to environmental and 
endogenous stresses that serves to render organisms resistant to chemical 
carcinogenesis and other forms of toxicity (Kensler and Wakabayashi, 2010, 
Sarkar, 2011, Ahn et al., 2010, Talalay et al., 2007).  A wide variety of studies 
have reported several natural and synthetic compounds such as curcumin, 
xanthohumol, sulforaphane and oltipraz as inducing NRF2, which in turn leads to 
chemoprevention in cancers (Grossman and Ram, 2013, Dietz et al., 2005, Lee 
et al., 2011, Balogun et al., 2003, Farombi et al., 2008, Rushworth et al., 2006, 
Clarke et al., 2008, Iida, 2004). 
In contrast, a number of studies have reported the protective role of NRF2 in 
cancer leading to increased cancer cell proliferation and survival, a situation that 
then leads to drug resistance. One of the reasons for NRF2 activation is a loss of 
proper interaction of the KEAP1 protein, with NRF2 leading to increasing and 
persistent nuclear accumulation of NRF2. This thereby activates antioxidant and 
anti-apoptotic gene expression, which in turn leads to drug resistance (McMahon 
et al., 2014, Kwak et al., 2003, Cho et al., 2008, Wang, 2008, Goldstein et al., 
2016, Wu et al., 2017).   
Interestingly some studies have reported on ways of overcoming this problematic 
side of NRF2. For, example, transient transfection of NRF2-siRNA, sensitizes 
cancer cells to be more susceptible to cisplatin and doxorubicin (Wang, 2008). In 
addition, the pharmacological inhibition of NRF2 as a way of overcoming 
chemoresistance and increasing the killing effect of anti-cancer drugs has been 
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demonstrated (Khalil et al., 2016a, Tsuchida et al., 2017). Therefore, the 
pharmacological inhibition or genetic knockdown of NRF2 in cancer would help in 
overcoming chemoresistance (Namani et al., 2014, Ahmed et al., 2017, Khalil et 
al., 2016a, Khalil et al., 2016b). 
1.14 Targeting NRF2 pathway for therapeutic intervention in cancer 
Several studies have reported an increased expression of NRF2 which is 
overexpressed in cancers compared to normal cells, with this being one of the 
chemoprotective roles of NRF2 in cancers discussed earlier (Lister et al., 2011, 
Khalil et al., 2015, Hayes and McMahon, 2009, Kweon et al., 2006, Jiang, 2010, 
Stacy et al., 2006, Kim et al., 2011). Evidence indicates that a dysregulated 
NRF2/KEAP1 system, for example KEAP1 mutation (Ohta et al., 2008, 
Padmanabhan et al., 2006) or NRF2 mutation (Shibata et al., 2008), is 
responsible for NRF2 overexpression in cancers that leads to enhanced cellular 
proliferation and chemoresistance (Lister et al., 2011, Pandey et al., 2017, 
Shibata et al., 2008, Ohta et al., 2008, Padmanabhan et al., 2006). NRF2 tends 
to be overexpressed in cancers when it is freed from KEAP1 anchoring in the 
cytoplasm at the oxidative state and then translocates to the nucleus, where it 
heterodimerizes with sMAF and binds to ARE. This, in turn, leads to the 
expression of cytoprotective and detoxifying genes, such as NAD(P)H 
dehydrogenase quinone 1 (NQO1) and heme oxygenase-1 (HO-1). This confers 
protection to cancer cells against reactive oxygen species (ROS)-induced 
apoptosis and DNA damage, thereby enabling cancer cell survival and growth. 
Nuclear NRF2 expression due to activation of NRF2-ARE signalling may promote 
tumour progression and drug resistance, and hence NRF2 inhibition could be a 
strategic path in cancer treatment (Namani et al., 2014, No et al., 2014, McMahon 
et al., 2014).  
As mentioned earlier, studies have now focussed on the inhibition of NRF2 to 
overcome the prolonged or uncontrolled activation of NRF2 in causing tissue 
damage or cancer progression and chemoresistance. However, the screening, 
discovery and development of specific, potent, and non-toxic NRF2 inhibitors, 
including retinoids (e.g. RA and bexarotene) remain challenging. The possible 
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ways of developing specific inhibitors include: (i) transcriptional down-regulation 
of NRF2; (ii) increased degradation of NRF2 mRNA for subsequently decreased 
translation; (iii) enhancement of NRF2 degradation, through up-regulation of 
KEAP1-CUL3 complex, β-TrCP-SCF or HRD1; (iv) blocking the translocation of 
NRF2 to the nucleus leading to antagonising or blocking the dimerization of NRF2 
with sMAF proteins, and (v) blocking the NRF2-sMAF DNA-binding domain 
(McMahon et al., 2014, Namani et al., 2014, No et al., 2014). 
A review by Namani et al (2014) described retinoids as structurally related to 
vitamin A and other natural and synthetic signalling compounds including retinol, 
retinal, RA and retinyl esters. They are reported to have an anti-cancer effect 
because of their proapoptotic and antioxidant activities. Retinoids are stimulated 
ligands via interaction with two different nuclear receptors called retinoic acid 
receptors (RARs) and retinoid X receptors (RXRs), and these are members of the 
steroid/thyroid hormone receptor super-family. The RARs themselves contain the 
three isotypes RARα, RARβ, and RARγ encoded by the RARA, RARB, and 
RARG genes, and function as ligand-dependent transcription factors. There are 
two important isoforms of RARα (α1 and α2) and RARγ (γ1 and γ2) with vital 
functions; however, RARβ isoform has β1, β2, β3, β4, and β1′) resultant from 
differential use of promoters and alternative splicing (McMahon et al., 2014, 
Namani et al., 2014, No et al., 2014). 
Mostly RARs form heterodimers with RXRs and in the absence of ligand, an 
RAR/RXR heterodimer can interact with multiple co-repressor proteins such as 
the nuclear receptor co-repressor and silencing mediator of RA that regulates the 
transcription of target genes (McMahon et al., 2014, Namani et al., 2014, No et 
al., 2014). Also, endogenous ligands such as RAs act as agonists and activate 
the RAR/RXR heterodimer complex, leading to a reduction in the affinity between 
the co-repressor and the complex. The coactivator proteins such as steroid 
receptor coactivators SRC-1, SRC-2, and SRC-3 and proteins that have histone 
acetyltransferase activity similar to p300-CBP, P300/CBP-associated factor, have 
general control of amino acid synthesis protein 5-like 2. This will then 
subsequently interact with high affinity for the RAR/RXR heterodimer, which 
transactivates the genes targeted by RA through binding to downstream DNA 
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response elements, known as RA response elements (RARE) (McMahon et al., 
2014, Namani et al., 2014, No et al., 2014). 
Nuclear receptors have been reported to have a role in cancer, and are hence 
considered as drug targets in the same way that NRF2 is. Nuclear receptors play 
vital physiological functions and are mostly found in the nucleus, where they bind 
to DNA sequences such as hormone-responsive elements and regulate gene 
expression. The nuclear receptors are regulated either in a ligand-dependent or a 
ligand-independent manner, for example, RXRα physically interacts with NRF2, 
forms a protein–protein complex and then negatively regulates ARE gene 
expression. Studies have reported that nuclear receptors play dual roles in the 
aetiology of cancer. For example, PPARγ has been reported to play the role of 
both tumour promoter and tumour inhibitor in cancers (McMahon et al., 2014, 
Namani et al., 2014, No et al., 2014). 
1.15 Silencing NRF2 gene expression using siRNA to improve cancer 
therapy 
Evidence from studies indicates the application of siRNA for targeting cancer to 
improve treatments so as to overcome resistance to chemotherapy and 
radiotherapy. This provides a promising therapeutic modality for cancer and other 
diseases (Huang et al., 2008, Guo et al., 2013, Kanninen et al., 2015, Duong et 
al., 2017, Esmaeili, 2016). Silencing genes exerts antiproliferative and 
proapoptotic effects upon cell culture systems, animal models in clinical trials and 
in most studies. The recognition of the siRNA mechanism and progress in this 
field has led to several new siRNA-based drugs being applied in clinical trial 
phases (Mansoori et al., 2014). In combination with standard chemotherapy, 
siRNA therapy may reduce the chemoresistance of certain cancers, thereby 
demonstrating the potential of siRNA therapy for treating many cancers (Huang et 
al., 2008), including ovarian. A combination of siRNA-mediated gene silencing 
with natural products has been reported to down-regulate the NRF2-dependent 
response and partly sensitise MCF-7/TAM cells to tamoxifen in a synergic 
manner (Esmaeili, 2016). Another study by Duong et al. (2017) reported that 
NRF2-mediated silencing using siRNA reduced the level of aldehyde 
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dehydrogenase 1 family, member A1 (ALDH1A1) and aldehyde dehydrogenase 3 
family and member A1 (ALDH3A1); as well as glutamate-cysteine ligase catalytic 
subunit (GCLC) expression leading to enhanced antiproliferative effects of the 
chemotherapeutic agent, 5-fluorouracil (5-FU) in pancreatic cancer cells (Duong 
et al., 2017). These studies have suggested that siRNA-mediated NRF2 
knockdown could increase the efficacy of chemotherapeutic drugs. 
1.16 ROS: their dual role in cancer and their relationship with the HER 
family and NRF2 
ROS are ions, molecules or radicals that have a single unpaired electron in their 
outermost shell of electrons. Because of this characteristic, they are highly 
reactive, and more so than molecular oxygen (Zhang et al., 2016a, Liou and 
Storz, 2010). ROS are classified into two groups: free oxygen radicals and non-
radical ROS. Free oxygen radicals include superoxide (O2•−), peroxyl radicals 
(ROO•), hydroxyl radical (•OH), nitric oxide (NO•), organic radicals (R•), alkoxyl 
radicals (RO•), thiyl radicals (RS•), disulfides (RSSR), sulfonyl radicals (ROS•) 
and thiyl peroxyl radicals (RSOO•). Non-radical ROS include hydrogen peroxide 
(H2O2), singlet oxygen (1O2), trioxygen/ozone (O3), organic hydroperoxides 
(ROOH), hypochloride (HOCl), peroxynitrite (ONO−), nitrosoperoxycarbonate 
anion (O=NOOCO2−), nitrocarbonate anion (O2NOCO2−), dinitrogen dioxide 
(N2O2), nitronium (NO2+) and highly reactive lipid-or carbohydrate-derived 
carbonyl compounds (Liou and Storz, 2010). Amongst these, superoxide, 
hydrogen peroxide and hydroxyl radicals are the most well studied ROS in cancer 
(Zhang et al., 2016a, Liou and Storz, 2010). 
Just like NRF2, ROS play a vital role in various cellular biological activities 
including proliferation, growth and apoptosis. They can also facilitate cancer cell 
proliferation as well as survive and adapt to hypoxia (Zhang et al., 2016b). 
Cancer cells increase their rate of ROS production in comparison with normal 
cells to induce the cell signalling pathways necessary for cellular transformation 
and carcinogenesis (Reczek and Chandel, 2017). Moreover, in order to maintain 
ROS homeostasis and evade cell death, cancer cells increase their antioxidant 
capacity relatively. Compared with normal cells, this altered redox environment of 
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cancer cells may increase their susceptibility to ROS-manipulation therapies 
(Reczek and Chandel, 2017).  
ROS are reported to have dual roles in cancer depending on their concentration 
in cells. ROS facilitate carcinogenesis and cancer progression with mild to 
moderately elevated levels, while excessive ROS damage cancer cells 
dramatically and lead to cell death (Zhang et al., 2016b). Studies have implicated 
the HER family, NRF2 and ROS in the promotion of cancer cell proliferation, 
increased detoxification potential and resistance to therapy (Kang et al., 2014b, 
Manandhar et al., 2012). In particular, the generation of ROS, which are key 
regulators of the NRF2 pathway (Kang et al., 2005), have been demonstrated as 
a regulator of the HER family complex and subsequent activation of its functions. 
Elevation of ROS oxidizes redox sensitive cysteine residues on KEAP1. This 
results in dissociation of NRF2 from KEAP1, which translocates to the nucleus, 
heterodimerizes with sMAF and binds to AREs for the initiation of expression of 
antioxidant genes. Elevation of ROS can trigger signalling pathways such as ERK 
MAPK and PI3K, which are induced following HER receptor family activation to 
activate NRF2. These new mechanisms place ROS in a central position where 
they might act as a point of convergence between the HER receptor family and 
NRF2. Taken together and in consideration of the dual roles of ROS as a point of 
convergence between these two cytoprotective pathways, increasing the level of 
ROS in cancer cells as a strategy could improve treatment. 
The foregoing overexpression of HER family receptors and NRF2 are well 
recognised in cancers and in conferring therapeutic resistance to cancers (Hayes 
and McMahon, 2009, Hayes and Ashford, 2012, Hayes et al., 2015, Marmor et 
al., 2004, Bianco et al., 2006, Friedlander, 1998, Psyrri et al., 2005, Phelps et al., 
2008, Ledermann and Raja, 2010). In addition, a report by Khalil et al. (2016b) 
recently demonstrated transcriptional regulation of HER2 and HER3 by NRF2. In 
addition to demonstrating a relationship between NRF2 function, HER2/HER3 
signalling, ROS generation and the sensitisation of ovarian cancer cells to the 
killing effects of the targeted therapeutics and trastuzumab, pertuzumab or their 
combination (Khalil et al., 2016b, Khalil et al., 2016a) along with reports that 
demonstrate the importance of inhibitors of NRF2, it is reasonable to make the 
following hypotheses: 
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1. Ovarian cancer develops chemoresistance as a result of overexpression of 
HER receptor family and NRF2.  
2. Since NRF2 is a transcription factor to several hundred genes including 
proto-oncogenes, it is feasible that HER receptors are transcriptional 
targets of NRF2 via direct or indirect means involving ROS. 
3. Inhibition of NRF2 function could improve the efficacy of HER receptor- 
targeted chemotherapeutics. 
1.17 The aims and objectives of this study 
1.17.1 Aim 
The main aim of this research is to investigate the regulation of the HER receptor 
family and NRF2 in ovarian cancer. 
1.17.2 Objectives 
1. To clone human HER1 and HER4 proximal gene promoter and reporter 
systems as novel tools for the study of the regulation of HER1 and HER4;  
2. To examine the regulations of HER1 and HER4 by NRF2 in ovarian 
cancer; 
3. To screen for potent inhibitors of the NRF2-ARE signalling pathway and 
then investigate their potential applications in ovarian cancer therapy; 
4. To suggest novel interventions that may improve ovarian cancer therapy. 
The overall findings of this study may add to the regulation of the overexpression 
of HER family receptors and NRF2 in cancer, which may be a contributing 
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Materials and Methods 
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2.1. Bioinformatics 
2.1.1 Putative NRF2 transcription factor binding sites in promoters HER1 
and HER4  
Approximately 1.5 kb and 1.3 kb proximal promoter regions of HER1 and HER4 
respectively were retrieved from the base (http://www.ensembl.org/index.html) 
subjected to transcriptional factor binding prediction program 
(http://consite.genereg.net/) (Sandelin et al., 2004) (Figure 2.1) to predict for 
putative NRF2 binding sites. The sequences were analysed at 75% stringency. 
 
Figure 2.1: Screen shot of the bioinformatics analysis of the retrieved sequences. This is used to 
predict for putative NRF2 binding sites from the consite tool.  
2.1.2 Primer design and analysis 
All the primer sequences designed in the current research were first analysed 
under different criteria before ordering. Primer analysis was performed using the 
primer analysis software, Oligo-Analyser (Integrated DNA technologies, UK) 
(Figure 2.2). First of all, it was made sure that the primer sequence designed had 
a length between 20-40bp, had a minimum GC content of 50%, and that the 
forward and reverse primers did not have self-complementation. Once, this was 
established, it was made sure that the primer sequences were specific for the 
Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 38 
 
gene of interest by carrying out basic local alignment search (BLAST) analysis 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Further analysis was performed using the Oligo- Analyzer web resource 
(https://www.idtdna.com/site/Order/oligoentry/set?seq=CACTCCAGGTACTAGC
CAAGG) which determined its melting temperature, a complementary sequence, 
hairpin formation, and possible self-dimers. 
 
 
Figure 2.2: Screen shot of the Bioinformatics analysis of the designed primer using the Oligo-
Analyser web tool. After the primers were found correct under all the set criteria, they were ordered 
(Integrated DNA technologies, UK) with PAGE purification. Once the primers arrived in lyophilized form, the 
primer vials were centrifuged at full speed for 3 min, and re-suspended in Nuclease free water (Invitrogen) to 
make a stock of 100 μM. 10 μL aliquots of 10 μM final stocks were made and stored at -20°C until used. 
2.2. Molecular biology 
2.2.1. Isolation of genomic DNA 
For the isolation of genomic DNA, buccal swabs were used following the Buccal 
swab spin® protocol (Qiagen). Buccal swabs were used as a less invasive 
alternative to a blood sample. The buccal swabs were collected by swabbing the 
inside of the cheek 5 times with a cotton swab (Whatman bioscience). The cotton 
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head was ejected in the eppendorf tube (Scientific laboratory supplies) and 
allowed to air dry for at least 2-3 h. Following this, the manufacturer’s instructions 
were followed to isolate total genomic DNA. The quality of the isolated DNA was 
examined by running 10 μL of the final DNA solution on 1% agarose gel and 
genomic DNA was spectrophotometrically quantified. 
2.2.2. PCR amplification 
In this study, two types of PCR techniques were performed. The first one was the 
conventional PCR amplification technique for the amplification and clonal 
manipulation of DNA using a template DNA either from bacterial miniprep 
extraction or genomic DNA extracted from buccal swabs. The second type was 
colony PCR where the bacterial colony used as a source of template DNA used 
to screen for positive clones for a gene of interest. PCR reaction mix was made 
on ice in PCR tubes (Fisher scientific) using commercially available PCR 
reagents (Promega). Typically, each PCR reaction volume was 50 μL. The 
following were added: 
GoTaq® flexi buffer (5x)..................................10 μL 
MgCl2 (25 mM)...............................................2.5 μL (final concentration 1.25 mM) 
Forward primer (10 μM stocks).......................1 μL (final concentration 0.2 μM) 
Reverse primer (10 μM stocks).......................1 μL (final concentration 0.2 μM) 
dNTP mix (10 mM each)..................................1 μL (final concentration 0.2 mM of 
each) 
DNA template...................................................0.25 μg 
GoTaq® DNA polymerase................................1.5 units (0.3 μL) 
Nuclease free water..........................................To 50 μL. 
In the case of colony PCR reactions, these were performed to screen for 
successful clones by using the bacterial cells directly as a source of template 
DNA and examining the presence of the gene of interest using primers specific 
for that gene. Following overnight growth of transformed cells and subsequent to 
the appearance of colonies, individual colonies were picked with the help of 
pipette tips and introduced into PCR tubes containing 5 μL of water. The same 
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tips were also streaked individually from each colony on another plate in order to 
preserve the clone. Then from that 5 μL cell suspension, 1μL was used as a DNA 
template in PCR mix. The total volume of PCR mix was set to 25μL in the 
following set up below: 
GoTaq® flexi buffer (5x)................................5 μL 
MgCl2 (25 mM).............................................1.25 μL (final concentration 1.25 mM) 
Forward primer (10μM stocks)......................0.5 μL (final concentration 0.2 μM) 
Reverse primer (10μM stocks)......................0.5 μL (final concentration 0.2 μM) 
dNTP mix (10mM each).................................0.5 μL (final concentration 0.2 mM of 
each) 
DNA template................................................1 μL of the resuspended colony 
GoTaq® DNA polymerase............................1 unit 
Nuclease free water......................................To 25 μL. 
Following completion of PCR reactions, the whole reaction mixes were run on 1% 
agarose gels using appropriate DNA ladders for analysis and subsequent 
required applications. 
2.2.3. Agarose gel electrophoresis 
The agarose gel electrophoresis was performed for the separation, validation, 
characterization and purification of DNA following PCR amplifications, restriction 
digestions, genomic DNA isolation, estimation of ligation ratios and other clonal 
manipulations required in molecular biology works in this study.  
Throughout the study, 0.5 to 1% solution of agarose (Sigma) was made in 1x 
TAE buffer in a conical flask. The percentage of agarose gel used depended 
upon the size of DNA (for DNA > 10 kb, 0.5 % of agarose was used). Agarose 
was dissolved in TAE by heating in a microwave for 2-3 min and once the 
agarose was fully dissolved, the solution was cooled to 40oC at room temperature 
or sometimes with the help of tap water. For staining the DNA, Gel red nucleic 
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acid stain (Biotium) was added at 5 μL/100 mL of gel. The gel solution was added 
to the agarose gel electrophoresis tank after assembling it and a comb-plate was 
inserted in the gel. After the gel solidified, the comb-plate was carefully removed 
and 1x TAE buffer was added into the gel tank to fully immerse the solidified gel 
in the buffer. Following this, 5 μL of 1 kb DNA ladder (Bioline) for estimation of 
bands was added in the first well and the DNA to be analysed was mixed with the 
DNA loading dye (Bioline) and carefully loaded into each well. In the case of PCR 
amplified products, all the content of tube (usually up to 50 μL) were added in 
each well, and for estimation of ligation ratios, or quality of gel purified DNA, 5 μL 
of DNA was used and for restriction screening, 15-20 μL of DNA was added. The 
lid of the tank was closed and the attached cables plugged into the power pack. 
Agarose gels were usually run for 1 h at 80-100volts. 
2.2.4. Visualisation of DNA bands and image capturing 
The DNA bands within agarose gels were visualised under UV by placing the gels 
on UV illuminator (UVP upland, USA). To capture the gel images, gels were 
placed within the Gel documentation machine (Alpha Innotech, USA), and loading 
the Alphaimager® software. Depending upon the intensity of bands, appropriate 
exposure time was set (usually between 500-1000 milli seconds) and image 
captured through the in-build camera. The images were saved in TIFF file format 
for later analysis. 
2.2.5. Purification of DNA from agarose gels 
Purification of DNA involves purifying different DNA molecules from a common 
mixture (e.g. vector DNA and the insert) or to clean DNA of buffers and salts (e.g. 
after PCR amplification and restriction digestion), DNA of interest was run on 
agarose gels and purified from gel using the gel purification kit (Qiagen). 
Before doing anything else, first, the gel was placed on UV the illuminator to 
visualise DNA. Protective equipment (UV face mask, gloves and lab coat) were 
worn and the UV was turned on. The DNA bands to be purified were carefully 
cleaved from the gel with the help of a scalpel, and straightaway placed in 
labelled eppendorf tubes. The rest of the protocols were followed according to 
manufacturer’s instructions (Qiagen). Once the DNA was purified, it was run on 
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an agarose gel to examine its quality and condition. Its quality and condition were 
assured when tight bands and less degradable levels (smears) of DNA were 
observed. 
2.2.6. Restriction digestion of DNA molecules 
Restriction digestion of DNA involves clonal manipulation of DNA and validating 
the identity of the successfully cloned constructs. The restriction digestions using 
restriction endonucleases were performed according to manufacturer’s 
(Promega) instructions. The final volume of digestion mix was made to 20 μL by 
adding the following: 
10x restriction buffer: To final concentration of 1x. 
DNA: 1 μg (Usual concentration of DNA was maintained at 1 μg/μL, hence 1 μL 
used). 
The contents were gently mixed by pipetting up and down. 
Enzyme-I (between 5-10 units) 
Enzyme-II (between 5-10 units) 
Sterile de-ionized water, (to the final volume of 20 μL). 
This restriction digestion mix was incubated for 1 h at 37oC in a water bath. 
However, for the restriction digestion of PCR amplified products, the DNA was 
first run on the agarose gel in order to gel purify it and then subjected to 
restriction digestion as above. For cloning purpose, the restriction digestion of 
plasmid vector was usually followed by Shrimp Alkaline Phosphatase (SAP) 
mediated (Promega) dephosphorylation of the 5’ overhangs. For this, after the 
completion of the above restriction digestion, the reaction mixture was subjected 
to 65oC for 15 min to inactivate restriction enzymes. This was allowed to cook 
and 1unit of SAP (Promega) was added and the mixture incubated for up to 15 
min at 37° C. SAP enzyme was heat inactivated by incubation at 74oC for 15 -20 
min. 
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2.2.7. Ligation of DNA molecules 
Ligation of the DNA molecules includes the gene of interest or insert and 
linearized cloning vector, both were first run on an agarose gel to have an 
estimate of their relative molar ratios as determined by their relative intensities 
and size. Based on those intensities, the following ligation ratios were made: 
Insert: Vector 3: 1 or 1:1 or 1: 3 
In these ratios, the volume of the vector was usually maintained constant while 
that of the insert was altered to achieve the above molar ratios. After estimating 
the volume of vector and insert needed, the following were added in the 
eppendorf tube in order to make a 10 μL ligation reaction: 
Insert (volume dependent upon molar ratio) 
Vector (volume dependent upon molar ratio) 
10x ligation buffer to the final concentration of 1x (Promega) 
T4 DNA ligase: 3 Weiss units (Promega) 
Nuclease free water, (to final volume of 10 μL). 
A non-insert control was also used where nuclease free water was added instead 
of the insert. The above reaction was incubated either at room temperature for 3 
h, or overnight at 4oC. Following this, the next step was bacterial transformation 
where 5 μL of the ligation mixture was usually used. 
2.2.8. Bacterial transformation 
Bacterial transformation by heat shock using DH-5α bacterial strain was 
employed in this study. In this method, chemo-competent cells were employed. 
For each transformation reaction, 50 μL of competent cells were used. First of all, 
bench surface was swabbed with 70% ethanol and burner was turned on to 
maintain a sterile environment. Frozen cells maintained at -80°C were taken out 
and immediately placed on ice. Cells were allowed to thaw slowly on ice and in 
the meantime, heat block was set to 42°C. After thawing, the chemo competent 
cells were very gently mixed with the help of pipette and 50 μL transferred to a 
pre-chilled and pre-labelled eppendorf tube. The plasmid-vector was next added 
gently to the tube containing 50 μL chemo-competent cells (either 1 μL or 5 μL of 
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vector added depending upon application) and the tube placed back on the ice 
and allowed to incubate for 30 min. After incubation, the tube was placed on the 
heat block maintained at 42°C and heat shock was given for 45 s during which, 
bacterial transformation takes place. The tube was put back on the ice for 2 min 
and then at room temperature. Pre-heated terrific broth (TB) at 37°C was taken 
out of water bath and 500 μL of that was gently added to the transformation tube. 
The tube was placed in the shaking incubator set at 37°C and allowed to incubate 
for 90 min while shaking at 125 revolutions per minute (rpm). In the meantime, 
TB-agar plates, made with appropriate antibiotic selection (either 50 μg/mL 
kanamycin or 100 μg/mL ampicillin) were taken out of the fridge, and placed, with 
lids off, in another incubator set at 37°C. 
After the 90 min incubation period, the transformation tube and the TB-agar 
plates were taken out and placed under the burner. The contents of the 
transformation tube were carefully transferred to the TB-agar plate and spread 
evenly with the help of spreader. The plates were taken to incubator maintained 
at 37°C and placed inverted overnight to allow the transformed bacteria to form 
colonies. 
2.2.9. Screening of the transformed bacterial colonies and making glycerol 
stocks 
Following the bacterial transformation, the growth of transformed bacterial 
colonies on agar plates made with appropriate antibiotics was checked after 16 h. 
Following this, using sterile technique, 5 mL of pre-warmed (37°C) TB medium 
was taken in a 15 mL centrifuge tube and antibiotics (ampicillin 100 μg/mL or 
kanamycin 50 μg/mL, as appropriate) was added into it. 
Based on the number of colonies on the control plate, colonies from the 
experimental plates were picked up using a sterile loop and inoculated in each of 
the 15 mL tubes and allowed to grow overnight at 37°C in a shaking incubator at 
125 rpm. Next day, the tubes with bacterial suspension were taken out and 
centrifuged at 5000 rpm at 4°C for 15 min. The media in the supernatant was 
discarded and the palette dried on a paper towel. After this, to extract the 
transformed plasmid from bacterial cells, Spin Miniprep kit for plasmid extraction 
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(Qiagen) was used according to the manufacturer’s instruction. To screen and 
verify the cloned insert, restriction digestions were performed using appropriate 
restriction enzymes. After successfully transformed bacterial cultures were 
identified, glycerol stocks were made in the following way. A 50% filtered sterile 
glycerol solution in TB containing the appropriate antibiotics (100 μg/mL, 
kanamycin 50 μg/mL) was made. 400 μL of this stock was mixed with 1 mL of the 
successfully transformed bacterial culture, mixed gently and stored in -80°C. 
Whenever required, these glycerol stocks were streaked on agar plates and 
grown overnight at 37°C to get colonies of transformed bacteria. 
2.2.10. Bacterial plasmid extraction: 
The subsequent day after transformation, once individual colonies of the 
transformed bacteria appeared on plates with an antibiotic selection, they were 
grown overnight in the presence of the same selection. The cloned plasmid was 
isolated from transformed bacteria by either microcentrifuge based plasmid 
Miniprep (Qiagen) or Midiprep (Qiagen). For techniques like propagation and 
clonal manipulation, plasmid Miniprep was performed. For transfection of 
mammalian cells, concentrated and high-quality DNA preparations were used 
with plasmid midiprep technique. A typical concentration of up to 0.25 mg/mL and 
up to 1 mg/mL DNA, were achieved by plasmid miniprep and midiprep techniques 
(Qiagen) respectively. 
In the midiprep technique, the glycerol stock sample of successfully transformed 
bacteria, confirmed to be correct clone following sequencing, was taken out of - 
80°C freezer and inoculated in 100 mL of TB with antibiotics in a 500 mL conical 
flask and grown overnight. Next day, the bacterial culture was transferred to 
individual 50 mL centrifuge tubes and centrifuged at 5000 rpm at 4°C for 15 min. 
The supernatant was discarded and palette dried on a paper towel. To extract the 
plasmid, a further procedure was followed according to manufacturer’s (Qiagen) 
instructions. 
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2.3. Mammalian tissue culture: 
2.3.1 Measures taken for the use of cell culture  
Measures such as authentication of cell line, cryopreservation, and avoidance of 
cross-contamination of cell lines were all taken. Furthermore, the cells were 
checked for microbial contamination (regular mycoplasma test).  
2.3.2. Cell lines: 
For all the cell lines listed (Appendix 1, table 9.1.1), the media was 
supplemented with filter sterilised 10% foetal bovine serum (FBS), 2 mM 
glutamine, 1 mM sodium pyruvate, 100 μg/mL streptomycin and 100 U/mL 
penicillin all purchased from Invitrogen UK. Cells were maintained at 37oC in a 
tissue culture incubator with an atmosphere containing 5% CO2. 
2.3.3. Sub-culturing the cells 
Sub-culturing of cells used in this study was performed regularly to ensure their 
survival, regular supply for the study and maintain proper growth conditions. It 
was routinely done with cells that reached 80-90% confluence either in flask or 
tissue culture plates. All the procedures were done using sterile techniques 
performed in a sterile tissue culture hood.  
Briefly, in the process of sub-culturing, the media, buffers and trypsin were placed 
in water bath at 37°C at least 30 min prior to subculturing the cells. Tissue culture 
lab coat and gloves were worn. The gloves were sprayed with 70% ethanol. The 
laminar flow in the hood was turned and the working surface of tissue culture 
hood was swabbed with 70% ethanol. Any apparatus, media, trypsin and buffers 
taken inside the hood was first swabbed by 70% ethanol except for tissue culture 
flasks and plates. The tissue culture flask needed to be sub-cultured (>80% cell 
confluence) was taken out of the incubator, observed under the microscope and 
placed into the hood. With the help of aspirator attached to the suction pump, the 
old medium was removed from the flask. 4 mL of PBS (Invitrogen) was added to 
the cells and the flask gently swirled to wash away the old media and dead cells. 
PBS was aspirated out. 1 mL of pre-warmed 0.25% trypsin (Invitrogen) was 
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gently added on top of cells with the help of serological pipette, and the flask 
swirled to ensure spreading of trypsin on the entire surface area of the flask. The 
flask was taken into tissue culture incubator maintained at 37oC with 5% CO2 
atmosphere and incubated for 5 min (or until the cells were detached as observed 
under the light microscope). After the cells detached, 4 mL of pre-warmed cell 
culture media was added to the flask to stop the further action of trypsin and 
dilute the cells. With the help of serological pipette, the cell suspension was 
mixed thoroughly by pipetting up and down to ensure total detachment and to 
break any cell clumps formed. After this, the number of cells in the suspension 
was determined and either seeded into other flasks for propagation and cell 
culture maintenance, or cryo-frozen for future use. The type of tissue culture 
flasks and plates employed, specific to experimental type with the number of cells 
seeded and the amount of growth media used in the current research study was 
listed in (Appendix I, table 9.1.2).               
2.3.4. Cell counting 
Throughout the course of this study, human cells were routinely counted for 
different experiments via counting chamber method. In this method, first of all, the 
counting chamber and the cover-slip used were cleaned with the help of lens 
paper and put under the light microscope. The coverslip was placed on top of the 
gridded area. The grid in the counting chamber was composed of squares of 
different areas. The cells to be counted were first trypsinized and then diluted in 
cell culture media. Every time micropipette is used to take 10 μL of cell 
suspension from the flask and put underneath the coverslip over the counting 
chamber where the cell suspension spreads quickly. The cells were counted in 
ten 0.04 mm2 squares in the grid. Then, the number of cells per μL was 
calculated with the following formula: 
Supposing, the number of cells counted in ten 0.04 mm2 squares = 20 cells 
(supposed)  
Total area in which 20 cells counted = (10 x 0.04) = 0.4 mm2 
Total volume = 0.4 mm2 x 0.1 (height of chamber) = 0.04 mm3 
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So, 20 cells in 0.04 mm3. 
1 mm3 = 1 μL, hence, 0.04 mm3 = 0.04 μL 
If 0.04 μL has 20 cells, 1 μL has = 20 x 1 μL ÷ 0.04 μL = 500 cells. 
Hence, 1 μL has 500 cells. 
2.3.5. Cryofreezing cells and reviving frozen cells 
In this case, the surplus cells were routinely cryo-frozen for future use. After the 
cells were trypsinized from a T75 flask, 5 mL of cell media was added to stop the 
action of trypsin, and the cell suspension was mixed thoroughly with the help of 
serological pipette attached to the pipette buoy. The cell suspension was 
transferred to a sterile 15 mL centrifuge tube, capped tightly and taken to the 
centrifuge machine set at 37°C. The cell suspension was centrifuged at 1000 rpm 
for 15 min to palette the cells. In the meantime, sterile cryotubes (Thermo 
Fischer) were labelled with cell details and passage number. After centrifugation, 
the tube was taken back to the hood, the supernatant was discarded and the cell 
palette was gently resuspended in 1 ml of freezing media. 
Following this, the cell suspension in freezing media was carefully transferred to 
cryotubes, capped properly and immediately taken for storage in -80°C freezer. 
When previously frozen cells were needed, the media was first warmed in the 
water bath at 37°C and 10 ml of media was transferred to the T75 flask. The 
cryotube with frozen cells was taken out and immediately put in the water bath at 
37°C. As soon as the frozen mixture was thawed (usually after 1- 2 min), the 
cryotube was taken to the tissue culture hood, and with the help of pipette, very 
gently transferred into the T75 flask with the media. After 16-24 h, old media was 
replaced by new media to replenish the nutrients and boost cell growth and after 
every 3-4 days, cell media was usually changed by first aspirating the old media, 
washing the cells with warm PBS, and transferring fresh media into the flask to 
boost the healthy condition of the growing cells. 
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2.3.6 Cell treatments with drugs 
The drugs used in this research work involved the preparation of stock solutions 
of these drugs and stored as instructed by their manufacturers. Working 
concentrations were achieved by diluting the stock in the media used and were 
based on prior literature. Prior to treatment with these drugs, cells to be treated 
were taken out of the incubator; old media removed and pre-warmed PBS added. 
Pre-warmed media was then transferred to falcon tubes (corning) in the tissue 
culture hood and the required amount of drug was added to achieve the working 
concentrations. The PBS over the cells was taken out and the media with the 
drug carefully added. The amount of media added was dependent upon the type 
of tissue culture vial in which the cells were grown. For example, the cell lines 
were maintained in RPMI 1640 media (Gibco® Invitrogen) supplemented with 
10% foetal bovine serum (FBS), 2 mM glutamine, 1 mM sodium pyruvate, 100 
μg/ml streptomycin and 100 U/ml penicillin in an atmosphere of 5% CO2 and 
incubated at 37°C. Before experimental treatments, cells were grown for 24 h in 
RPMI 1640 media prepared as above. Heregulin-β1 (HRG, Sigma) was used by 
preparing 1 μM stock solution made with 5% trehalose, 10% FBS in PBS and 
diluted to a final concentration of 1nM with media during treatments. All the drugs 
were used by directly diluting the drugs in media to desired final concentrations. 
For drugs that are sensitive to light, stock solutions were made in in amber 
Eppendorf tubes pre-aired with nitrogen gas. Once the stock solution was made, 
it was bubbled again with nitrogen gas and closed, stored at -80°C. (Appendix II, 
sub-section 9.2.29) provides the detailed information about the drugs used, their 
storage and working concentrations and their manufacturers. 
 2.3.7. Cell transfection 
Cell transfections were carried out by liposome mediated gene transfer via the 
use of commercially available transfection reagent (Lipofectamine 3000, 
Invitrogen). The transfections aimed at performing Dual-Luciferase based 
promoter assay or siRNA transfections for gene silencing. Briefly, 16-24 h prior to 
transfection, cells were seeded desired 24 well plates containing normal cell 
culture media. Next day, the plates were taken out (with 70-90% confluent cells) 
and put in the tissue culture hood and old media was removed. Cells were 
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washed once with warm PBS and 250 μL of pre-warmed serum-free and 
antibiotic free media (Opti-MEM®, Invitrogen) was added per plate and put back 
in the incubator. Next was to prepare the transfection complexes for subsequent 
transfection in the following way: 
1. 0.5-1 μg DNA was diluted in 50 μL serum and antibiotic free media in an 
eppendorf tube labelled tube A.  
2. 1-3 μL transfection reagents was slowly added to 50 μL of serum and 
antibiotic free media in another eppendorf tube labelled tube B.  
3. Both tubes were allowed to stand for 5 min.  
4. The contents of tube A were gently mixed with the contents of tube B in 
another eppendorf tube labelled tube C.  
5. Tube C was incubated at room temperature (inside tissue culture hood) for 
30 min to form the complex.  
6. 150 μL of serum free and antibiotic free media was added to a 1.5 mL 
effendorf tube, and the contents of tube C were gently introduced into it. 
The total volume in this effendorf tube now was 250 μL and was called the 
transfection media.  
7. The cells to be transfected were taken out of tissue culture hood, old 
(serum free, antibiotic free) media was aspirated and the 250 μL of 
transfection media was added on top of these cells gently.  
8. The plate was placed back in the tissue culture hood and allowed to 
incubate for 5 h.  
9. After 5-6 h, the transfection media was removed and pre-warmed normal 
cell culture media was added to the cells. Cells were allowed to grow for 
16-24 h. For transfections involving siRNA, cells were allowed to grow for 
24-96 h depending on the type of experiment before further studies.  
2.4 Biochemistry 
2.4.1 Antibodies and the detection systems used in the study: 
The different primary antibodies employed in the current study are listed in 
(Appendix 1, Table 9.1.1 ). To study different HER receptor family and NRF2 
proteins, this research employed different biochemical detection systems as a 
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requirement of the employed biochemical techniques. The secondary antibody 
detection systems used, its dilution, the name of the technique employed, and the 
manufacturer are listed in (Appendix 1, Table 9.1.2). 
2.4.2 Protein extraction 
For western blot analysis of different proteins, total protein content was extracted 
from cells grown in 60 mm tissue culture plates at 90% confluency (0.5 x 106 – 1 x 
106) during treatment and protein extraction. The entire extraction process was 
done on ice as much as possible and cells were never allowed to dry. 
Tissue culture plates with cells were taken out of tissue culture incubator and 
placed on ice. The old media was discarded from the plates and cells were 
washed three times with 5 mL of ice-cold PBS. After the third wash, 495 μL of ice 
cold PBS was taken in an eppendorf tube, and 5 μL of 100x protease and 
phosphatase inhibitor cocktail (Pierce Biotechnology) added to it and mixed. The 
PBS with the inhibitors added was transferred to the tissue culture plate. 
With the help of a tissue culture cell scraper, the cell monolayer was scraped off 
by gently tilting the plate, and scraping off cells to the bottom. The complete 
monolayer was scraped off to produce a cell suspension. This suspension was 
transferred to a pre-chilled eppendorf tube and centrifuged at 800 rpm for 5 min 
at 4°C to collect the cells in the palette. In the meantime, 1mL of 
radioimmunoprecipitation assay (RIPA) lysis buffer (Thermo Scientific, UK) was 
taken in another tube and 10 μL of the protease and phosphatase inhibitor 
cocktail (Pierce Biotechnology) was added into it and placed on ice. After the 
centrifugation step, the tube with the cell palette and a supernatant was taken out 
and its supernatant discarded. The cell palette was then resuspended in 200 μL 
of RIPA lysis buffer (now with inhibitors added) and thoroughly mixed with the 
help of micropipette. The cell lysate was also subjected vortex for 3 min, followed 
by centrifugation at 10,000 rpm for 15 min at 4°C. After centrifugation, the cell 
lysate was placed back on the ice, and 150 μL of supernatant (extracted protein) 
was transferred into a pre-chilled and labelled eppendorf tubes. This protein 
lysate was either further processed or quantified or stored in -80°C for future use. 
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Subsequently, all protein extracts were quantified using the Bradford reagent 
(Sigma-Aldrich, UK) against BSA as a standard. 
2.4.3 Quantification of extracted protein 
Protein quantification of the extracted proteins was performed with the help of 
Bradford assay by using Bradford assay reagent (Pierce Biotechnology) in 96 
well-plate formats. Before performing the assay for the extracted protein lysates, 
a standard curve was established with a protein with known concentration. 
The protein lysates prepared were taken out of -80°C freezer and allowed to thaw 
on ice. The tubes were centrifuged at 10,000 rpm for 5 min at 4°C. In the 
meantime, the working stock of Bradford reagent (Sigma-Aldrich, UK) was 
prepared by mixing 1 part in 4 parts of distilled water. After the centrifugation 
step, 20 μL of each protein was transferred in triplicates to each well of the 96-
well plate and mixed with 180 μL of the Bradford reagent per protein sample. The 
protein lysate and the Bradford reagent mix was allowed to incubate at room 
temperature for 5-10 min. Next, the 96-well plate was placed in a 
spectrophotometer (Thermospectronic, USA) and its reading at 595 nm was 
recorded. Mean of the readings from three wells for each protein sample were 
taken and quantified by plotting it on the standard curve obtained by performing 
Bradford assay with a known standard protein (Appendix 1, Table 9.1.4). 
Once the concentration of each protein sample was determined, they were all 
mixed with (4x) lithium dodecyl sulfate (LDS) sample buffer (Nupage, Invitrogen) 
to the final concentration of 1x. Sample reducing agent (10x) (Nupage®Sample 
reducing agent, Invitrogen, UK) was added to 1x to the protein lysate boiled at 
100oC for 10-20 min then loaded straight away into the sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel or stored at -20°C or -80°C 
until further use. 
2.4.4 Processing of proteins for Immunoblotting 
The quantified proteins (1 mg/mL) mixed and stored in LDS-sample buffer were 
taken out of -20°C freezer and allowed to thaw at room temperature. The 
samples were then placed on a thermomixer, heated for 15min at 95°C while 
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shaking. After heating the samples, they were centrifuged at 15000 rpm for 15 
min. 15-20 μL (20 μg) of the supernatant of the centrifuged samples were usually 
loaded (unless otherwise stated) in the SDS-PAGE gels (Novex® Nupage, 
Invitrogen) for further analysis.  
2.4.5 Immunoblotting 
Proteins processed for immunoblotting were first subjected to SDS-PAGE by 
running the samples on precast gels (Novex® Nupage, Invitrogen) using 
commercially available SDS-PAGE apparatus (XCell SureLock Mini-Cell system, 
Invitrogen, UK), transferring them to  polyvinylidene difluoride (PVDF) using a 
new and improved Invitrogen™ iBlot™ 2 Dry Blotting System, a fast western 
transfer which last for only 7 min and processing by enhanced 
chemiluminescence (ECL) reagent and visualizing proteins by syngene G-BOX 
visualising machine. For all the proteins blotted in this study, 4-12% gradient, pre-
cast gels were used. Also, unless otherwise stated in figure legends, 20μg of 
protein was loaded per well of these gels. Two pre-cast gels (Novex® Nupage, 
Invitrogen) were used within the SDS-PAGE apparatus (Novex® Nupage, 
Invitrogen). The gel apparatus was assembled and two pre-cast gels were 
installed. The inserted comb plates in the gels were carefully removed and the 
wells gently washed with distilled water. The SDS-PAGE running buffer was 
poured into the inner chamber until the wells were submerged and in the outer 
chamber until the whole base was submerged. In the first well of each gel, 15 μL 
of pre-stained protein standard (Invitrogen) was loaded followed by loading the 
samples. The lid of the gel apparatus was fitted at its position and the cables 
were connected to the power pack. Gels were run at 150-200 V for 1-2 h or until 
the dye in the protein standard and samples, providing a measure of migration, 
reached the bottom of the gel. After the run was complete, the lid of the gel tank 
was taken off, and the gel plates were carefully taken out. The gel was very 
carefully taken out of the plates and immediately put in the gel trays and given a 
wash in the transfer buffer to remove SDS and excess buffer. While the gels still 
in transfer buffer, filter papers of the right size were soaked distilled water, and 
then all the other set up for iBlot dry transfer system are being made and then 
finally the gel is carefully placed on the bottom stack containing PVDF with the 
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support of the filter paper at the back of the gel and the used the roller to remove 
the bubbles. Following this, the top stack was placed on and the machine was 
started at 20 V for 7 min transfer. 
After the transfer was completed, the machine was disassembled and the PVDF 
membrane transferred to the tray with the help of forceps. The PVDF membrane 
was washed gently with distilled water up to three times to wash away any salts 
and any gel residues. The membrane was examined visually for proper transfer 
of proteins by looking at the transfer efficiency of pre-stained protein standard. 
However, to better examine the transfer efficiency and band separation, the 
PVDF membrane was also stained with Amido black or Ponceau stain (Sigma-
Aldrich UK). Next, to prevent non-specific reactivity, the membrane was blocked 
with either, 5% non-fat dry milk or 5% BSA prepared in 1X TBST (washing 
buffer), a mixture of tris-buffered saline (TBS) and Polysorbate 20 (also known as 
Tween 20) in based blocking buffer for 1h at room temperature with mild shaking. 
Primary antibodies were diluted in antibody blocking buffer according to 
manufacturer’s instructions, typically at 1 in 1000 dilution in 8-10 mL of blocking 
buffer. 
Following 1 h blocking, the blocking buffer was discarded off the membrane and 
primary antibody was added. Primary antibody incubation was performed at 4°C 
overnight with gentle shaking. The subsequent day, the membrane was washed 
three times with washing buffer, each wash for 5 min with gentle shaking. In the 
last washing step, 1 in 1000 dilution of anti-mouse or anti-rabbit IgG, the HRP-
linked secondary antibody was made in washing buffer. The washing buffer in the 
last washing step was discarded from the membrane and the diluted HRB-
conjugated secondary antibody was added. The membrane was incubated for 1-2 
h at room temperature with mild shaking. After incubation with secondary 
antibody, the membrane was washed three times with washing buffer for 5 min 
each with gentle shaking. In the last washing step, pierce ECL 2 western blotting 
substrate (Thermoscientific) was taken out of fridge and equal volume each of 
solution A and solution B on the membrane and incubated for 1-2 min and then 
the membrane was taken and place on clean, clear and transparent flat bag and 
removed the bubbles, the membrane while inside the flat bag was taken 
straightaway to the gel documentation machine for the visualization of bands. 
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Syngene G-BOX was used to capture the images with the attached camera. The 
images were saved in TIFF file format for later analysis typically involving the 
calculation of relative abundance via integrated optical densitometry analysis of 
each protein band. To establish a loading control, the same blot was stripped off 
from previous antibodies by incubating the membrane with stripping buffer and 
then blocked for one hour and reprobing with the β-actin antibody. 
2.4.6 Densitometry 
Densitometry was calculated using Image J software and Densitometry 1 
Channel plugin. All values shown are the protein of interest divided by the 
respective β-actin loading control value. 
2.4.7 Cell viability assay 
The CellTiter-Glo® 2.0 assay kit (Promega) was used to determine cell viability, 
as described by the manufacturer. Briefly, cells were seeded in a luminometer 
compatible 96-well plate and allowed to adhere for 18-24 h. Following treatments 
using different concentrations of the compounds, the plate and its contents  were 
equilibrated to room temperature for approximately 30 min, a volume of CellTiter-
Glo 2.0 reagent equal to the volume of cell culture medium present in each well 
the contents were then mixed for 2 min on an orbital shaker to induce cell lysis 
and the plate was then incubated at room temperature for 10 min to stabilize the 
luminescent signal and finally the luminescence was recorded using luminometer 
(MODULUS, Promega). The luminescent signal is proportional to the amount of 
ATP in the sample, which indicates the presence of metabolically active cells. 
2.4.8 siRNA transfection  
siRNA was used to knockdown NRF2 (Qiagen). For siRNA transfection, cells 
were seeded in triplicate either in 96-well plates in triplicate (2×104) or in 24-well 
plates (0.5 × 105 cells) or in 60 mm plates (0.5 × 106 cells), and allowed to grow 
for 24 h. Following this, cells were co transfected using either 7 pmol of siRNA 
(96-well plate) or 20 pmol siRNA and 1 μg of different PGL3 promoter constructs 
(24-well plates) or 75 pmol siRNA only (60 mm plates) or and incubated for a 
further 24 h or 48 h or as required. Cells transfected in 96 well plates were 
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processed for either cytotoxicity assay, ROS assay or total GSH assay, those in 
24-well plate were further processed for dual luciferase assay while those in 
60 mm plates were harvested for immunoblotting. In all cases, scrambled siRNA 
was used as a control while transfection was performed using Lipofectamine 
3000 (Life Technologies) according to manufacturer’s instructions. 
2.4.9 Luciferase activity assay 
Luciferase activity was measured using the Luciferase Assay System (Promega), 
according to the manufacturer’s instructions to determine NRF2 dependent 
transcriptional antioxidant response following different treatments, stable clones 
of MCF7 cells carrying PGL3 vector with a cloned 8 copies of cis- AREs reporter 
construct (AREc32). Briefly, MCF7-AREc32 cells were seeded in luminometer-
compatible 96 well plates at a density of 1.5×104 cells per well and allowed to 
attach for 18 h. Next day, cells were washed with pre-warmed PBS and 100 µL of 
media containing the required treatments was added and further allowed to 
incubate for 24 h, at the end of treatment, cells in each well of a 96-well plate 
were washed with PBS and lysed in 30 µL of the lysis buffer provided with the kit. 
A 5 µL portion of the lysate was mixed with 25 µL of Luciferase assay reagent 
and the luminescence was quantified (McMahon et al., 2014) using luminometer 
(MODULUSTM, Promega). To normalise the luminescence signal, 2 µL portion of 
the lysate was mixed with 98 µL Bradford reagent assay to estimate protein 
content using to Bradford assay.  
2.4.10 ROS Detection 
ROS detection assay was performed by using 2′,7′-Dichlorofluorescin diacetate 
(DCFDA) staining (Sigma). Briefly, cells were seeded in triplicate at a density of 
0.2 × 105 cells/well of opaque flat-bottom 96-well tissue culture plates in 100 μL 
media without phenol red and allowed to grow for 18 h. Following this, cells were 
either left untreated or treated at a desired time points. A 50 mM stock solution of 
DCFDA was added to each well containing 100 μL pre-existing media to achieve 
a final concentration of 25 μM and incubated for 45 min at 37°C. Fluorescence 
signal intensities indicating ROS levels were recorded by taking readings using 
96-well fluorescent multiplate reader (MODULUS, Promega) using excitation and 
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emission spectra of 485 nm/535 nm. To normalise the fluorescence signal, cells 
in the same wells were stained with Coomassie brilliant blue stain (Sigma) for 1 h 
and washed with distilled water and 10% SDS solution was added to release the 
absorbed dye for 10 min while shaking. The absorbance values at 595 nm were 
then recorded using a multiplate absorbance reader (MODULUS, Promega) data 
used after normalising the fluorescence values. 
2.4.11 Dual-Luciferase-based promoter Assay 
To perform Dual-Luciferase based HER family promoter assay, the HER1 and 
HER4 promoter region was first amplified from the human genomic DNA using 
promoter-specific primers, cloned into the luciferase reporter vector, PGL-3 basic, 
and transfected into human epithelial cell lines, PEO1, OVCAR3 and SKOV3 (For 
all the data of HER1 and HER4 promoter cloning, see CHAPTER 3). Transfection 
of the HER1 and HER4 promoter reporter vector was carried out using 
Lipofectamine 3000 (Thermoscientific, UK) and the vector pRL-CMV was used as 
an internal control for transfection efficiency. Each transfection for a particular 
experiment was performed in triplicates. Transfection was carried out in 24-well 
format by first seeding the cells at a density of 5 x 104 for 24 h prior to 
transfection. At the time of transfection, the cells were 70-90% confluent. 
Old media was removed and cells were gently rinsed with 1 mL of pre-warmed 
PBS. 0.5 mL of serum free and antibiotic free media (Opti-MEM®, Invitrogen, UK) 
was added per well and the plate placed back in the incubator. For transfection, 
the DNA to be transfected i.e. pHER1/PGL3 and prHER4/PGL3, the empty PGL3 
basic vector and the internal control vector (pRL-CMV) and the transfection 
reagent (Lipofectamine 3000, Invitrogen, UK) were taken out and placed in the 
hood. For each well, 0.5 μg of DNA to be transfected (either prHER1/PGL3 or 
prHER4 or empty PGL3 basic vector) and 0.1 μg of pRL-CMV were mixed 
together with 25 μL of serum free and antibiotic free media Opti-MEM®. Next, 1 
μL of the transfection reagent was mixed with 25 μL of Opti-MEM® in a separate 
eppendorf tube. The tubes were incubated for 5 min and their contents mixed 
together and further incubated for 20 min to allow the DNA complex to form. 
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After the incubation, 0.4 mL of Opti-MEM® was added to the tube containing the 
DNA complex and gently mixed together. The contents of this tube were added to 
each well and the plate incubated for 5 h for transfection to take place. After 
incubation, the old media was removed and 0.5 mL of pre-warmed cell culture 
media was added and plates incubated for at least 16 h before further 
experiments and analysis. 
After 16-24 h of transfection, the old media was discarded, cells rinsed once with 
pre-warmed PBS and treatments with the required drug solutions in media were 
performed. On the day of performing the luciferase assay, 1x passive cell lysis 
buffer (Dual Luciferase assay kit, Promega, UK) was prepared. The 24-well plate 
was taken out of incubator, old media discarded, each well gently rinsed with 0.5 
mL of PBS, and 125 μL of the 1x passive lysis buffer added to each well. The 
plates were placed on the shaker and gently rocked (50 rpm) for 30 min to form 
the cellular protein lysates. In the meantime, the Luciferase assay reagent (LAR-
II, Promega) was reconstituted and by means of the multi-channel pipette for 
faster and accurate pipetting, 50 μL of this reconstituted reagent was added per 
well of black bottom, opaque 96-well plate (Sigma-Aldrich). The LAR-II reagent 
provided a substrate of luciferase activity generating a stabilised luminescent 
signal with the addition of the cell lysate. 
Next, 20 μL of the cell lysates from each transfection (done in triplicates) were 
transferred (in quadruplets) to each well of the 96-well plate with the added LAR-
II reagent with the help of multi-channel pipette. Hence, four independent 
readings were taken in 96-well plate for each transfection done in triplicates. After 
the addition of cell lysate, the plate was immediately placed in the 96-well 
Luminometer (Modulus template® Turner biosystems) for measuring the 
luminescence. 
Dual luciferase assay program was set up with 2 s of pre-measurement delay 
followed by measuring luminescence via the inbuilt luminescence filter at 0.5 
second measurement period per well. After the reading, the plate was taken out 
and 50 μL of the reconstituted Stop and Glo® was added per well using a 
multichannel pipette. The addition of the second reagent stopped the 
luminescence generated by Firefly luciferase (sourced from prHER1/PGL3 or 
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prHER4/PGL3) and provided a substrate for Renilla luciferase (sourced from 
pRL-CMV). The plate was returned to the luminometer and another reading was 
taken as above. The first reading (After LAR-II addition) was normalised to the 
second reading (after Stop and Glo® addition). The means of the luminescence 
signals acquired from the quadruplet treatments were taken, with each 
transfection done in triplicates. The mean values were normalised to the mean 
value of untreated controls for that experiment and expressed as 1. 
2.4.12 Measurement of Total Glutathione (GSH) 
The measurement of total GSH was performed using GSH/GSSG-Glo™ Assay 
(Promega) according to manufacturer’s protocols. Briefly 1x104 cells where 
seeded in luminometer-compatible 96-well plates and allow to grow overnight at 
37°C in a 5% CO2 culture incubator. The following day, the cells were treated 
accordingly. Following this, the contents in the cell were removed. Then 50 µL 
per well of GSH Lysis Reagent, that was prepared no longer than 30 min before 
use, was added. The lysate was shaken at room temperature for 5 min on a plate 
shaker. Following this, 50 µL per well of Luciferin Generation Reagent was added 
to all wells. The Luciferin Generation Reagent was prepared within 30 min before 
use. The plates were then shaken briefly and incubated at room temperature for 
30 min. Finally, 100 µL per well of Luciferin Detection Reagent was added and 
the plates were shaken briefly, waited for 15 min to stabilize the luminescent 
signal and finally the luminescence was recorded using luminometer (MODULUS, 
Promega). 
2.4.13 Statistical Analysis 
All statistical analyses were performed using GraphPad Prism Software version 
6. Test for normality of data was determined by Shapiro-Wilk and D'Agostino-
Pearson tests. The significance (value) of differences of pooled results was 
determined by independent t-tests, one-way or two-way analysis of variance 
(ANOVA) followed by post hoc Tukey’s tests. The reason for choosing these 
types of analysis in this study is that, the study wanted to find out the differences 
between two unrelated groups or the means of three or more independent 
(unrelated) groups or  compares the mean differences between groups that have 
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been split on two independent variables so as understand if there is an interaction 
between the two independent variables on the dependent variable, hence the 
choice of the independent t-test (also called the two sample t-test), one-way 
ANOVA and two-way ANOVA respectively. Independent t-test is an inferential 
statistical test that determines whether there is a statistically significant difference 
between the means in two unrelated groups. The one-way ANOVA is used to 
determine whether there are any statistically significant differences between the 
means of three or more independent (unrelated) groups. It compares the means 
between the groups that are of interest and determines whether any of those 
means are statistically significantly different from each other. It is important to 
note that the one-way ANOVA is an omnibus test statistic and cannot tell which 
specific groups were statistically significantly different from each other only that at 
least two groups were. To determine which specific groups differed from each 
other post hoc tests need to be applied. Post hoc tests attempt to control the 
experiment wise error rate (usually alpha = 0.05) in the same manner that the 
one-way ANOVA is used instead of multiple t-tests. Post hoc tests are termed a 
posteriori tests that are performed after the events; the events in this case are 
after independent t-test and one-way ANOVA. The two-way analysis of variance 
is an extension to the one-way analysis of variance. The Assumptions in two-way 
ANOVA are when the populations from which the samples were obtained are 
normally or approximately normally distributed, the samples are independent, the 
variances of the populations are equal and the groups must have the same 
sample size.  Data presented are the means ± S.D. of n = 3 independent 
experiments performed either in triplicates or in quadruplicates. Significant 
difference was defined as (ns: P > 0.05*: p<0.05, **: p<0.01, ***: p<0.001 and ****: 
p<0.0001), ns= not statistically different, *= statistically significant (*< **<***<****). 
For western blots, images are representative of at least two independent 
experiments for each condition.  
2.4.14 Imaging and Analysis 
Images were camera captured using Syngene G-BOX Chemi-XX6 Gel 
Documentation System (Synoptics, UK). Syngene has unique flatfix technology 
which eliminates saturation from images by using an Auto Aperture feature. The 
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images were saved in TIFF file format and analysed typically involving the 
calculation of relative abundance via integrated optical densitometry analysis of 
each protein band. Densitometry was calculated using Image J software and 
Densitometry 1 Channel plugin (NIH, USA). The band intensities of all the 
untreated/scrambled siRNA and treatment groups were normalized on the band 
intensities of their corresponding β-actin loading controls. The normalized data 
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Cloning of the Proximal Promoter 
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3.1 Abstract 
Human HER1 and HER4 are members of the HER family receptors, including 
HER2 and HER3. The HER receptor family of RTKs are one of the most 
extensively studied for their role in aetiology and development, human cancers. 
The cloning of proximal regulatory regions of HER1 and HER4 genes is reported 
here. Approximately 1.5 kb and 1.3 kb DNA fragments encompassing the 
proximal promoters of HER1 and HER4 genes, respectively, were each placed 
upstream of the luciferase reporter gene in the pGL3 vector to be prHER1 and 
prHER4, respectively. These were used to transiently transfect a panel of ovarian 
cell lines (OVCAR3, PEO1 and SKOV3), in order to examine their constitutive 
expression. Both prHER1 and prHER4 showed a high and differential basal level 
of expressions in all the cell lines tested when compared to the control pGL3 
vector. This suggests the functionality of the promoter constructs and their 
feasibility as tools to study the regulation of expression of HER1 and HER4 
receptors. 
3.2 Introduction 
The uniquely close relationship between the members HER receptor family 
suggests that they have evolved from a common ancestral gene. All the genes 
have been linked to cancer transformation. Both HER1 and HER4 are the cellular 
homolog of the oncogene v-erbBB and are all reported to be overexpressed in 
cancers including ovarian. The majority of HER1 and HER4 activities involves 
transcriptional activation, tumour cell proliferation, growth suppression (Jones, 
2008, Sheng and Liu, 2011).The analysis of mechanisms controlling the 
regulation of expression of genes for growth factor receptors is therefore 
important for understanding of the malignant state (Tal et al., 1987). 
Studies have reported that identification of promoter sequences and transcription 
factors essential for transcriptional regulation of the gene may greatly contribute 
to understanding its molecular mechanisms of regulation (Takakura et al., 1999, 
Li et al., 2010). Expression of a target gene in both prokaryotic cell and eukaryotic 
cell has been a common research goal of researches of genes of interest (Cao et 
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al., 2017), since initiation of the genetic engineering by Herbert Boyer and 
Stanley N. Cohen in 1972 (Cohen et al., 1973). PCR has been essential for gene 
cloning because it can provide target gene fragments in vitro in large amount and 
short time without the limitation of restriction sites. The established strategy for 
the construction of recombinant expression vector includes two cloning steps: 
PCR cloning (cloning of PCR amplified target gene into cloning vector) and 
restriction enzyme mediated sub-cloning of the target gene from cloning vector 
into expression vector (Cao et al., 2017). Here in this chapter, the core proximal 
promoter regions of HER1 and HER4 genes were cloned and their activity was 
examined in ovarian cancer cells. Thus, the study in this chapter was undertaken 
to address the following aim and objectives.  
3.3 Aims and objectives 
3.3.1 The aim 
The main aim of this chapter is to clone human HER1 and HER4 gene proximal 
promoters as gene reporter systems.  
3.3.2 The objectives are: 
1. To retrieve approximately 1.5 kb and 1.3 kb of the proximal promoter 
regions of human HER1 and HER4 genes respectively  
2. To analyse and identify the putative NRF2 binding sites present in each 
promoter 
3. To design the primers and then clone the promoter regions of human 
HER1 and HER4 genes 
4. To generate functional HER1 and HER4 proximal DNA promoter gene 
reporter constructs as novel tools for the study of the transcriptional 
regulation of HER1 and HER4. 
The generation of functional proximal core promoters of human HER1 and HER4 
gene reporter constructs would be valuable novel tools in examining NRF2 as an 
important transcriptional regulator of the HER family genes in ovarian cancers. 
The findings of such a study may partly explain the overexpression of HER family 
receptors in cancer and may have implications to the success and/or failure of 
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HER targeted therapies involving RTK inhibitors. Chemotherapies are limited 
when tumour cells circumvent action of therapeutic agents’ due to the 
readjustments in coexpression of the receptors, their ligand binding dynamics, or 
changing preference for the dimerizing partner (Nagumo et al., 2009a, Goltsov et 
al., 2014b) suggest that the anticancer effect of these agents might be better 
predicted by effectively limiting HER receptor family expression at the DNA level 
or at least identifying a common regulatory centre of their transcription. Thus, the 
identification of factors such as NRF2 that coordinately mediate or modulate the 
transcriptional expression of HER receptors will be vital (Khalil et al., 2016b) . 
Consequently, the functionality of the promoter constructs was examined for 
basal activity, when the cloned promoters were transiently transfected in a panel 
of ovarian cell lines with a differential basal level of NRF2, 
PEO1>SKOV3>OVCAR3 (Khalil et al., 2015). 
3.4 Results 
3.4.1 Putative NRF2 transcription factor binding sites found along 5’ 
upstream region of in promoters HER1 and HER4 at 75% cut off score 
Approximately 1.5 kb and 1.3 kb of the proximal promoter regions of HER1 and 
HER4 gene sequences respectively were retrieved from Ensembl Genome 
database (http://www.ensembl.org/index.html). The sequences were subjected to 
bioinformatics analysis (Figure 3.1) insilico; (http://consite.genereg.net/cgi-
bin/consite) (Sandelin et al., 2004) to ascertain the putative NRF2 binding sites 
present in each of the promoters. The sequence was analysed at 75% stringency. 
The 75% stringency was chosen as a fine balance between the identification of a 
putative and likely functional binding sites as against the possibility of predicting 
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Sequence From To Score Strand 
NRF-2    CACTCCAGGT 1 10 6.292 - 
NRF-2    AAATTCCTGT 321 330 6.335 - 
NRF-2    GCAGGAAGCA 591 600 6.091 + 
NRF-2    AAAGGAACAG 683 692 6.514 + 
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    1 CACTCCAGGT ACTAGCCAAG GACTACAAAA TCAACGTGAA TGTCAGCTTT 
 
   51 TGTATCAAAA GCTCAAAGGA GAAACTCAAA CTTTACATAG ATGTCCCATG 
 
  101 AAGATGTTCA GCAAACCCAT TCTTCTCTGT TCCCTGGAAT CCATCCCAGT 
 
  151 ATTGTGCTAT GTGTGTGTCT AGTAATTCTT TACAAAAAGC TCTGTTTCTT 
 
  201 GTGATGCTAT CAGATCACAT TGAAGAATAT ACAAGCCGTA CTATGAAGGC 
 
  251 TGTTGTCTCA TATAGTCCTA ACGTAGTGAG AACTGATGTT CTTACATGCT 
 
  301 GTCTTTTTGG GCACTCAAAG AAATTCCTGT ACAGTCTTAC AAATCAGTTG 
 
  351 TAGCTTAAAT TGATTTGTGT TGTGACTTGT ACACACAGGT CACATTCCCT 
 
  401 TGACAGAAAA TATAGTTTAA AACCAAATTT GCAGCCCTTG TTAAGTGAAT 
 
  451 GCACAGGACT TTATTGTATT CAGGTCTTTT ATTGTAAGAC TCACTCCTGT 
 
  501 CTTCATTTTA TGTTCCACTG TTGTGCTTCC CATTTGCCTT TCTCTAGTTT 
 
  551 TGTTTTCTGT GTTTCTACGG ACTGCTCTCA GCCCAGGTGT GCAGGAAGCA 
 
  601 CACACATGCC TGCAGAGCCT TCATGGCCTC TGCATTCAGG GCATGACTTC 
 
  651 AACGCACAGT GGCTGTACTG ATTTGTTAAA ACAAAGGAAC AGATTACTTC 
 
  701 TCCTAATTCA CAGGGAAGTT CCAGGTTGTG CGGGCAGTGA GCAGACCTGT 
 
  751 GTCTGTCTGC GCTTGCCCTG GTGAAAAACC CCACCGTTCA GGCTGCAGGG 
 
  801 TGCGAGACCC AGGCACAAAC ATTTTGCTGG ATGAGGAGGA AAGATGTAAG 
 
  851 GTTGCTCCCC TTCAGAGACA GCAAAGGGCA GGTCTGTAGC TTCACTTACT 
 
  901 TCAGGATTGT GATTTTTGAC AGAGCCGAGA GATCAGGGTT GTTGAACCAG 
 
  951 GCCTGAAGGT CCTAGTGAAT CTCGTGAAGA GAGGAGGGGT CTGGCTGTAA 
 
 1001 CATGGACCTA GAGGACATTT TTACTGCAGG AGAAGGAACA GTGGGGATGG 
 
 1051 GGTGGACTTG CCAAAGGAAT ATAGCTCAAG TTCCTGCAGC CCAAAAAAGC 
 
 1101 TCAGTTTCTT TTGGCCAAAG CTTCCGCGAG TTTCCCTGGC ATTTCTCCTG 
 
 1151 CGGGAGCTAC AGGGGCAGTG GGACACTTAG CCTCTCTAAA AGCACCTCCA 
 
 1201 CGGCTGTTTG TGTCAAGCCT TTATTCCAAG AGCTTCACTT TTGCGAAGTA 
 
 1251 ATGTGCTTCA CACATTGGCT TCAAAGTACC CATGGCTGGT TGCAATAAAC 
 
 1301 ATTAAGGAGG CCTGTCTCTG CACCCGGAGT TGGGTGCCCT CATTTCAGAT 
 
 1351 GATTTCGAGG GTGCTTGACA AGATCTGAAG GACCCTCGGA CTTTAGAGCA 
 
 1401 CCACCTCGGA CGCCTGGCAC CCCTGCCGCG CGGGCACGGC GACCTCCTCA 
 
 1451 GCTGCCAGGC CAGCCTCTGA TCCCCGAGAG GGTCCCGTAG TGCTGCAGG 
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Sequence From To Score Strand 
      
NRF-2    CAAGGAAGGG 334 343 7.140 + 
      
NRF-2    TCCGTAAGCG 875 884 6.049 + 
      
NRF-2    GAGGGAAGAC 939 948 6.142 + 
      
NRF-2    AGCTTCCCCT 989 998 6.091 - 
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    1 GAGTGGGAAA TGGAGATCAA GGTCTCAAAT GAAAGGCAGG GTGGTTTGAT 
 
   51 TTTTAAGCTC CCCTGATACT TTTTATTTAT ATATTTGCTG CTTCTAGAAA 
 
  101 AACCAAAAAA GGAAAGTGAT TCATACATAG AATGCCTGTA CAAATAGCAA 
 
  151 ACCAATAACT ACCCCCAGCA GATTCTGGCC CTTGCCAGGG TGCGGTTTCA 
 
  201 GAGCTGTAAA AGGCAAGGGA TATGTACATT GAAATGACCC AGTCCCAGAA 
 
  251 TATTTTAGAT TCAGAAAAGG TCAGAGACTT TCGTAACTAG CAATGACCTC 
 
  301 CAGATTAGGG ACCATGAATG TGCAGAGTGA GGACAAGGAA GGGGCCTAAA 
 
  351 GCTGGGTCTA CTGTAGAATA AACAGAATCA TTTAAGGTTA ATTATGTTCT 
 
  401 GATGTGGCCT CCTTAAATTC TTTCAGGCTG GGGACAATTT CTAGCCCTTT 
 
  451 AAGATCAAAT CAGTGGCTTT GGACTAGAAT CTGCTTAATA AGAATGAACT 
 
  501 CCAAAGGTGA AAAAAAAACA TAAAATCTAA AAATCAAAGG ATATGCCTTT 
 
  551 ATAAATGTGA AAGTTTAGTT TGGCTCAATG TTGGTCAGTT TAGAAATGTG 
 
  601 GGAGTAATCG GAGAGATGGC ATAACTGGGG GCGGGAGGCG GGGCGGTGAT 
 
  651 TATACCCCTA CCACTACCTA ATCCTCAGGG GCTACCAGTT ACTTGCTGTA 
 
  701 CACACTTTTA AAGTACTTTC TAATTGTGGA CCATGAGTGG CAGAGTACTG 
 
  751 CGGGCGGAGG CTTTTTGCTG AAAGCAACAT TGACTTTTAT TTCTAGGGAA 
 
  801 AGTCTTGTCT GTAGATGAGC ACCGTGGGGC AACGGAGAAA ATGCTGACTT 
 
  851 TCTTGTTTAA AAAAAAAAAA AATTTCCGTA AGCGGCCCTC CAATGGTCCG 
 
  901 TCCACTCAGC AGGCCAGCTG TCCCAGGCCT CTGCCAGGGA GGGAAGACGA 
 
  951 GTGCTTCAGT GCATGGCTTC GGTGAGCCCT TTAAATCCAG CTTCCCCTGC 
 
 1001 CCCCACCAAG AGGCTCCCTT TCCCTGACAG GTGTTTTCCC AACTCCGGAG 
 
 1051 GCCCAGGATT TTGGGGAGTG GCTGAGCCAA TAAGATTTCC CTTTGGAAGG 
 
 1101 GGGGGGGAAG GGCGTGGCTA GTTGGGTCAG AGCATGGGCG GGGTTTGCGC 
 
 1151 GGCTGAGCAG AGCCGGCCTG GTTGCGTGGA GGGTTGTTTT ATTCCCACCG 
 
 1201 CCCCCCGCAC CTTTTTTTTT TTTTTTTCTG GAGTCTTATT AATTTCTCTG 
 
 1251 TGGGCTGCAG CTGGAGACCG CGGAGCGCTG GAAATGACGC TCGGAGCTTT 
 
 1301 AATTACCGCA GCCGCCGGAC AAGTGTGAGG AAAGCTGAGA G 
 
b. Putative transcription factor binding sites found along HER4 promoter 
Figure 3.1: An in-silico analysis of HER1 and HER4 promoter sequences. (a) 1.5 kb promoter region of 
HER1 gene was obtained from the database (ensemble.org) and subjected to transcriptional factor binding 
prediction program (http://consite.genereg.net/cgi-bin/consite) to predict for putative NRF2 binding sites as 
indicated. (b) The same analyses were performed for HER4 promoter. In (a) and (b), +1 indicate the 
transcriptional start site (predicted from (http://www.cbs.dtu.dk/services/Promoter/) sequences highlighted in 
blue show NRF2 binding sites as predicted by ConSite, and sequences in bold brown represent transcription 
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3.4.2 Designing primers for PCR 
Following the in-silico analysis where the putative NRF2 binding site was 
analysed from the promoter sequence of the HER1 and HER4 gene, specific 
primers to amplify this region were designed and analysed for physical properties 
using primer 3.0 (https://www.ncbi.nlm.nih.gov/gquery/?term=primer+blast) and 
OligoAnalyzer 3.1( (https://eu.idtdna.com/calc/analyzer). In order to maximise the 
chance of capturing the promoter elements upstream of the promoters, the 
reverse primer was constrained to be within the 5’ UTR and situated as close as 
possible to the transcription start codon. The forward primers were constrained to 
be within a tRNAlys sequence approximately 1500 bp 5’ of HER1 and 1300 bp 5’ 
of HER4 genes, respectively. In order to ensure primer specificity, stringent 
primer design parameters were utilised. The Nucleotide BLAST tool from Human 
Genome at National Centre for Biotechnology Information (NCBI, 
https://www.ncbi.nlm.nih.gov/projects/genome/guide/human/) was used to 
perform a genome-wide homology searches and alignment. 
HER1 promoter primers: 
Forward: CACTCCAGGTACTAGCCAAGG 
GC: 57.1, Tm: 56.8 
Kpn1 forward: GG-GGTACC- CACTCCAGGTACTAGCCAAGG 
Reverse: GTG CCA TTA TCC GAC GCT G 
GC: 57.9, Tm: 56.4 
XhoI Reverse: GTG CCA TTA TCC GAC GCT G-CTCGAG-CGG 
HER4 Promoter Primers: 
Forward: GAGTGGGAAATGGAGATCAAGGTC 
GC: 50, Tm: 57.2 
XhoI Forward: CCG- CTCGAG-GAGTGGGAAATGGAGATCAAGGTC 
Reverse: GGA CAA GTG TGA GGA AAG CTG AGA G 
GC: 52, Tm: 59.2 
NcoI Reverse: GGA CAA GTG TGA GGA AAG CTG AGA G-CCATGG-CATG 
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3.4.3 Polymerase chain reaction (PCR) 
Human genomic DNA was used as a template to obtain PCR amplified products 
using the specific primers designed for HER1 and HER4 genes. The expected 
size 1.5 kb and 1.3 kb (Figure 3.2) were extracted and gel purified using the 
Qiagen extraction kit. The PCR products were run and extracted from agarose 
gel (Qiagen), digested using the restriction enzymes (Promega) Kpn1 and XhoI 
for HER1 and XhoI and NcoI for HER4, and ligated into PGL3 vector (Promega) 
to create HER1 and HER4 promoter constructs prHER1 and prHER4 
respectively. These are HER1 and HER4 gene reporter constructs driving the 
expression of luciferase gene for utilisation in dual luciferase reporter assay 
(Promega) (Figure 3.3). More details of the cloning, verification and evaluation of 




Figure 3.2: A 1% agarose gel purification of amplified prHER1 and HER4. 25 μL of PCR products were 
run on gel and 5 μL of DNA hyperLadder 1 kb was used, the gel was run at 100 V for 1 h (Note: lane 1 is a 
ladder, 2 and 3 are for prHER1 and 4 and 5 are for prHER4) 
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3.4.4 Excision of HER1 1.5 kb and HER4 1.3 kb gene promoter sequence 
bands from Agarose Gel 
The amplified HER1 and HER4 gene promoter fragments were excised from their 
respective gels, and subsequently weighed prior to gel purification, in accordance 
with the QIAquick Gel Extraction Kit Protocol according to manufacturer’s 
instructions and as described in the (Chapter 2)  
3.4.5 Ligation, transformation, clonal selection, glycerol stock and Miniprep 
of pGem-T Easy-HER1 1.5 kb and pGem-T Easy-HER4 1.3 kb 
In order to explore and propagate the cloning of (HER1 1.5 kb and HER4 1.3 kb) 
PCR product, the promoter sequences were respectively ligated into the pGEM-
T-Easy Cloning Vector (Promega) (Figure 3.3) in accordance with the 
methodology. Successful growth of bacterial colonies following bacterial 
transformation (with the respective ligation mixtures), spread plating and 24 h of 
incubation were observed. Both blue and white colonies were present. White 
colonies denoted successful ligations as transformed bacteria that have 
assimilated the pGEM-T Easy Vector (Promega) contain the respective insert 
DNA. Blue colonies denoted unsuccessful ligations as transformed bacteria that 
have assimilated the pGEM-T Easy Vector (Promega) do not contain the 
respective insert DNA. 
A single white bacterial colony with respect to each transformation was inoculated 
into 15 ml centrifuge tube (Corning Incorporated) containing 5 ml of LB-Media 
with Ampicillin selection. Inoculated cultures were grown in a shaking incubator at 
37oC for 24 h. Following 24 h of incubation, duplicate glycerol was made and 
stored at -80oC in accordance with the protocol. Remaining bacterial culture was 
used to isolate and purify high-quality plasmid DNA from the bacteria using 
Miniprep (Isolate Plasmid Mini Kit - Bioline). 
3.4.6 Restriction digests of pGem-T Easy-HER1.5 kb and pGem-T Easy-
HER4 1.3 kb constructs and DNA sequencing 
The restriction digest was carried out on the Miniprep DNA samples to further 
verify the successful ligation and cloning of the gel purified DNA fragments of 
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HER1 and HER4 genes. The EcoR1 restriction enzyme (Promega) was used to 
perform a single enzyme digest of the pGEM-T Easy-HER1 and -HER4 gene 
constructs. This was possible owing to multiple EcoR1 recognition sites on both 
sides of the multiple cloning regions in the pGEM-T Easy Vector. Figures 3.4A 
and 3.4B show successful restriction digest. Linearised pGEM-T-Easy vector 
fragments are clearly visible on the agarose gel.  
 
Figure 3.3:  pGEM®-T Vector Map and Sequence Reference Points. pGEM®-T Easy Vectors which are 
linearized vectors with a single 3´-terminal thymidine at both ends. The T-overhangs at the insertion site 
greatly improve the efficiency of ligation of PCR products by preventing recircularization of the vector and 
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Figure 3.4: EcoR1 restrictions digest of purified pGEM-T Easy-HER1 and HER4 (1.5 kb and 1.3 kb) 
plasmid DNA. Gel was ran for 45 min at 80 volts (a) Lane 1, is 2 µL of 10 kb DNA Hyper ladder I (Bioline). 
Lanes 3, 5, 7 etc, 5 µL of pGEM-T Easy-HER1 1.5 kb restriction digest mixture. (b) Lane 1, is 2 µL of 10 kb 
DNA Hyperladder I (Bioline). Lanes 3, 5, 7 and 9, are 5 µL of pGEM-T Easy-HER4 1.3 kb restriction digest 
mixture.  
Thus, the successful restriction digest of the Miniprep samples signified that 
insert ligation into pGEM-T Easy Vector (Promega) was also successful.  
3.4.7 Restriction digests of PGL3 prHER1.5 kb and prHER4 1.3 kb for sub-
clone to PGL3 vector 
The restriction digest was carried out on the DNA samples of PGL3, prHER1 and 
prHER4 in order create to a sticky end compatible for its respective PGL3 
vectors. HER1 promoter was digested using KpnI and XhoI restriction enzymes at 
the 5’ and 3’ ends of the HER1 promoter respectively and HER4 was digested 
using XhoI and NcoI restriction enzymes at the 5’ and 3’ ends of the HER4 
promoter respectively. Two sets of PGL3 vector were digested with either KpnI 
and XhoI restriction enzymes suitable for ligating HER promoter or XhoI and NcoI 
restriction enzymes suitable for ligating HER4 promoter successful ligation and 
cloning. It is worth knowing that PGL3 vector (Promega) contain all these 
restriction enzymes used (Figure 3.5) 
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Figure 3.5. PGL3-Basic Vector circle map. Additional description: luc+, cDNA encoding the modified 
firefly luciferase: Ampr, gene conferring ampicillin resistance in E. coli; f1 ori, origin of replication derived 
from filamentous phage; ori, origin of replication in E. coli. Arrows within luc+ and the Ampr gene indicate the 
direction of transcription; the arrow in the f1 ori indicates the direction of ssDNA strand synthesis. (Figure 
from Promega) 
3.4.8 Ligation, transformation, clonal selection, glycerol stock and Miniprep 
of PGL3-HER1 1.5 kb and PGL3-HER4 1.3 kb  
In order to explore and propagate the cloning of (HER1 1.5 kb and HER4 1.3 kb) 
PCR product, the promoter sequences were respectively ligated into the PGL3 
cloning vector (Promega) in accordance with the methodology. Successful growth 
of bacterial colonies following bacterial transformation (with the respective ligation 
mixtures), spread plating and 24 h of incubation were observed. A single bacterial 
colony with respect to each transformation was inoculated into 15 ml centrifuge 
tube (Corning Incorporated) containing 5 ml of TB-Media with Ampicillin selection. 
Inoculated cultures were grown in a shaking incubator at 37oC for 24 h. Following 
24 h of incubation, duplicate glycerol was made and stored at -80oC in 
accordance with the protocol. Remaining bacterial culture was used to isolate and 
purify high-quality plasmid DNA from the bacteria using Miniprep (Isolate Plasmid 
Mini Kit - Bioline). 
Subsequently, the successful restriction digest of the Miniprep samples (Figure 
3.6) signified that insert ligation into PGL3 vector (Promega) was successful. 
Therefore, two eppendorfs each containing 10 µL elution buffer and a 5 µL 
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Miniprep sample (HER1 1.5 kb HER4 1.3 kb) were prepared and sequenced 
(DNA Sequencing and Services, College of Life Sciences, University of Dundee, 
Scotland). Following this, the Nucleotide BLAST tool from NCBI 
(http://blast.ncbi.nlm.nih.gov/Blast.cg) was used to perform a genome-wide 
homology search to verify the cloned and sequenced gene promoter (HER1 1.5 
kb and HER4 1.3 kb) as being HER1 and HER1.  
 
Figure 3.6: Restrictions digest of purified PGL3-HER1 and PGL3- HER4 (1.5 kb and 1.3 kb) plasmid 
DNA. Gel was ran 45 min at 80 volts (a) Lane 1, is 2 µL of 10 kb DNA Hyper ladder I (Bioline). Lanes 2-9 are 
for PGL3-pHER4, digested with NcoI/XhoI and DNA in lane 5 i.e the digested of lane 4) was chosen as the 
successful clone. Lanes 10-17 are for PGL3-pHER1, digested with KpnI/XhoI and all of them were 
successful clones. 
3.4.9 Verification of sequenced DNA by BLAST analysis of cloned and 
sequenced HER1 and HER4 gene promoters 
The Nucleotide BLAST tool from NCBI (http://blast.ncbi.nlm.nih.gov/Blast.cg) was 
used to perform a genome-wide homology search to verify the cloned and 
sequenced gene promoter (HER1 1.5 kb and HER4 1.3 kb) as being HER1 and 
HER4.  
3.4.7.1 Pairwise alignment of the cloned and sequenced DNA with retrieved 
HER1 and HER4 promoter sequences from Ensemble 
The EMBOSS needle nucleotide alignment tool (http://www.ebi.ac.uk/Tools/ 
psa/emboss_needle/nucleotide.html) was used to examine the homology 
between the sequenced DNA (HER1 1.5 kb and HER4 1.3 kb) and the retrieved 
HER1 and HER4 promoter sequences from Ensembl (Ensemble Genome 
Browser, 2016; European Bioinformatics Institute, 2012). Figures 3. 7 (A  and B) 
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shows a base pair identity and a 99.8% sequence similarity and the homology 
demonstrated by the sequence alignments verified that the HER1 and HER4 
promoters have successfully been cloned and sequenced. 
A 
EMBOSS_001         1 CACTCCAGGTACTAGCCAAGGACTACAAAATCAACGTGAATGTCAGCTTT     50 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001         1 CACTCCAGGTACTAGCCAAGGACTACAAAATCAACGTGAATGTCAGCTTT     50 
 
EMBOSS_001        51 TGTATCAAAAGCTCAAAGGAGAAACTCAAACTTTACATAGATGTCCCATG    100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001        51 TGTATCAAAAGCTCAAAGGAGAAACTCAAACTTTACATAGATGTCCCATG    100 
 
EMBOSS_001       101 AAGATGTTCAGCAAACCCATTCTTCTCTGTTCCCTGGAATCCATCCCAGT    150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       101 AAGATGTTCAGCAAACCCATTCTTCTCTGTTCCCTGGAATCCATCCCAGT    150 
 
EMBOSS_001       151 ATTGTGCTATGTGTGTGTCTAGTAATTCTTTACAAAAAGCTCTGTTTCTT    200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       151 ATTGTGCTATGTGTGTGTCTAGTAATTCTTTACAAAAAGCTCTGTTTCTT    200 
 
EMBOSS_001       201 GTGATGCTATCAGATCACATTGAAGAATATACAAGCCGTACTATGAAGGC    250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       201 GTGATGCTATCAGATCACATTGAAGAATATACAAGCCGTACTATGAAGGC    250 
 
EMBOSS_001       251 TGTTGTCTCATATAGTCCTAACGTAGTGAGAACTGATGTTCTTACATGCT    300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       251 TGTTGTCTCATATAGTCCTAACGTAGTGAGAACTGATGTTCTTACATGCT    300 
 
EMBOSS_001       301 GTCTTTTTGGGCACTCAAAGAAATTCCTGTACAGTCTTACAAATCAGTTG    350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       301 GTCTTTTTGGGCACTCAAAGAAATTCCTGTACAGTCTTACAAATCAGTTG    350 
 
EMBOSS_001       351 TAGCTTAAATTGATTTGTGTTGTGACTTGTACACACAGGTCACATTCCCT    400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       351 TAGCTTAAATTGATTTGTGTTGTGACTTGTACACACAGGTCACATTCCCT    400 
 
EMBOSS_001       401 TGACAGAAAATATAGTTTAAAACCAAATTTGCAGCCCTTGTTAAGTGAAT    450 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       401 TGACAGAAAATATAGTTTAAAACCAAATTTGCAGCCCTTGTTAAGTGAAT    450 
 
EMBOSS_001       451 GCACAGGACTTTATTGTATTCAGGTCTTTTATTGTAAGACTCACTCCTGT    500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       451 GCACAGGACTTTATTGTATTCAGGTCTTTTATTGTAAGACTCACTCCTGT    500 
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EMBOSS_001       501 CTTCATTTTATGTTCCACTGTTGTGCTTCCCATTTGCCTTTCTCTAGTTT    550 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       501 CTTCATTTTATGTTCCACTGTTGTGCTTCCCATTTGCCTTTCTCTAGTTT    550 
 
EMBOSS_001       551 TGTTTTCTGTGTTTCTACGGACTGCTCTCAGCCCAGGTGTGCAGGAAGCA    600 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       551 TGTTTTCTGTGTTTCTACGGACTGCTCTCAGCCCAGGTGTGCAGGAAGCA    600 
 
EMBOSS_001       601 CACACATGCCTGCAGAGCCTTCATGGCCTCTGCATTCAGGGCATGACTTC    650 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       601 CACACATGCCTGCAGAGCCTTCATGGCCTCTGCATTCAGGGCATGACTTC    650 
 
EMBOSS_001       651 AACGCACAGTGGCTGTACTGATTTGTTAAAACAAAGGAACAGATTACTTC    700 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       651 AACGCACAGTGGCTGTACTGATTTGTTAAAACAAAGGAACAGATTACTTC    700 
 
EMBOSS_001       701 TCCTAATTCACAGGGAAGTTCCAGGTTGTGCGGGCAGTGAGCAGACCTGT    750 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       701 TCCTAATTCACAGGGAAGTTCCAGGTTGTGCGGGCAGTGAGCAGACCTGT    750 
 
EMBOSS_001       751 GTCTGTCTGCGCTTGCCCTGGTGAAAAACCCCACCGTTCAGGCTGCAGGG    800 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       751 GTCTGTCTGCGCTTGCCCTGGTGAAAAACCCCACCGTTCAGGCTGCAGGG    800 
 
EMBOSS_001       801 TGCGAGACCCAGGCACAAACATTTTGCTGGATGAGGAGGAAAGATGTAAG    850 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       801 TGCGAGACCCAGGCACAAACATTTTGCTGGATGAGGAGGAAAGATGTAAG    850 
 
EMBOSS_001       851 GTTGCTCCCCTTCAGAGACAGCAAAGGGCAGGTCTGTAGCTTCACTTACT    900 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       851 GTTGCTCCCCTTCAGAGACAGCAAAGGGCAGGTCTGTAGCTTCACTTACT    900 
 
EMBOSS_001       901 TCAGGATTGTGATTTTTGACAGAGCCGAGAGATCAGGGTTGTTGAACCAG    950 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       901 TCAGGATTGTGATTTTTGACAGAGCCGAGAGATCAGGGTTGTTGAACCAG    950 
 
EMBOSS_001       951 GCCTGAAGGTCCTAGTGAATCTCGTGAAGAGAGGAGGGGTCTGGCTGTAA   1000 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       951 GCCTGAAGGTCCTAGTGAATCTCGTGAAGAGAGGAGGGGTCTGGCTGTAA   1000 
 
EMBOSS_001      1001 CATGGACCTAGAGGACATTTTTACTGCAGGAGAAGGAACAGTGGGGATGG   1050 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1001 CATGGACCTAGAGGACATTTTTACTGCAGGAGAAGGAACAGTGGGGATGG   1050 
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EMBOSS_001      1051 GGTGGACTTGCCAAAGGAATATAGCTCAAGTTCCTGCAGCCCAAAAAAGC   1100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1051 GGTGGACTTGCCAAAGGAATATAGCTCAAGTTCCTGCAGCCCAAAAAAGC   1100 
 
EMBOSS_001      1101 TCAGTTTCTTTTGGCCAAAGCTTCCGCGAGTTTCCCTGGCATTTCTCCTG   1150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1101 TCAGTTTCTTTTGGCCAAAGCTTCCGCGAGTTTCCCTGGCATTTCTCCTG   1150 
 
EMBOSS_001      1151 CGGGAGCTACAGGGGCAGTGGGACACTTAGCCTCTCTAAAAGCACCTCCA   1200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1151 CGGGAGCTACAGGGGCAGTGGGACACTTAGCCTCTCTAAAAGCACCTCCA   1200 
 
EMBOSS_001      1201 CGGCTGTTTGTGTCAAGCCTTTATTCCAAGAGCTTCACTTTTGCGAAGTA   1250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1201 CGGCTGTTTGTGTCAAGCCTTTATTCCAAGAGCTTCACTTTTGCGAAGTA   1250 
 
EMBOSS_001      1251 ATGTGCTTCACACATTGGCTTCAAAGTACCCATGGCTGGTTGCAATAAAC   1300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1251 ATGTGCTTCACACATTGGCTTCAAAGTACCCATGGCTGGTTGCAATAAAC   1300 
 
EMBOSS_001      1301 ATTAAGGAGGCCTGTCTCTGCACCCGGAGTTGGGTGCCCTCATTTCAGAT   1350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1301 ATTAAGGAGGCCTGTCTCTGCACCCGGAGTTGGGTGCCCTCATTTCAGAT   1350 
 
EMBOSS_001      1351 GATTTCGAGGGTGCTTGACAAGATCTGAAGGACCCTCGGACTTTAGAGCA   1400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1351 GATTTCGAGGGTGCTTGACAAGATCTGAAGGACCCTCGGACTTTAGAGCA   1400 
 
EMBOSS_001      1401 CCACCTCGGACGCCTGGCACCCCTGCCGCGCGGGCACGGCGACCTCCTCA   1450 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1401 CCACCTCGGACGCCTGGCACCCCTGCCGCGCGGGCACGGCGACCTCCTCA   1450 
 
EMBOSS_001      1451 GCTGCCAGGCCAGCCTCTGATCCCCGAGAGGGTCCCGTAGTGCTGCAGGG   1500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1451 GCTGCCAGGCCAGCCTCTGATCCCCGAGAGGGTCCCGTAGTGCTGCAGGG   1500 
 
EMBOSS_001      1501 GAGGTGGGGACCCGAATAAAGGAGCAGTTTCCCCGTCGGTGCCATTATCC   1550 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1501 GAGGTGGGGACCCGAATAAAGGAGCAGTTTCCCCGTCGGTGCCATTATCC   1550 
 
EMBOSS_001      1551 GACGCTG   1557 
                     ||||||| 
EMBOSS_001      1551 GACGCTG   1557 
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EMBOSS_001         1 GAGTGGGAAATGGAGATCAAGGTCTCAAATGAAAGGCAGGGTGGTTTGAT     50 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001         1 GAGTGGGAAATGGAGATCAAGGTCTCAAATGAAAGGCAGGGTGGTTTGAT     50 
 
EMBOSS_001        51 TTTTAAGCTCCCCTGATACTTTTTATTTATATATTTGCTGCTTCTAGAAA    100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001        51 TTTTAAGCTCCCCTGATACTTTTTATTTATATATTTGCTGCTTCTAGAAA    100 
 
EMBOSS_001       101 AACCAAAAAAGGAAAGTGATTCATACATAGAATGCCTGTACAAATAGCAA    150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       101 AACCAAAAAAGGAAAGTGATTCATACATAGAATGCCTGTACAAATAGCAA    150 
 
EMBOSS_001       151 ACCAATAACTACCCCCAGCAGATTCTGGCCCTTGCCAGGGTGCGGTTTCA    200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       151 ACCAATAACTACCCCCAGCAGATTCTGGCCCTTGCCAGGGTGCGGTTTCA    200 
 
EMBOSS_001       201 GAGCTGTAAAAGGCAAGGGATATGTACATTGAAATGACCCAGTCCCAGAA    250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       201 GAGCTGTAAAAGGCAAGGGATATGTACATTGAAATGACCCAGTCCCAGAA    250 
 
EMBOSS_001       251 TATTTTAGATTCAGAAAAGGTCAGAGACTTTCGTAACTAGCAATGACCTC    300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       251 TATTTTAGATTCAGAAAAGGTCAGAGACTTTCGTAACTAGCAATGACCTC    300 
 
EMBOSS_001       301 CAGATTAGGGACCATGAATGTGCAGAGTGAGGACAAGGAAGGGGCCTAAA    350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       301 CAGATTAGGGACCATGAATGTGCAGAGTGAGGACAAGGAAGGGGCCTAAA    350 
 
EMBOSS_001       351 GCTGGGTCTACTGTAGAATAAACAGAATCATTTAAGGTTAATTATGTTCT    400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       351 GCTGGGTCTACTGTAGAATAAACAGAATCATTTAAGGTTAATTATGTTCT    400 
 
EMBOSS_001       401 GATGTGGCCTCCTTAAATTCTTTCAGGCTGGGGACAATTTCTAGCCCTTT    450 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       401 GATGTGGCCTCCTTAAATTCTTTCAGGCTGGGGACAATTTCTAGCCCTTT    450 
 
EMBOSS_001       451 AAGATCAAATCAGTGGCTTTGGACTAGAATCTGCTTAATAAGAATGAACT    500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       451 AAGATCAAATCAGTGGCTTTGGACTAGAATCTGCTTAATAAGAATGAACT    500 
 
EMBOSS_001       501 CCAAAGGTGAAAAAAAAACATAAAATCTAAAAATCAAAGGATATGCCTTT    550 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       501 CCAAAGGTGAAAAAAAAACATAAAATCTAAAAATCAAAGGATATGCCTTT    550 
Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 81 
 
 
EMBOSS_001       551 ATAAATGTGAAAGTTTAGTTTGGCTCAATGTTGGTCAGTTTAGAAATGTG    600 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       551 ATAAATGTGAAAGTTTAGTTTGGCTCAATGTTGGTCAGTTTAGAAATGTG    600 
 
EMBOSS_001       601 GGAGTAATCGGAGAGATGGCATAACTGGGGGCGGGAGGCGGGGCGGTGAT    650 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       601 GGAGTAATCGGAGAGATGGCATAACTGGGGGCGGGAGGCGGGGCGGTGAT    650 
 
EMBOSS_001       651 TATACCCCTACCACTACCTAATCCTCAGGGGCTACCAGTTACTTGCTGTA    700 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       651 TATACCCCTACCACTACCTAATCCTCAGGGGCTACCAGTTACTTGCTGTA    700 
 
EMBOSS_001       701 CACACTTTTAAAGTACTTTCTAATTGTGGACCATGAGTGGCAGAGTACTG    750 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       701 CACACTTTTAAAGTACTTTCTAATTGTGGACCATGAGTGGCAGAGTACTG    750 
 
EMBOSS_001       751 CGGGCGGAGGCTTTTTGCTGAAAGCAACATTGACTTTTATTTCTAGGGAA    800 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       751 CGGGCGGAGGCTTTTTGCTGAAAGCAACATTGACTTTTATTTCTAGGGAA    800 
 
EMBOSS_001       801 AGTCTTGTCTGTAGATGAGCACCGTGGGGCAACGGAGAAAATGCTGACTT    850 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       801 AGTCTTGTCTGTAGATGAGCACCGTGGGGCAACGGAGAAAATGCTGACTT    850 
 
EMBOSS_001       851 TCTTGTTTAAAAAAAAAAAAAATTTCCGTAAGCGGCCCTCCAATGGTCCG    900 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       851 TCTTGTTTAAAAAAAAAAAAAATTTCCGTAAGCGGCCCTCCAATGGTCCG    900 
 
EMBOSS_001       901 TCCACTCAGCAGGCCAGCTGTCCCAGGCCTCTGCCAGGGAGGGAAGACGA    950 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       901 TCCACTCAGCAGGCCAGCTGTCCCAGGCCTCTGCCAGGGAGGGAAGACGA    950 
 
EMBOSS_001       951 GTGCTTCAGTGCATGGCTTCGGTGAGCCCTTTAAATCCAGCTTCCCCTGC   1000 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       951 GTGCTTCAGTGCATGGCTTCGGTGAGCCCTTTAAATCCAGCTTCCCCTGC   1000 
 
EMBOSS_001      1001 CCCCACCAAGAGGCTCCCTTTCCCTGACAGGTGTTTTCCCAACTCCGGAG   1050 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1001 CCCCACCAAGAGGCTCCCTTTCCCTGACAGGTGTTTTCCCAACTCCGGAG   1050 
 
EMBOSS_001      1051 GCCCAGGATTTTGGGGAGTGGCTGAGCCAATAAGATTTCCCTTTGGAAGG   1100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1051 GCCCAGGATTTTGGGGAGTGGCTGAGCCAATAAGATTTCCCTTTGGAAGG   1100 
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EMBOSS_001      1101 GGGGGGGAAGGGCGTGGCTAGTTGGGTCAGAGCATGGGCGGGGTTTGCGC   1150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1101 GGGGGGGAAGGGCGTGGCTAGTTGGGTCAGAGCATGGGCGGGGTTTGCGC   1150 
 
EMBOSS_001      1151 GGCTGAGCAGAGCCGGCCTGGTTGCGTGGAGGGTTGTTTTATTCCCACCG   1200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1151 GGCTGAGCAGAGCCGGCCTGGTTGCGTGGAGGGTTGTTTTATTCCCACCG   1200 
 
EMBOSS_001      1201 CCCCCCGCACCTTTTTTTTTTTTTTTTCTGGAGTCTTATTAATTTCTCTG   1250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1201 CCCCCCGCACCTTTTTTTTTTTTTTTTCTGGAGTCTTATTAATTTCTCTG   1250 
 
EMBOSS_001      1251 TGGGCTGCAGCTGGAGACCGCGGAGCGCTGGAAATGACGCTCGGAGCTTT   1300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1251 TGGGCTGCAGCTGGAGACCGCGGAGCGCTGGAAATGACGCTCGGAGCTTT   1300 
 
EMBOSS_001      1301 AATTACCGCAGCCGCCGGACAAGTGTGAGGAAAGCTGAGAG   1341 
                     ||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1301 AATTACCGCAGCCGCCGGACAAGTGTGAGGAAAGCTGAGAG   1341 
 
Figure 3.7: Pairwise alignment of the cloned and sequenced: HER1 1.5 kb and HER4 1.3 kb gene 
promoter with retrieved HER1 1.5 kb and HER4 1.3 kb sequence from Ensemble (Ensemble Genome 
Browser, 2016), (A) is for HER1 and (B) HER4. 
3.4.10 Midiprep of PGL3, pGL3-HER1 and pGL3-HER4 and 
spectrophotometric analysis 
A single white bacterial colony with respect to each transformation (PGL3, pGL3-
HER1 and pGL3-HER4) was inoculated into 15 mL centrifuge tubes (Corning 
Incorporated) containing 5 mL of LB-Media with Ampicillin selection. Inoculated 
cultures were grown in a shaking incubator at 37oC for 24 h. The following day, 
one ml of each remaining bacterial culture was used to inoculate 3 separate 
sterile conical flasks containing 100 mL TB media with Ampicillin selection. The 
bacterial cultures were grown in a shaking incubator for 24 h. These bacterial 
cultures were subsequently used to isolate and purify high-quality plasmid DNA 
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Table 3.1: Plasmid DNA was produced form midiprep. The concentration of 
vector or vector/insert was quantified spectrometrically  
MidiPrep DNA Purity Ratio (260/280) Concentration (ng/µl) 
PGL3-Vector 1.897 690 
pGL3-HER1 1.5 kb 1.890 900 
pGL3-HER4 1.3 kb 1.880 800 
 
3.4.11. Examining the functionality of the cloned promoter constructs 
Previous study by our group has reported a significant high basal level and 
differential expression of HER2/HER3 among the cell lines (Khalil et al., 2016b). 
Here similar transcriptional reporter assays to demonstrate basal and differential 
expression of HER1/HER4 alongside the already studied promoters HER2/HER3 
(Khalil et al., 2016b), was investigated. To examine the functionality of cloned 
promoters, 1.5 kb and 1.3 kb DNA fragments encompassing the HER1 and HER4 
gene proximal promoters, as well as that of HER2 and HER3 clone by Khalil et 
al., 2016b were each placed upstream of the luciferase reporter gene in the pGL3 
vector to be prHER1, prHER2, prHER3 and prHER4 accordingly. These were 
used to transiently transfect a panel of ovarian cell lines (OVCAR3, PEO1 and 
SKOV3) in order to examine their constitutive expression. All prHER1, prHER2, 
prHER3 and prHER4 showed a high and differential basal level of expressions in 
all the cell lines tested when compared to the control pGL3 vector (Figure 3.8). 
This suggests the functionality of the promoter constructs and their feasibility as 
tools to study the regulation of HER family receptors. 
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Figure 3.8: Examining the basal activity of the promoters. All the promoters showed a high and 
differential basal level of expression in all the cell lines tested when compared to the control pGL3-basic 
vector. Briefly SKOV3, OVCAR3 and PEO1, cells were transfected with either empty PGL3 basic vector or 1 
𝜇g PGL3 basic vector with cloned fragments of either HER1 (prHER1) HER2 (prHER2) HER3 (prHER3) or 
HER4 (prHER4) promoter driving the expression of luciferase gene. Co-transfection with 0.2 𝜇g pRL-CMV 
plasmid was performed as an internal transfection control. Following 24 h of transfections the lysates were 
prepared and luciferase activity was measured using Dual luciferase reporter assay (Promega) in multiplate 
reader (MODULUSTM, Promega). Data presented are the means ± S.D. of n = 3; independent experiments 
performed in quadruplicates and expressed in fold change to PGL3 with statistical significance determined 
by ONE WAY ANOVA followed by Tukey’s post hoc test (∗: p < 0.05, ∗∗: p < 0.01, ∗∗∗: p < 0.001 and ∗∗∗∗: 
p< 0.0001). Note that, the already studied prHER2 and prHER3 (Khalil et al., 2016b) are used as positive 
controls here. This study cloned only pHER1 and pHER4.  
3.5. Key findings 
This chapter has reported the information about the cloning of promoter regions 
of HER1 and HER4, and indicate differences in relative basal activity of the 
promoter regions. The computer-based sequence analysis performed had 
revealed that both HER1 and HER4 promoters contain putative NRF2 
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transcription factor response element (Figure 3.1). Following this, the chapter has 
reported the successful clones (Figure 3.6) and sequences (Figure 3.7) of the 
promoter regions of HER1 and HER4 gene, and then finally determine their 
functionality using dual luciferase assays by transfecting their respective DNA 
constructs into the ovarian cancer cell lines (3.8). The presence of conserved cis 
elements for these factors suggests possible additional ways of HER1 and HER4 
regulation and expression.  
Taken together, this section has reported the cloning of the promoter regions of 
the human HER1 and HER4 genes, and testing them, confirmed their activity and 
functionality. This chapter has provided novel tools for the study of the regulations 
of the expression of HER1 and HER4 genes by NRF2, which will be investigated 















Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 86 
 
 






Regulation of HER1 and HER4 by 






Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 87 
 
4.1. Abstract 
The HER family cell surface receptors dimerize upon ligand binding to activate 
their tyrosine kinase domains which subsequently lead to the phosphorylation of 
tyrosine residues in the intracellular domain of the receptors. These receptors are 
the regulators of normal cellular proliferation, differentiation and survival, as well 
as determinants of cancer initiation, maintenance, and progression. NRF2 is an 
essential transcription factor for multiple genes encoding antioxidants and 
detoxification enzymes. NRF2 is implicated in promoting cancer therapeutic 
resistance by its detoxification function and link with proliferative pathways. 
However, the linkage between NRF2 and HER family growth factor-induced 
proliferative pathway remains poorly understood. Here, it is demonstrated that 
pharmacological activation of NRF2 by tBHQ or pharmacological and genetic 
inhibition of NRF2 by RA and siRNA upregulates or downregulates HER1 and 
HER4 expression at both transcriptional and protein levels. Also, inhibition of 
NRF2 led to reduced total GSH and an elevation of ROS in all the cell lines used 
in this study. Hence, NRF2 regulates both HER1 and HER4 receptors, via direct 
or indirect means involving ROS, suggesting that regulation of both HER1 and 
HER4 gene expression could be both at the transcriptional and translational 
levels. 
4.2. Introduction 
The HER receptor kinase family and NRF2 are the regulators of cellular 
proliferation, differentiation and survival as well as the casual factors leading to 
cancer initiation, maintenance, and progression (Yarden, 2001, Yarden and 
Sliwkowski, 2001, Normanno et al., 2006, Gschwind et al., 2004, Ritter and 
Arteaga, 2017, Marmor et al., 2004, Gui and Shen, 2012, Cao et al., 2008). 
Overexpression of the HER receptor family and NRF2 acting in synergy with 
various molecular pathways have been shown to correlate with poor survival 
outcomes in cancers including ovarian (Marmor et al., 2004, Bianco et al., 2006, 
Friedlander, 1998, Psyrri et al., 2005, Phelps et al., 2008, Ledermann and Raja, 
2010, Alečković and Kang, 2015, Clayton et al., 2004, Hough et al., 2000, 
Barbosa et al., 2014, Gomperts et al., 2009, Allard et al., 2016, Anuranjani and 
Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 88 
 
Bala, 2014, Akhdar et al., 2009, Chen et al., 2013, Ahmed et al., 2017, Namani et 
al., 2014). 
tBHQ, the major metabolite of butylated hydroxyanisole, induces an antioxidant 
response through NRF2. However, the mechanism by which tBHQ induces NRF2 
activity is not entirely understood (Imhoff and Hansen, 2010, Farhoosh and 
Tavassoli-Kafrani, 2010). A rich body of evidence has demonstrated that tBHQ is 
effective in protecting against cellular dysfunction induced by oxidative stress 
inducers, such as alcohol, dopamine, hydrogen peroxide, and glutamate, in 
various cell types (Li et al., 2014). It has been well-established that tBHQ exerts 
its antioxidant function through a mechanism whereby it increases NRF2 protein 
stability via repression of KEAP1-mediated ubiquitination (Turley et al., 2015, 
Alarcón-Aguilar et al., 2014, Li et al., 2014).  Based on these observations, tBHQ 
has become one of the most widely employed NRF2 activators in a number of 
studies 
Retinoids such as RA and bexarotene, on the contrary, are chemopreventive and 
chemotherapeutic agents that inhibit NRF2. RA regulates cell proliferation, 
differentiation, and morphogenesis (Garattini et al., 2014, Wang et al., 2007, Heo 
et al., 2016). It inhibits tumorigenesis through suppression of cell growth and 
stimulation of cellular differentiation (Garattini et al., 2014). Also, RA promotes 
apoptosis and this property may contribute to its antitumor properties. The effects 
of retinoids are mediated by specific nuclear receptors, namely, retinoic acid 
receptors (RAR-α, -β, and -γ) and retinoid X receptors (RXR-α, -β, and -γ). RXRs 
form heterodimers with RARs or other nuclear hormone receptors and function as 
transcriptional regulators. RA, for example, activates RAR-RXR heterodimers and 
exerts its biological actions by binding to retinoic acid response elements 
(RAREs). In addition, retinoids can either activate or repress gene expression 
through RAR/RXR heterodimers interacting with other transcription factors, such 
as AP-1, estrogen receptor α, and NF-κB activities (Heo et al., 2016, Hayes et al., 
2016, Hayes and McMahon, 2009, Wang et al., 2007). 
Based on the previous reports, it is assumed that tBHQ, via activating NRF2, may 
confer protective effects on cancer cells leading to chemoresistance and 
therefore modulating NRF2 could be a great strategy in overcoming the 
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resistance (Khalil et al., 2016b, Li et al., 2014). Both HER receptors and NRF2 
are recognised as agents in cellular proliferation and adaptation to ROS leading 
to therapeutic resistance to cancers. Moreover, NRF2 activation and KEAP1 
inactivation mutations leading to permanent constitutive adaptive activation of the 
NRF2 pathway are often observed in cancers (Khalil et al., 2016b). Number 
therapeutic approaches such as anti-cancer radio- and chemotherapy greatly 
depend on ROS manipulation to induce cytotoxicity. Studies have implicated HER 
family, NRF2, and ROS in the promotion of cellular proliferation and therapeutic 
resistance in cancer cells. (Khalil et al., 2016b, Lu et al., 2017, Roy et al., 2016, 
Chen et al., 2016, Leone et al., 2015, Kovac et al., 2015, Jayakumar et al., 2015, 
Li et al., 2015). This study aims to investigate and identify the link between NRF2 
and the HER family receptors signalling pathway, in order to determine a way of 
improving responses to therapies (Khalil et al., 2016a, Khalil et al., 2016b). 
In this chapter, gene transcriptional reporter assays were generated, followed by 
pharmacological activation and inhibition or siRNA knockdown of NRF2. 
4.3. Aims and objectives 
The main aim of this chapter is to examine the regulations of the HER1 and 
HER4 by NRF2 in ovarian cancer. 
4.3.1 The aim 
4.3.2. The objectives are: 
1. To test the effect of pharmacological activation of NRF2 on HER1 and 
HER4 expression in ovarian cancer cells.  
2. To test the effect of pharmacological and genetic inhibition of NRF2 on 
HER1 and HER4 expression in ovarian cancer cells.  
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4.4.    Results 
4.4.1. Treatment with tBHQ causes transcriptional and translational 
upregulation HER1 and HER4  
Several studies have shown that NRF2 promotes resistance to chemotherapeutic 
agents and contributes to general cytoprotection, metabolic reprogramming, and 
cell survival (Abdullah et al., 2012, Ahmed et al., 2017, Hayes et al., 2016, Hayes 
and Ashford, 2012, Hayes and Dinkova-Kostova, 2014, McMahon et al., 2014). 
Conversely, RTK targeted therapies involving inhibitory monoclonal antibodies 
and small molecules against HER receptors has generated interest in recent 
years as a potential strategy to overcome ovarian cancer cell therapeutic 
resistance (Khalil et al., 2016a, Khalil et al., 2016b, Langdon et al., 2010, 
Langdon and Cameron, 2013).  Here a panel of ovarian cells transfected with the 
prHER1 and prHER4 for reporter assays were exposed to increasing 
concentrations of tBHQ to explore the nature of this transcriptional regulation. 
Interestingly, all the cell lines exhibited significant dose-dependent transcriptional 
upregulation of HER1 and HER4, as well as the other members of HER family 
when tested with varying concentrations of tBHQ (Figure 4.1). 
Furthermore, tBHQ treatment caused upregulation of both total NRF2 and 
phospho Akt alongside total HER1 and HER4 levels (Figure 4.2) in all the ovarian 
cancer cell lines tested (PEO1, OVCAR3 and SKOV3). These results 
demonstrated that pharmacological activation of the NRF2 protein caused 
transcriptional upregulation of HER receptors pathway with concomitant 
translational induction of total HER1 and HER4 proteins. This implied that the 
HER receptor pathways might be subjected to coregulatory mechanisms by the 
antioxidant response pathway and NRF2. 
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Figure 4.1: Treatment with tBHQ causes transcriptional and protein induction of HER1 and HER4. 
tBHQ causes transcriptional induction of HER1 and HER4 and induction of ARE in a concentration 
dependent manner. MCF7-AREc32 which already contains stably cloned 8 x cis-AREs driving NRF2 
dependent expression of luciferase gene was left without any transfection while PEO1, OVCAR3 and 
SKOV3 cells were transfected with either empty PGL3 basic vector or 1 μg PGL3 basic vector with promoters 
of HER1 cloned driving HER1 expression of luciferase gene. Co-transfection with 0.2 μg pRL-CMV plasmid 
was performed as an internal transfection control. Where required PEO1, SKOV3 and OVCAR3 cell lines 
and MCF7-AREc32 stable cell line were treated in quadruplicate with different concentrations of tBHQ as 
indicated at normal condition for 24 h. Data shown are the means ± S.D. of n = 3 independent experiments. 
Each independent experiment consists four replicates. Statistical significance determined by ONE WAY 
ANOVA followed by Tukey’s post hoc test (*: p<0.05, **: p<0.01, ***: p<0.001 and ****: p<0.0001). 
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Figure 4.2. Treatment with tBHQ causes protein induction of HER1 and HER4.  Immunoblot analysis 
following treatment with tBHQ demonstrated protein induction of HER1 and HER4 receptor and also 
activation of total and with an increase of pAKT.  Briefly exponentially growing cells were either left untreated 
(UT) or treated with 100 μM tBHQ for 24 h before being harvested and processed for immunoblotting using 
relevant antibodies. Bar chart shows total NRF2, total HER1, HER4 and phospho-AKT levels in PEO1, 
OVCAR3 and SKOV3 cell lines by quantifying immunoblot signal intensities obtained and normalised to the 
value of UT and expressed as fold change. Images are representative of at least two independent 
experiments performed. 
4.4.2. Treatment with RA inhibited NRF2 pathway leading to downregulation 
of HER1 and HER4  
To further delineate the role of NRF2 in the regulation of HER1 and HER4 
receptors expression, the expression of HER1 receptor following the antagonism 
of NRF2 and its function was examined. Previous studies have used RA to 
pharmacologically inhibit NRF2 and its function (Wang et al., 2007, Wu et al., 
2014, Khalil et al., 2016a). To confirm this, the ovarian cancer cells were treated 
with RA to pharmacologically inhibit NRF2. The generated gene transcriptional 
reporter HER1 and HER4 and western blot analysis of HER1, HER4 and NRF2 
levels were used to delineate the role of NRF2 in the regulation of HER1 and 
HER4 receptor expression. The cell lines were individually transfected with the 
constructs of prHER1 and prHER4, except MCF7-AREc32 stable cell line with 
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served as positive control. This time, the cells were either left untreated or treated 
with 2.5 µM RA for 24 h. The results revealed a significant transcriptional 
downregulation of HER1 and HER4 in all the cell line, PEO1, OVCAR3 and 
SKOV3 as well as MCF7-AREc32 cell lines (Figure 4.3). Moreover, the protein 
level has shown a significant protein repression of total NRF2, HER1, HER4 as 
well as pAKT (Figure 4.4). These results demonstrated that pharmacological 
inhibition of NRF2 protein caused inhibition of HER receptor pathway and 
transcriptional and translational downregulation of HER1 and HER4. This 
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Figure 4.3: Treatments with RA causes inhibition of NRF2 and transcriptional downregulation HER1 
and HER4. Luciferase assay showing transcriptional downregulation of HER1 and HER4 following NRF2 
inhibition by RA in PEO1, OVCAR3 and SKOV3 cell lines. Exponentially growing PEO1, SKOV3 and 
OVCAR3 excluding MCF7-AREc32 cell lines were transfected with either empty PGL3 basic vector or 1 µg 
PGL3 basic vector with cloned NRF2-AREs driving the expression of luciferase gene. Co-transfection with 
0.2 µg pRL-CMV plasmid was performed as an internal transfection control as described in the materials and 
methods. At 24h post-transfection, cells were either left untreated or treated with 100 µM tBHQ or 2.5 µM RA 
for 24 h. Following treatments, lysates were prepared and luciferase activity was measured using Dual 
luciferase reporter assay (Promega) in multiplate reader (MODULUSTM, Promega). Data shown are the 
means ± S.D. of n=3 independent experiments performed in quadruplicates triplicates with statistical 
significance determined by ONE WAY ANOVA followed by Tukey’s post hoc test (*:p<0.05, **:p<0.01, 
***:p<0.001 and ****:p<0.0001). 
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Figure 4.4: Treatments with RA causes repression of NRF2 as well as downregulation HER1 and 
HER4. Immunoblot analysis following treatment with RA demonstrated protein downregulation of both HER1 
and HER4 receptors and decrease of NRF2, pNRF2, HO-1 and pAKT. Exponentially growing cells were 
either left untreated (UT) or treated with 2.5 μM RA for 24 h before being harvested and processed for 
immunoblotting using relevant antibodies. Bar chart shows total NRF2, phosphor-NRF2, HO-1, total HER1, 
total HER4, and phospho-AKT levels in PEO1, OVCAR3 and SKOV3 cell lines by quantifying immunoblot 
signal intensities obtained. Images are representative of at least two independent experiments performed.  
4.4.3. Genetic knockdown of NRF2 causes downregulation HER1 and HER4 
Studies have used siRNA to genetically inhibit NRF2 and its function (Huang et 
al., 2008, Guo et al., 2013, Kanninen et al., 2015, Duong et al., 2017, Esmaeili, 
2016). To assess the effect of siRNA on NRF2 and HER1 and HER4 receptors 
expression, the expression of HER1 and HER4 receptors following the siRNA-
mediated knockdown of NRF2 was examined. The generated gene transcriptional 
reporter for HER1 and HER4 and western blot analysis of HER1, HER4 and 
NRF2 levels were investigated. The PEO1, OVCAR3 and SKOV3 cell lines were 
individually transfected with the constructs of prHER1 and prHER4. Following 
this, cells were co-transfected with 75 pmol NRF2 specific siRNA for 24 h. The 
results revealed a significant transcriptional downregulation of HER1 and HER4 
(Figure 4.5). At the protein level, following the knockdown with siRNA for 24 h 
and 48 h there was a significant protein repression of HER1, HER4 as well as 
pAKT, and with a significant inhibition of total NRF2 (Figure 4.6). Taken together, 
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these interesting results demonstrated that inhibition of NRF2 protein caused 
inhibition of HER receptor pathway and transcriptional and translational 
downregulation of HER1 and HER4. This also supported the implication that both 
antioxidant response and HER receptor family pathways might be subjected to 
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Figure 4.5: Genetic knockdown of NRF2 causes transcriptional downregulation HER1 and HER4 
Knockdown of NRF2 causes inhibition its transcriptional antioxidant program and the transcriptional level of 
HER1 and HER4 in both constitutive and tBHQ induced states. MCF7-AREc32 which already contains stably 
cloned 8 x cis-AREs driving NRF2 dependent expression of luciferase gene was left without any transfection 
while PEO1, OVCAR3 and SKOV3 cells were transfected with either empty PGL3 basic vector or 1 μg PGL3 
basic vector with promoters of HER1 and HER4 cloned driving HER1 and HER4 expression of luciferase 
gene. Co-transfection with 0.2 μg pRL-CMV plasmid was performed as an internal transfection control. 
Where required, cotransfection with either scrambled RNA (Sc) or NRF2 siRNA was performed using 
20 pmol siRNA. At 24 h after transfection, treatment with 100 μM tBHQ was performed where indicated for 
4 h following which, cells were processed for dual luciferase reporter assay (Promega) to record luciferase 
activity in multiplate reader (MODULUS, Promega). Data are the means with ±S.D. of n=3 independent 
experiments in triplicates, with statistical significance determined by ONE WAY ANOVA followed by Tukey's 
post hoc test. ∗ p < 0.05, ∗∗   p < 0.01, ∗∗∗ p < 0.001 and **** p <0.0001 
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Figure 4.6: Genetic knockdown of NRF2 causes protein downregulation HER1 and HER4. Immunoblot 
analysis following knockdown of NRF2 demonstrated protein downregulation of both HER1 and HER4 
receptors and decrease of NRF2, pNRF2, HO-1 and pAKT in PEO1, OVCAR3 and SKOV3 cell lines. Cells 
were either transfected with scrambled siRNA (Sc) or transfected with 75 pmol of NRF2 siRNA (Si). After 24h 
and 48 h, cells were being harvested processed for immunoblotting using relevant antibodies. β-actin of the 
same blot was used as loading control. Bar chart shows the levels relevant proteins by quantifying 
immunoblot signal intensities obtained and expressed as fold change. Images are representative of at least 
two independent experiments performed. 
4.4.4. Treatment with tBHQ reduces the knocking down effect of siRNA 
Based on the results obtained following activation and inhibition of NRF2 by tBHQ 
and siRNA respectively (Figures 4.5 and 4.6), it is thought that tBHQ dependent 
induction of antioxidant pathways in the cell lines would disrupt the depletion of 
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NRF2 following knockdown by siRNA and to confirm this, cells were exposed 
either genetic inhibition of NRF2 with siRNA or pharmacological activation of 
NRF2 by tBHQ following the genetic depletion of NRF2. The evidence to 
implicate NRF2 in the regulation of HER1 and HER4 expression was obtained 
when co-treatment of ovarian cancer and MCF7 AREc32 cells with tBHQ and 
NRF2-siRNA compromised the tBHQ-dependent induction of either HER1 or 
HER4 promoters-driven or ARE-driven luciferase gene expression in the ovarian 
cancer cells or in MCF7 AREc32 cells (Figure 4.7), respectively. This inhibitory 
effect of siRNA on the tBHQ-dependent induction of gene expression (Figure 4.8) 
appeared to be concomitant with decreased total NRF2 levels in all the cells 
tested, thereby supporting the earlier conclusions drawn from Figure 4.7.
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Figure 4.7: Treatment with tBHQ reduces the knocking down effect of siRNA. Knockdown of NRF2 cause inhibition its transcriptional antioxidant program and the 
transcriptional level of HER1 in both constitutive and tBHQ induced states. MCF7-AREc32 which already contains stably cloned 8 x cis-AREs driving NRF2 dependent 
expression of luciferase gene was left without any transfection while PEO1, OVCAR3 and SKOV3 cells were transfected with either empty PGL3 basic vector or 1 μg PGL3 
basic vector with promoters of HER1 cloned driving HER1 expression of luciferase gene. Co-transfection with 0.2 μg pRL-CMV plasmid was performed as an internal 
transfection control. Where required, cotransfection with either scrambled RNA (Sc) or NRF2 siRNA was performed using 20 pmol siRNA. At 24 h after transfection, treatment 
with 100 μM tBHQ was performed where indicated for 4 h following which, cells were processed for dual luciferase reporter assay (Promega) to record luciferase activity in 
multiplate reader (MODULUS, Promega). Data are the means with ±S.D. of n=3 independent experiments performed in quadruplicates, with statistical significance determined 
by ONE WAY ANOVA followed by Tukey's post hoc test. ∗ p < 0.05, ∗∗   p < 0.01, ∗∗∗ p < 0.001 and ∗∗∗∗ p < 0.0001
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Figure 4.8: Action of tBHQ reduces the knocking down effect of siRNA. Immunoblotting analysis 
showing repression of NRF2 following NRF2 knockdown by siRNA in PEO1, OVCAR3 and SKOV3 cell lines. 
Cells were either transfected with scrambled siRNA (Sc) or transfected with 75 pmol of NRF2 siRNA (Si). 
After 24 h, cells were either left untreated or treated with 100 μM tBHQ (T) for 4 h, before being processed for 
immunoblotting using relevant antibodies. β-actin of the same blot was used as loading control. Bar chart is 
the average of n=3 independent experiments performed showing NRF2 levels by quantifying immunoblot 
signal intensities obtained and expressed as fold change. Images are representative of at least two 
independent experiments performed.  
4.4.5. Pharmacological inhibition and Genetic knockdown of NRF2 by RA 
siRNA respectively elevates the level of ROS 
Based on the above results describing the effects and mechanisms of NRF2 
knockdown and inhibition by siRNA and RA respectively. ROS are expected to 
accumulate as consequential to the loss of NRF2 function. In order to confirm the 
direct relationship between of NRF2 and ROS, the total basal ROS was 
quantified following NRF2 inhibition and knockdown to determine whether NRF2 
depletion caused elevation of ROS. To achieve this, the treated cells were loaded 
with 2′,7′-Dichlorofluorescin diacetate dye which is a fluorescent marker of 
intracellular ROS. The results confirmed an elevation of ROS resulting from both 
NRF2 inhibition and knockdown (Figure 4.9).  
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Figure 4.9:  Inhibition and Knockdown of NRF2 by RA and siRNA respectively elevates the level of 
ROS. (A) RA treatment and (B) knockdown of NRF2 by siRNA causes increase in ROS levels. Exponentially 
growing cells were seeded in triplicates in opaque flat bottom black walled 96-well plates for 24 h. Following 
this, cells were either left untreated (UT)/Scramble (SC) or treated with 2.5 μM RA or 7 pmol of siRNA for 
different time points as indicated. Following incubations, cells were loaded with DCFDA fluorescent stain for 
45 min and assayed for ROS by measuring fluorescence as described in Materials and Methods. Data are 
the mean ± SD of n=3 independent experiments performed in triplicates and shown as fold change of RA or 
siRNA treated cells to UT with statistical significance determined by TWO WAY ANOVA followed by Tukey's 
post hoc test. ∗ p < 0.05, ∗∗   p < 0.01, ∗∗∗ p < 0.001 and **** p <0.0001.   
4.4.6. Action of RA and siRNA on NRF2 causes depletion of total GSH 
Following the observed inhibition of NRF2 and increase in ROS in these cell lines 
following treatment with RA and siRNA, next, it is asked whether NRF2 
knockdown and treatment with RA would cause a depletion of total cellular GSH. 
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To address this, cells were either left untreated or treated with RA or siRNA. 
Here, HRG which is reported to induce total cellular GSH was used as positive 
control. At 24 h, treatment with HRG induced total cellular glutathione, while both 
RA and siRNA significantly reduced this level in all cells (Figure 4.10). This study 
demonstrates that whatever happens to NRF2 also could affect enzymes it 
controls. 
 
Figure 4.10: Pharmacological treatment with RA and Knockdown with siRNA on NRF2 causes 
depletion of total GSH level. (A) RA and (B) siRNA causes depletion of total GSH. Exponentially growing 
cells where seeded in luminometer-compatible 96-well plates and allow to grow overnight at 37°C in a 5% 
CO2 culture incubator. The following day, the cells were either left untreated (UT)/Scramble(SC) or treated 
with media containing 1nM Heregulin alone (HRG) or with co-treatment 2.5 µM RA or 7 pmol siRNA for 24 h 
before being processed for glutathione assay. Data is the mean ± SD of n=3 independent experiments 
performed in triplicates and were normalized and expressed as fold change to the UT and compared to 
HRG. Statistical significance was determined by independent t-test according to the scale * p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 
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4.5. Key findings 
This chapter has confirmed the transcriptional and translational regulatory role of 
NRF2 on HER1 and HER4 receptors. It started by indicating that, NRF2 
activation by tBHQ not only induced the NRF2 dependent antioxidant response 
pathway as expected but interestingly also induced both transcriptional (Figure 
4.1) and protein levels of HER1 and HER4 (Figure 4.2). NRF2 inhibition by RA 
(Figures 4.3 and 4.4) and knockdown by siRNA (Figures 4.5 and 4.6), also 
repressed NRF2 dependent antioxidant response pathway as well as 
downregulated both transcriptional and protein level of HER1 and HER4. The 
disruption of the knockdown effect of siRNA was observed when tBHQ was 
introduced in the treatment (Figures 4.7 and 4.8). 
Also in order to examine the consequence of NRF2 inhibition and confirm the 
direct link between of NRF2 and ROS, the total basal ROS as well as total GSH, 
following NRF2 inhibition and knockdown were quantified. This will determine 
whether NRF2 depletion caused elevation of ROS. The data indicated that NRF2 
repression led to the elevation of ROS (Figure 4.9) and depletion of total GSH 
(Figure 4.10) in all the cell lines. Thus, these results confirmed the transcriptional 
regulatory role of NRF2 for HER1 and HER4 receptors and illustrated alteration of 
protein abundance as a result of such transcriptional regulation. The data 
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5.1. Abstract 
NRF2 is a transcription factor that governs the expression of a battery of genes to 
combat oxidative and electrophilic stress. However, modification of KEAP1 by 
ROS stabilises NRF2 by escaping from degradation in the cytoplasm to the 
nucleus. NRF2 then binds to AREs in the promoter region of the cluster of various 
genes. NRF2-ARE pathway hyperactivation can protect cancer cells from 
oxidative stress and promote cell proliferation. Moreover, activation of the NRF2 
pathway is critical for resistance to chemotherapeutic agents. In this chapter, a 
total of ten potent NRF2 inhibitors were screened and then the most potent 
among them were used to provide a molecular and rational basis for the use of 
NRF2 inhibitors in overcoming chemoresistance in ovarian cancer. This would 
give a possible NRF2-inhibiting mechanism of these compounds, their effects of 
sensitizing cancer cells to chemotherapeutic agents, and the prospect of applying 
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5.2. Introduction 
Drug screening is the process by which potential drugs are tested, identified and 
optimized before selection of a candidate drug to progress to clinical trials. It can 
involve screening large libraries of chemicals for a particular biological activity in 
high-throughput screening assays. The screening would help to find small 
molecular compounds that possess the potential to interact with specific 
biomacromolecules, mostly proteins, thereby bringing the desired effect in the 
functioning of the target molecules (Malik et al., 2017). Cell-based screenings are 
essential for the identification and characterization of drug candidates (Agus and 
Janovjak, 2017). These assays are used to measure cell proliferation, viability 
and cytotoxicity and are commonly used to monitor the response of cells in 
culture after treatment with various stimuli. The luciferase assays and Intracellular 
ATP-based luciferase assays would be suitable for the screening of chemical 
libraries because they allow for simple, efficient, rapid-evaluation of the activities 
of test compounds with signal detection within a short period of time (Suganuma 
et al., 2017). 
NRF2 activity is tightly controlled, suggesting that opportunistic stimulation of 
NRF2 signalling by drugs used in the treatment of cancer is undesirable. NRF2 
contribute to the survival and proliferation of cancer cells leading to chemo 
resistance because of its ability to induce drug detoxifying genes. While transient 
activation of NRF2 in normal cells is desirable, persistent activation of NRF2 is 
detrimental (McMahon et al., 2014). Interrupting the NRF2 activity may be an 
effective way to sensitize cancer cells to chemotherapy and radiotherapy (Arlt et 
al., 2013). In this chapter, cell based assays such as luciferase assay, ATP-
dependent assay, ROS assay as well as total GSH assay were employed. The 
contemporary chemical inhibitors of the NRF2 signalling pathway, their effects in 
cancer cells and their potential clinical applications were examined. 
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5.3. Aims and objectives 
5.3.1 The aim 
The main aim of this chapter is to screen for potent inhibitors of the NRF2-ARE 
signalling pathway and then investigate their potential applications in ovarian 
cancer therapy 
5.3.2 The objectives are: 
1. To firstly, perform the cytotoxicity assay of all the compounds to be 
screened in order to obtain the low-lethal concentration 
2. To screen the compounds using MCF7-AREc32 luciferase reporter stable 
cell line to obtain the most potent modulators of NRF2/ARE-dependent 
activity 
3. To use any of the most potent compounds obtained for further 
investigations of its potency in ovarian cancer therapy.  
5.4. Results 
5.4.1. Cytotoxic screening of the spectrum collection the compounds as 
inhibitors of NRF2 in cancerous cells. 
Firstly, the cytotoxicity of all the compounds was investigated to evaluate the less 
toxic concentration of the compounds to be used for further screening as NRF2 
inhibitors. To address this, an exponentially growing MCF7-AREc32 cell line 
stably expressing 8xcis-ARE were either left untreated (DMSO vehicle) or treated 
with different concentrations of the tested compounds (Figure 5.1).  It was noticed 
that almost all the compounds were less toxic in range of 0-10 µM and therefore 
that range of concentration was chosen for further studies. 
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Figure 5.1: Cytotoxic screening of the spectrum collection the compounds. Briefly, exponentially growing MCF7-AREc32 cells were seeded in a 96-well plate and allowed 
to adhere for 18-24 h. Following 72 h treatments using different concentrations of the compounds, the plate and its contents  were equilibrated to room temperature for 
approximately 30 min, a volume of CellTiter-Glo 2.0 reagent equal to the volume of cell culture medium present in each well the contents were then mixed for 2 min on an 
orbital shaker to induce cell lysis and the plate was then incubate at room temperature for 10 min to stabilize the luminescent signal and finally the luminescence was recorded 
using luminometer (MODULUS, Promega). The luminescent signal which is proportional to the amount of ATP in the sample, also which indicates the presence of metabolically 
active cells is expressed in %. 
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5.4.2. Determination of activities and effects of compounds on NRF2-ARE 
signalling pathway 
To identify novel small molecule inhibitors that will disturb the NRF2/ARE binding 
pathway, a group of compounds, of which some were reported to influence 
NRF2- KEAP1 pathway (McMahon et al., 2014, Kwak and Kensler, 2010), were 
examined. MCF7-AREc32 stable cell line which is known to contain low levels of 
NRF2 (McMahon et al., 2014, Wang et al., 2007), and therefore low levels of 
luciferase expression were used in this investigation. This makes it an excellent 
cell model with which to identify drugs that activate or inhibit NRF2 signalling 
(McMahon et al., 2014, Wang et al., 2007). A total of 10 drugs, which target a 
variety of biochemical pathways were investigated The selection of most of the 
compounds, however, just as reported by Machmahon et al (2014), was made 
with no foreknowledge or preconception of their likelihood to activate or inhibit 
NRF2 signalling (McMahon et al., 2014) except those used as control. The 
screening confirmed that some of the drugs elevated and some inhibited 
luciferase activity in the MCF7-AREc32 cell line (Figure 5.2). Collectively, these 
data showed that all the compounds tested altered NRF2-ARE signalling either 
by activating or by inhibiting it. The improved ability to identify potent inhibitors of 
NRF2 through in vitro screening described here improves the speed and cost 
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Figure 5.2: Screening of panel of compounds gives rise to activation and inhibition of NRF2 
dependent antioxidant response pathway. Exponentially growing MCF7-AREc32 cell line stably 
expressing 8xcis-AREs driving the expression of luciferase gene in an NRF2 dependent manner were either 
left untreated (UT) or treated with different compounds at 2.5 µM, 5 µM or 10 µM. For siRNA treatment, cells 
were treated with scrambled or with NRF2 siRNA (2.5 pmol, 5 pmol, 10 pmol) for 24h. Following this, cell 
lysates were prepared and assayed for Luciferase activity (BrightGlo Luciferase system, Promega). Data are 
the mean values ± S.D of n=3 independent experiments performed in quadruplicates with statistical 
significance determined by ONE WAY ANOVA followed by Tukey’s post hoc test according to the scale ** P 
<0.05, **P <0.01 ***P <0.001. 
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MCF7-AREc32 stable cell line carries a luciferase reporter gene under the control 
of the ARE. Both the basal and the inducible ARE-luciferase activities in these 
cells are primarily regulated by NRF2. Therefore, this cell line provides an ideal 
cell-based assay for screening for antagonists of NRF2.  
Based on the results obtained in (Figure 5.2) and the context of the aim of 
screening to identify the compounds that show more potency towards inhibiting 
NRF2-ARE pathway, the compounds that appeared to be most promising were 
selected for further investigations as described below. 
5.4.3. Potent NRF2-ARE inhibitors repress NRF2, pNRF2 and HO-1 and 
generate ROS 
Although the beneficial effects of NRF2 activation have been demonstrated in 
various healthy cell systems, there is cumulative evidence demonstrating the dark 
side of NRF2 in cancers. NRF2 is reported to contribute tumour resistance to a 
variety of anti-cancer drugs through detoxification of drug-induced ROS thereby 
preventing cellular accumulation of drugs and reducing the efficacy the drugs 
(Choi and Kwak, 2016). Furthermore, ROS which is reported to be a regulator of 
NRF2 stability and activity have also been shown to trigger the ARE pathway, 
implicating the modulation of ROS level by NRF2 function (Khalil et al., 2016b). 
To investigate this matter, the compounds that inhibited the antioxidant 
transcriptional program, were further examined in MCF7-AREc32 cell lines for 
effects at the protein level and then determined their level of ROS generation 
capacity. Exposure of MCF7-AREc32 cell lines to these compounds at 2.5 µM 
caused a decrease in pNRF2, total NRF2 and HO-1 levels (Figure 5.3). 
Interestingly the decrease was more significant in the presence of bexarotene. 
The compounds-induced reduction in NRF2 levels suggests that they can be 
used in targeting NRF2. Next, using the same set of compounds, it was found 
that they also elevated ROS levels (Figure 5.4). These findings suggested that 
while these compounds inhibit NRF2 dependent ARE pathway, such treatment 
also elevates cellular ROS levels in MCF7-AREc32 cell lines. Importantly, 
treatment with bexarotene was found to significantly induce more ROS when 
compared to all the other compounds tested. 
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Figure 5.3: Treatments with panel of compounds causes inhibition of NRF2 dependent antioxidant 
response pathway and generates ROS. (A) Western analysis showing repression of NRF2, pNRF2 and 
HO-1 levels following the compounds treatment in MCF7-AREc32 cell lines. Exponentially growing cells were 
either left untreated or treated with 2.5 μM RA or 9-Cis or bexarotene or tBHQ or Brusatol for 24 h before 
being harvested to prepare protein lysates or processed as described in Materials and Methods. Beta-actin 
(β- actin) was used as loading control and bars indicate total NRF2, phosphor-NRF2 and HO-1 levels 
following quantification of immunoblot signal intensities obtained in (A) and normalized to the value of UT 
and expressed as fold change. The signal intensities of bands were quantified through integrated optical 
densitometry measurement. Images are representative of at least two independent experiments performed.  
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Figure 5.4 Treatment with panel of compounds causes persistent elevation of ROS in MCF7-AREc32. 
Exponentially growing MCF7-ARE cells were seeded in triplicates in opaque flat bottom black walled 96-well 
plates for 24 h. Following this, cells were either left untreated (UT) or treated with 2.5 μM RA or 9-Cis or 
bexarotene or tBHQ or Brusatol for 24h. Following incubations, cells were loaded with DCFDA fluorescent 
stain for 45 min and assayed for ROS as described in Materials and Methods. Data are the mean values ± 
S.D of n=3 independent experiments performed in quadruplicates with statistical significance determined by 
ONE WAY ANOVA followed by Tukey’s post hoc test according to the scale ** P <0.05, **P <0.01 ***P 
<0.001. 
5.4.4. Low-lethal dose of lapatinib and erlotinib causes repression of NRF2-
dependent transcription and generation of ROS 
Following the observation of the effect of the tested compounds on NRF2, the 
widely known RTK inhibitors lapatinib and erlotinib that inhibits HER receptor 
family pathway activation (Ryan et al., 2008, Rolfo et al., 2014, Geyer et al., 
2006, Kuang et al., 2010), were then investigated after establishing their IC50 (15 
µM and 20 µM respectively) to further ascertain whether they will inhibit NRF2-
dependent transcription. To address this the MCF-AREc32 cell line, containing a 
stably expressing 8 copies of NRF2 dependent cis-regulatory AREs, as a 
luciferase reporter was used here as well. The results indicated that both lapatinib 
and erlotinib were toxic at the highest concentration (10 µM) (Figure 5.5A), and 
were able to inhibit the NRF2/ARE dependent transcription (Figure 5.5B) and 
generate ROS (Figure 5.5C) both at the low-lethal dose of 0-10 µM. 
Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 115 
 
 
Figure 5.5: Treatment with low-lethal dose of lapatinib and erlotinib involves repression of NRF2-
dependent transcription and generation of ROS. (A) Treatment with low-lethal dose of lapatinib and 
erlotinib in cell survival. Exponentially growing MCF7-AREc32 cells were seeded in triplicates in 96-well 
plates for 24 h, Following this, were treated with different concentrations of lapatinib and erlotinib (0-10 µM) 
as indicated, following this, cell number was assessed indirectly by use of the cell titre glo assay as 
described in Materials and Methods.  (B) Treatment with low-lethal dose of lapatinib and erlotinib involves 
repression of NRF2-dependent transcription. Exponentially growing AREc32 cell line stably expressing cis-
regulatory AREs driving the expression of luciferase gene in an NRF2 dependent manner were treated with 
different concentrations of lapatinib and erlotinib (0-10 µM). Following this, cell lysates were prepared and 
assayed for Luciferase activity as described in materials and method. (C) Treatment with sub-lethal dose of 
lapatinib and erlotinib involves generation of ROS. Exponentially growing MCF7-AREc32 cells were seeded 
in triplicates in opaque flat bottom black walled 96-well plates for 24 h. Following this, were treated with 
different concentrations of lapatinib and erlotinib (0-10 µM) as indicated. Following incubations, cells were 
loaded with DCFDA fluorescent stain for 45 min and assayed for ROS as described in Materials and 
Methods. Data shown are mean values ± S.D of n=3 independent experiments performed quadruplicates, 
normalized to untreated (UT) and expressed as fold change with statistical significance determined by ONE 
WAY ANOVA followed by Tukey’s post hoc test according to the scale *: p<0.05, **: p<0.01, ***: p<0.001. 
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Based on all the information obtained in (Figures 5..2 and 5.3), in addition to 
being in clinical use (Hatton and Yee, 2008, Farol and Hymes, 2004), bexarotene 
is chosen as the compound for further studies. Further, the cell viability assays of 
lapatinib and erlotinib (as RTK inhibitors) and bexarotene (as NRF2 inhibitor) 
were performed in PEO1, OVCAR3 and PEO1 ovarian cancer cells in order to 
choose the required concentrations for subsequent studies. 
5.4.5. Cell viability of lapatinib, erlotinib and bexarotene in ovarian cancer 
To determine the required concentration of these drugs (lapatinib, erlotinib, and 
bexarotene) for further use, exponentially growing PEO1, OVCAR3 and SKOV3 
cell lines were either left untreated (DMSO vehicle) or treated with different 
concentrations of the tested compounds, lapatinib (Figure 5.6A), erlotinib (Figure 
5.6B) and bexarotene (Figure 5.6C).  It was noticed that almost all the 
compounds are less toxic to the range between 0-10 µM and therefore that range 
of concentration was chosen for further studies. 
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Figure 5.6: Cell viability assay: (A) lapatinib (B) erlotinib and (C) bexarotene in three ovarian cancer 
cells, SKOV3, PEO1 and OVCAR3. Cell viability assay was performed in order choose the less toxic 
consent rations for further studies. Briefly, exponentially growing cells were seeded in a 96-well plate and 
allowed to adhere for 18-24 h. Following 72 h treatments using different concentrations of the drugs, the 
plate and its contents  were equilibrated to room temperature for approximately 30 min, a volume of 
CellTiter-Glo 2.0 reagent equal to the volume of cell culture medium present in each well the contents were 
then mixed for 2 min on an orbital shaker to induce cell lysis and the plate was then incubate at room 
temperature for 10 min to stabilize the luminescent signal and finally the luminescence was recorded using 
luminometer (MODULUS, Promega). The luminescent signal which is proportional to the amount of ATP in 
the sample, also which indicates the presence of metabolically active cells is expressed in %. 
5.4.6. Treatment with lapatinib, erlotinib and bexarotene cause 
transcriptional downregulation of HER receptor family in ovarian cancer. 
Following the determination of cytotoxicity of lapatinib, erlotinib and bexarotene in 
PEO1, OVCAR3 and SKOV3 cell lines, further studies were undertaken to, 
investigate the effects these drugs on the transcription of HER1, HER2, HER3 
and HER4 genes. To address this, the cloned promoter regions of HER1, HER2, 
HER3 and HER4 genes as luciferase-based reporter assays (known as prHER1, 
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prHER2, prHER3, and prHER4 respectively) were used. These reporters were 
used to directly report and measure any transcriptional perturbation of the HER 
family receptors.  The prHER1, prHER2, prHER3, prHER4 were transfected into 
the ovarian cancer cell lines, treated the cells with the drugs for 96 h, and then 
assayed for luciferase activity (Figures 5.7, 5.8 and 5.9). Untreated cells or cells 
treated with tBHQ were used as controls. These experiments clearly 
demonstrated transcriptional inhibition of HER1, HER2, HER3 and HER4 genes 
by all the three drugs tested. 
 
Figure 5.7: Lapatinib, erlotinib and bexarotene causes transcriptional downregulation of HER1, 
HER2, HER3 and HER4 in PEO1 cell line. Briefly cells were transfected in quadruplicate with either empty 
PGL3 basic vector or 1 𝜇g PGL3 basic vector with cloned fragments of either HER1 (prHER1) or HER2 
(prHER2) or HER3 (prHER3) or HER4 (prHER4) promoter driving the expression of luciferase gene for 24 h. 
Co-transfection with 0.2 𝜇g pRL-CMV plasmid was performed as an internal transfection control. Following 
this, cells either left untreated or treated with 100 µM tBHQ or 5 µM each of either lapatinib or erlotinib or 2.5 
µM bexarotene for 24 h. Following this, cell lysates were prepared and assayed for Luciferase activity 
(luciferase assay and stop and glo Luciferase system, Promega). Data presented are the means ± S.D. of n 
= 3; independent experiments performed in quadruplicates with statistical significance determined by ONE 
WAY ANOVA followed by Tukey’s post hoc test according to the scale *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
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Figure 5.8: Lapatinib, erlotinib and bexarotene causes transcriptional downregulation of HER1, 
HER2, HER3 and HER4 in OVCAR3 cell line. Briefly cells were transfected in quadruplicate with either 
empty PGL3 basic vector or 1 𝜇g PGL3 basic vector with cloned fragments of either HER1 (prHER1) or 
HER2 (prHER2) or HER3 (prHER3) or HER4 (prHER4) promoter driving the expression of luciferase gene 
for 24 h. Co-transfection with 0.2 𝜇g pRL-CMV plasmid was performed as an internal transfection control. 
Following this, cells either left untreated or treated with 100 µM tBHQ or 5 µM each of either lapatinib or 
erlotinib or 2.5 µM bexarotene for 24 h. Following this, cell lysates were prepared and assayed for Luciferase 
activity (luciferase assay and stop and glo Luciferase system, Promega). Data presented are the means ± 
S.D. of n = 3; independent experiments performed in quadruplicates with statistical significance determined 
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Figure 5.9: Lapatinib, erlotinib and bexarotene causes transcriptional downregulation of HER1, 
HER2, HER3 and HER4 in SKOV3 cell line. Briefly cells were transfected in quadruplicate with either empty 
PGL3 basic vector or 1 𝜇g PGL3 basic vector with cloned fragments of either HER1 (prHER1) or HER2 
(prHER2) or HER3 (prHER3) or HER4 (prHER4) promoter driving the expression of luciferase gene for 24 h. 
Co-transfection with 0.2 𝜇g pRL-CMV plasmid was performed as an internal transfection control. Following 
this, cells either left untreated or treated with 100 µM tBHQ or 5 µM each of either lapatinib or erlotinib or 2.5 
µM bexarotene for 24 h. Following this, cell lysates were prepared and assayed for Luciferase activity 
(luciferase assay and stop and glo Luciferase system, Promega). Data presented are the means ± S.D. of n 
= 3; independent experiments performed in quadruplicates with statistical significance determined by ONE 
WAY ANOVA followed by Tukey’s post hoc test according to the scale *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
5.5. Key findings 
In this section, ten compounds that alter NRF2/ARE signalling in the MCF7-
AREc32 reporter cell line were investigated. The investigation included 
cytotoxicity screening and the ability of the compound to either cause production 
or sequestration of ROS. The results indicated that these compounds were able 
to engage and the NRF2-KEAP1 either by positive or negative feedback loop 
directly to stimulate or disrupt NRF2 activity and function (Figures 5.2 and 5.3). 
The data also indicated compounds such as RA, 9-cis RA, brusatol and 
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bexarotene inhibited elevated the level of ROS (Figure 5.4) and then lapatinib, 
erlotinib and bexarotene downregulated the transcriptional level of HER family 
receptors in ovarian cancer cell (Figures 5.7, 5.8 and 5.9). This work has 
demonstrated the feasibility of using bexarotene to treat ovarian cancers. 
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6.1 Abstract 
In the previous chapters, it is observed that tBHQ and retinoid treatment led to 
transcriptional upregulation and downregulation of HER1 and HER4, suggesting 
that NRF2 is involved in regulating the receptor expression and as such may 
influence responses to targeted therapies involving HER RTK inhibitors, lapatinib 
and erlotinib. This important question was investigated by treating PEO1, 
OVCAR3, SKOV3 and MCF7-AREc32 cells with, either lapatinib or erlotinib 
alone, or by co-treatment with tBHQ and/or bexarotene to examine the 
consequences of NRF2 activation and/or inhibition on drug responses. It is found 
that pharmacological activation of NRF2 by tBHQ and/or inhibition by bexarotene 
alone was sufficient to enhance or reduce the proliferation of all the cell lines for 
up 72 h. Further, exposure of cells to lapatinib and erlotinib, inhibited the 
proliferation of all the cell lines for up to 72 h of treatment, with slight loss of 
inhibitory effect at 96 h. Interestingly however, pre-treatment of cells with 100 μM 
tBHQ for 5 h before the introduction of the HER family RTK inhibitors significantly 
protected cells from the growth inhibitory action of the subsequently added drugs. 
Moreover, pre-treatment of cells with 2.5 μM bexarotene for 5 h before the 
introduction of HER family RTK targeted drugs significantly increases their 
cytotoxicity. This was consistent in all the cell lines and for all the treatment days 
tested. The combination of tBHQ with the inhibitors did not only protect the cells 
but increased their survival even beyond the untreated levels on all days in all the 
cell lines. The combination of bexarotene with the inhibitors increases the 
cytotoxicity of the drugs and decreased the survival of the ovarian cancer cells far 
below the untreated level. This demonstrated that NRF2 activation is not only 
implicated in resistance to other agents as previously demonstrated but can also 
lead to resistance to chemotherapies involving lapatinib and erlotinib whose 
actions otherwise are very specific to HER family receptors with no clear relation 
to antioxidant response element. Thus, blockade of the cellular anti-oxidative 
system by NRF2 inhibition significantly augmented the lapatinib and erlotinib 
cytotoxicity and can potentially overcome resistance to therapies involving 
lapatinib and erlotinib. Taken together, it is demonstrated that bexarotene alone 
and its combination with either lapatinib or erlotinib exerts inhibition of the NRF2 
to improve ovarian cancer treatment for a better outcome. 
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6.2. Introduction 
There are several studies that highlight the relationship between ROS and NRF2 
and the involvement of NRF2-ARE and HER receptor family pathways (Khalil et 
al., 2016a, Khalil et al., 2016b, Manandhar et al., 2012, Kang et al., 2014b). 
NRF2 is known to promote resistance to chemotherapeutic agents, in addition to 
its contribution to general cytoprotection, metabolic reprograming, and cell 
survival (Hayes and McMahon, 2009, Hayes and Ashford, 2012, Hayes et al., 
2015, Wang et al., 2007, Tang et al., 2011). Moreover, targeted chemotherapy 
involving RTKi against HER family receptors has generated interest as a strategy 
to overcome chemoresistance in breast, ovarian, and other forms of cancers 
(Khalil et al., 2016b, Goltsov et al., 2014a, Khalil et al., 2016a, Langdon et al., 
1988, Langdon et al., 2010, Langdon and Cameron, 2013, Mullen et al., 2007, 
Tang et al., 2011, Tu et al., 2013, Messersmith and Ahnen, 2008, Paez et al., 
2004, Regales et al., 2009).  
Studies have examined the crosstalk between growth promoting MAPK and PI3K 
pathways and NRF2 antioxidant pathways in numerous cell systems (Kang et al., 
2005, He et al., 2012, Kang et al., 2000, Zipper and Mulcahy, 2000, Khalil et al., 
2016a). However, in the majority of such studies, the focus was on the regulation 
of NRF2 activity and its functions by these kinases. While the interaction and 
complex formation of NRF2 with HER2 has been reported to enhance HER 
signalling (Kang et al., 2005, He et al., 2012, Kang et al., 2000, Zipper and 
Mulcahy, 2000), studies by Khalil et al., (2016a and 2016b) recently 
demonstrated the transcriptional regulation of HER2 and HER3 by NRF2  (Khalil 
et al., 2016b, Khalil et al., 2016a). Further, they demonstrated a novel relationship 
between NRF2 function, HER2/HER3 signalling, ROS generation and the 
sensitisation of ovarian cancer cells to the killing effects of the targeted therapy 
agents, trastuzumab, pertuzumab, or combination of the two (Khalil et al., 2016b, 
Khalil et al., 2016a). Interestingly, the work here (in chapters 4, 5 and 6) and 
(Khalil et al., 2016b) suggests that all the members of the HER family receptors 
are regulated by NRF2 in ovarian cancer cells. Furthermore, a mechanism of 
action of lapatinib and erlotinib, like trastuzumab, pertuzumab (Khalil et al., 
2016b), likely involves inhibition of NRF2-ARE function, accumulation of ROS and 
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the subsequent killing of the cancer cells. This led us to hypothesize that 
inhibition of NRF2 function and concomitant cellular accumulation of ROS are 
possible mechanistic components and basis of action of HER2-targeted small 
molecule RTK inhibition. This may equally be the basis and a contributing 
determinant of resistance to RTK inhibitors like lapatinib and erlotinib. 
6.3. Aims and objectives 
6.3.1 The aim 
The main aims of this chapter are: 
1.  To examine whether a novel mechanism of action of lapatinib and 
erlotinib, as RTK inhibitors, involves NRF2 inhibition and the accumulation 
of ROS to sensitise ovarian cancer cells to the killing effect of RTKi 
chemotherapeutic drugs. 
2. To examine and develop novel interventions that may be more effective to 
treat and overcome chemoresistance to RTK inhibition in ovarian cancer. 
6.3.2 The objectives are: 
1. To investigate whether the mechanism of action of RTK inhibitors, 
lapatinib and erlotinib, involves the modulation of NRF2 function in 
ovarian cancer cells  
2. To investigate the effectiveness and the enhancement of the cytotoxic 
action of lapatinib and/or erlotinib and when combined with additional 
NRF2 inhibitor 
3. To identify the connectivity of NRF2 and HER family receptor pathways 
that will open up for a novel strategy of improving cancer treatment. 
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6.4. Results 
6.4.1. Pharmacological activation of NRF2 by tBHQ enhances cellular 
survival and attenuates the cytotoxicity caused by HER family targeting 
RTK inhibitory chemotherapeutic agents in ovarian cancer 
NRF2 is shown to promote resistance to chemotherapeutic agents and to 
increase the proliferation and survival of cancer (Hayes and McMahon, 2009, 
Hayes and Ashford, 2012, Hayes et al., 2015, Wang et al., 2007, Tang et al., 
2011). However, several chemotherapeutic drugs including lapatinib and erlotinib 
are used to treat HER family overexpressing cancers including ovarian cancer 
(Kuang et al., 2010, Roskoski Jr, 2014, Geyer et al., 2006, Ryan et al., 2008). In 
this study, cell lines, PEO1, SKOV3 and OVCAR3 which are known to have 
different expressions of HER family and NRF2 (Khalil et al., 2015, Khalil et al., 
2016a, Mullen et al., 2007) were used. Firstly, it is examined whether 
pharmacological preactivation of NRF2 would change the cytotoxic responses of 
ovarian cells to lapatinib (5 μM) or erlotinib (5 μM). In order to achieve this, cells 
were grown in media containing 5% charcoal-stripped FBS and 1 nmol/L 
Heregulin (HRG) and then all the relevant treatments were done. 
Pharmacological activation of NRF2 by tBHQ alone was sufficient to enhance the 
proliferation of all the cell lines at all the time points (24 h, 48 h, 72 h and 96 h) 
(Figure 6.1). However, and as expected, exposure of these cells to the RTK 
inhibitors, lapatinib or erlotinib, inhibited the proliferation of all the cell lines for up 
to 72 h of treatment, while each drug slightly loses its inhibitory effect after 96 h. 
Interestingly, pretreatment of cells with 100 μM tBHQ for 5 h before the 
introduction of either lapatinib or erlotinib significantly protected cells from the 
growth inhibitory action of the subsequently added RTK inhibitor. These were 
consistent in all the 3 cell lines and for all the treatments time points tested 
(Figure 6.1). Thus, combining tBHQ with the RTK inhibitors did not only protect 
the cells but also enhanced their proliferation and survival significantly in all cell 
lines (Figure 6.1). Therefore, this indicated that NRF2 and its activation is 
modulating the action and effectiveness of the RTK inhibitors, lapatinib and 
erlotinib. Thus, NRF2 is not only implicated in resistance to agents as previously 
demonstrated (Hayes and McMahon, 2009, Hayes and Ashford, 2012, Hayes et 
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al., 2015, Wang et al., 2007, Tang et al., 2011) but can also may be mediating the 
resistance to chemotherapies involving lapatinib and erlotinib whose actions are 
more specific to HER receptors than NRF2-KEAP-1 or ARE pathway. 
 
Figure 6.1: NRF2 activation causes cytoprotection from HER family chemotherapeutic agents, 
lapatinib and erlotinib in ovarian cancer cells. Briefly, exponentially growing cells were seeded in 
triplicates in 96-well plates for 24 h. Following this, cells were either left untreated in media containing 1nM 
Heregulin (H) or treated with same media containing in the presence of 1 nM HRG with 5 μM each of 
lapatinib (H+L) or erlotinib (H+E) or treated with combination 5μM lapatinib and 100 μM tBHQ (H+L+T) or 
combination of 5 μM erlotinib and 100 μM tBHQ (H+E+T) at different time points. Cell number was assessed 
by use of the cell titre glo assay. Data shown are means ± S.D. of n= 3 independent experiments performed 
in triplicates, normalised to (H), expressed in fold change with statistical significance was calculated by ONE 
WAY ANOVA followed by Tukey’s post hoc test according to the scale :(*: p<0.05, **: p<0.01, ***:p<0.001, 
and ****:p<0.0001). 
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6.4.2. Pharmacological inhibition of NRF2 by bexarotene reduces the 
proliferation and survival of Ovarian Cancer Cells by increasing the 
Cytotoxicity Caused by HER Family RTK Targeted Chemotherapeutic 
Agents 
The transcriptional control of HER family by NRF2 and the way that NRF2 
hindrance prompted to the transcriptional constraint of these kinases family gives 
a vital way to sensitisation towards drugs that will thus be more lethal to the 
ovarian tumour (Khalil et al., 2016b, Khalil et al., 2016a).  
To address this and to further confirm that NRF2 is modulating the cytotoxic 
action and effectiveness of lapatinib and erlotinib, cells (PEO1, OVCAR3 and 
SKOV3) were grown in media containing 5% charcoal-stripped FBS and 1 nmol/L 
HRG and then exposed to lapatinib (5 μM) or/and erlotinib (5 μM) alone or their 
combination with bexarotene (2.5 μM) (Figure 6.2). First, it was found that 
treatment with lapatinib alone or erlotinib alone causes cytotoxicity compared to 
the untreated in all the cell lines. Importantly, bexarotene co-treatment greatly 
enhanced both lapatinib and erlotinib cytotoxicity in all the cell lines resulting in 
lower cell survival in comparison with their corresponding single treatments alone 
at all the time points (24 h, 48 h, 72 h, 96 h) with a regain of survival at 96 h. 
These important results demonstrated that bexarotene treatment, which was 
shown to repress NRF2 activity and disrupt the antioxidant response pathway 
reduces ovarian cancer cell proliferation and survival by increasing the 
cytotoxicity caused by lapatinib and erlotinib. This confirms a role for NRF2 in 
modulating the action and effectiveness of RTK inhibitors, lapatinib and erlotinib, 
and makes this a strategy representing a novel finding by which ovarian cancer 
cell proliferation and survival could be diminished and eradicated. 
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Figure 6.2: NRF2 inhibition increases the chance of cytotoxicity of HER family-targeted agents, 
lapatinib and erlotinib in ovarian cancer cells. Briefly, exponentially growing cells were seeded in 
triplicates in 96-well plates for 24 h. Following this, cells were either left untreated in media containing 1 nM 
Heregulin (H) or treated with same media containing in the presence of 1 nM HRG with 5 μM each of 
lapatinib (H+L) or erlotinib (H+E) or treated with combination 5 μM lapatinib and 2.5 μM Bexarotene 
(H+L+BEX) or combination of   5 μM erlotinib and 2.5 μM Bexarotene (H+E+BEX) at different time points. 
Cell number was assessed by the use of the cell titre glo assay. Data shown are means ± S.D. of n=3 
independent experiments performed in triplicates, normalised to (H), expressed in fold change with statistical 
significance was calculated by ONE WAY ANOVA followed by Tukey’s post hoc test according to the scale 
:(*: p<0.05, **: p<0.01, ***: p<0.001, and ****:p<0.0001). 
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6.4.3 Chemotherapeutic action of lapatinib and erlotinib involves generation 
of ROS in ovarian cancer 
The biochemical and physiological oxidative processes in the body lead to the 
production of ROS which plays a major role in the initiation and progress of 
various human diseases which are associated with numerous physiological and 
pathophysiological processes. ROS has a vital effect when it is in low amount in 
the cell; a role that involves regulating intracellular signalling and homeostasis, 
processes that favour cell growth, cell division and survival (Prasad et al., 2017). 
Moreover, studies have illustrated the co-modulatory role and interaction of ROS 
with HER family receptors and other growth promoting pathways (Khalil et al., 
2016a). Based on the observation in (Figures 6.1 and 6.2) and the previous work 
reported by Khalil et al. (2016a and 2016b) it is further hypothesised that the 
cytotoxic action of RTK inhibition targeting HER receptor (lapatinib and erlotinib) 
involves cellular accumulation of ROS concomitant to the disruption of NRF2 and 
its function. 
To address this hypothesis using lapatinib and erlotinib, firstly total ROS levels in 
basal, HRG stimulated and drug-inhibited states in all three cell lines were 
studied. Here as well, HRG which is known to be a potent ligand for HER 
receptors, was used. The data in Figure 6.3A illustrates that HRG stimulation 
alone led to a significant increase in ROS levels in all three cell lines as 
compared to basal levels in unstimulated cells. Moreover, it is seen that 
treatments with lapatinib, erlotinib, their combination or their combination with 
bexarotene led to ROS generation in all the ovarian cancer cell line models. ROS 
elevation was seen at all the time points (24 h, 48 h, 72 h and 96 h) tested with 
an observed elevation of ROS being differential in cell- and time-dependent 
fashion (Figure 6.3B). 
Investigation of the single drug treatment (lapatinib or erlotinib), in all the cell lines 
(Figure 6.3B), showed that lapatinib often generated more ROS than erlotinib, 
while their combination failed to generate significant higher levels of ROS than 
their singular administration at all the time points investigated. However, the fact 
that administration of these drugs led to the generation of ROS (Figure 6.3B), 
suggests ROS could be a contributing factor in cellular cytotoxicity of lapatinib 
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and erlotinib and implicates the engagement of AR pathway and inhibition of 
NRF2 function during drug action. Thus, it is next sought to investigate the status 





Figure 6.3: Chemotherapeutic treatment with lapatinib and erlotinib generates reactive ROS in 
ovarian cancer cells: (A) Heregulin treatment causes persistent elevation of ROS in ovarian cancer cells. 
Exponentially growing cells were seeded in triplicates in opaque flat bottom black walled 96-well plates for 24 
h. Following this, cells were either left untreated (UT) or treated with 1 nM Heregulin for different time points 
as indicated. Following incubations, cells were loaded with DCFDA fluorescent stain for 45 min and assayed 
for ROS as described in Materials and Methods. (B) Lapatinib, erlotinib and their combination cause ROS 
generation. Cells were seeded as in (A) and treated with either 1 nM HRG alone or with co-treatment of 5 
µM lapatinib (LAP), erlotinib (ERLO) or their combination (COMB) for different time points as indicated and 
ROS assay was repeated. For both (A) and (B), the fluorescence reading recorded from each well was 
normalized to total cell abundance within the same wells using Bradford assay as described in Materials and 
Methods. Data shown are mean values ± S.D of n=3 independent experiments performed in triplicates, 
normalized to UT in (A) or HRG in (B) and expressed as fold change. Statistical significance was determined 
between treatment groups by TWO WAY ANOVA followed by post hoc Tukey’s test as appropriate and 
significance expressed according to the scale :(*: p<0.05, **: p<0.01, ***: p<0.001, and ****: p<0.0001). 
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6.4.4 Lapatinib and erlotinib followed with pharmacological inhibition of 
NRF2 by Bexarotene disrupts its antioxidant transcription, suppresses 
NRF2 and HO-1 protein levels and elevates cellular ROS  
Bexarotene which on its own is reported to be an anticancer agent, has 
previously been shown to inhibit NRF2/ARE in an NRF2 dependent manner 
(Garattini et al., 2014, Saito-Hakoda et al., 2015, Qi et al., 2016, Wu et al., 2014, 
Heo et al., 2016). In order to extend the observations reported in the previous 
section, the consequences of NRF2 inhibition following exposure to the 
chemotherapeutic drugs was further investigated. Experiments were performed, 
firstly in the ovarian cancer cell line models and subsequently in MCF7-AREc32 
cell line in order to validate and confirm the inhibitory action of bexarotene and 
also drugs (lapatinib and erlotinib) on the NRF2 dependent AR pathway. 
Exposure to bexarotene alone caused a decrease in total NRF2 levels in 
OVCAR3 and SKOV3 cells (Figure 6.4A). Interestingly the levels of NRF2 in 
these cell lines were further decreased following co-treatment with combined 
chemotherapy (lapatinib and erlotinib) in PEO1 cells. This drug-induced reduction 
in NRF2 levels suggests that chemotherapy is also targeting NRF2. Next, using 
the luciferase ARE reporter MCF7-AREc32 cell line, it was found that bexarotene 
treatment significantly inhibited the transcriptional activity of NRF2 at all the time 
points tested (Figure 6.4B). Bexarotene treatment of MCF7-AREc32 reporter cell 
line also elevated ROS levels (Figure 6.4C). Furthermore, bexarotene enhanced 
the inhibitory action of the combination of lapatinib and erlotinib on AR pathway. It 
is also observed that bexarotene alone and in combination with lapatinib and 
erlotinib reduced the level of HO-1 (Figure 6.4A). These findings suggest that 
while bexarotene inhibits the NRF2 dependent ARE pathway, such treatment 
might also elevate cellular ROS levels in the ovarian cancer cell lines. Indeed, it is 
found that treatment with bexarotene significantly represses total NRF2 and 
induced ROS in the three cell lines tested (Figures 6.4A and 6.4C). 
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Figure 6.4: Combined treatment with bexarotene causes inhibition of NRF2 dependent antioxidant 
response pathway and generates ROS. (A) Western analysis showing repression of NRF2 and HO-1 
levels following bexarotene treatment in PEO1, OVCAR3 and SKOV3 cell lines. Exponentially growing cells 
were either left untreated, treated with 2.5 μM bexarotene or a combination of 2.5 μM bexaroene together 
with 5 µM of lapatinib and erlotinib for 24 h before being harvested to prepare protein lysates and processed 
as described in Materials and Methods. Beta actin (β-actin) was used as loading control. The bars indicate 
NRF2 and HO-1 levels following quantification of immunoblot signal intensities obtained in (A) and 
normalized to the value of UT and expressed as fold change. The signal intensities of bands were quantified 
through integrated optical densitometry measurement. Images are representative of at least two independent 
experiments performed. (B) Bexarotene treatment causes inhibition of NRF2 dependent transcription. 
Exponentially growing AREc32 cell line stably expressing 8xcis-AREs driving the expression of luciferase 
gene in an NRF2 dependent manner were either left untreated (UT), treated with bexarotene alone, or with 
bexarotene and combination of lapatinib and erlotinib for different time points as indicated. Following this, 
cell lysates were prepared and assayed for Luciferase activity (BrightGlo Luciferase system, Promega). (C) 
Bexarotene treatment causes increase in ROS levels. Exponentially growing AREc32 cell line stably 
expressing 8xcis-AREs driving the expression of luciferase gene in an NRF2 dependent manner were 
seeded in triplicates in opaque flat bottom black walled 96-well plates for 24 h. Following this, cells were 
either left untreated (UT), treated with bexarotene alone or with bexarotene and combination of lapatinib or 
erlotinib for different time points as indicated. Following incubations, cells were loaded with DCFDA 
fluorescent stain for 45 min and assayed for ROS as described in Materials and Methods. Data are the mean 
values ± S.D of n=3 independent experiments performed in quadruplicates, with statistical significance 
determined by TWO WAY ANOVA followed by Tukey’s post hoc test according to the scale * P <0.05, **P 
<0.01, ***P <0. 001. 
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6.4.5 Activity of lapatinib, erlotinib and bexarotene involves repression of 
NRF2-dependent transcription and depletion of total GSH 
Based on the additionally decreased levels of NRF2 observed in MCF7-AREC32 
stable cell line following combined lapatinib and erlotinib with bexarotene (Figure 
6.4A), a single treatment with lapatinib or erlotinib or combination was 
investigated to confirm the inhibition of NRF2-dependent transcription. The 
MCF7-AREc32 cell line, stably expressing 8 copies of NRF2 dependent cis-
regulatory AREs, as a luciferase reporter was used. The results (Figure 6.5) show 
that stimulation with HRG, a potent ligand for HER receptors only, a significant 
induction of antioxidant response pathway was observed. However, the co-
treatment with the combination of lapatinib and erlotinib and with the single drug 
alone disrupted and suppressed the ARE-dependent induction significantly 
thereby inhibiting the NRF2 function. A combination of either lapatinib and 
bexarotene or erlotinib and bexarotene also disrupted the function of NRF2, and 
the greatest inhibition of NRF2/ARE activity was observed when the cells were 
treated with a combination of lapatinib, erlotinib and bexarotene (Figure 6.5).  
Moreover, to investigate whether NRF2 repression would also lead to depletion of 
total cellular glutathione, the ovarian cancer cells (PEO1, OVCAR3 and SKOV3) 
were treated for 72 h. It is found out that the 72 h treatment with HRG induced 
total cellular GSH levels, while the combination of HRG with lapatinib, erlotinib or 
bexarotene significantly reduced the GSH levels in all the cell lines (Figure 6.6). 
Generally, the combination of lapatinib with erlotinib, lapatinib with bexarotene, or 
erlotinib with bexarotene caused more significant GSH depletion than singular 
treatments. These results indicated that NRF2 inhibition, ROS accumulation and 
GSH depletion may be contributing to the unique mechanism of cytotoxicity of 
lapatinib or erlotinib and that bexarotene enhances the mechanism of action and 
the cytotoxicity of lapatinib and/or erlotinib. Overall this provides support and 
strengthens the hypothesis that the cellular cytotoxicity of lapatinib and/or 
erlotinib involves the engagement of the AR pathway and the concomitant 
inhibition of NRF2 function during drug action. 
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Figure 6.5: Treatments with lapatinib, erlotinib and Bexarotene causes inhibition of NRF2 dependent 
transcription. Single and combination of lapatinib and erlotinib cause inhibition of NRF2 dependent 
transcription. Exponentially growing MCF7-AREc32 cell line stably expressing cis-regulatory AREs driving 
the expression of luciferase gene in an NRF2 dependent manner were treated with 1 nM HRG alone or with 
co-treatment of 5 µM lapatinib and erlotinib either individually or in combination for different time points as 
indicated. Following this, cell lysates were prepared and assayed for Luciferase activity as described in 
Materials and Methods. Data shown are mean ± S.D of n=3 independent experiments performed in 
quadruplicates. Statistical significance is determined by ONE WAY ANOVA followed by Tukey’s post hoc 
test. Asterisks indicate significant differences between individual groups as indicated and according to the 
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Figure 6.6: Treatments with lapatinib, erlotinib and Bexarotene causes depletion of total GSH levels. 
Single and combination of lapatinib and erlotinib causes decrease in glutathione level. Exponentially growing 
cells where seeded in luminometer-compatible 96-well plates and allow to grow overnight at 37°C in a 5% 
CO2 culture incubator. The following day, the cells were either left untreated (UT) or treated with media 
containing 1nM Heregulin alone HRG) or with co-treatment of 5 µM lapatinib or 5 µM erlotinib or 2.5 µM 
bexarotene their combinations for 72 h before being processed for glutathione assay. Data are mean ± S.D 
of n=3 independent experiments performed in quadruplicates. Statistical significance was determined by 
ONE WAY ANOVA followed by Tukey’s post hoc test according to the scale * p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
6.4.6 Co-treatment of lapatinib and erlotinib with bexarotene reduces the 
HER family and NRF2 protein levels 
The observation that retinoid (bexarotene, RA) or tBHQ treatment caused 
downregulation or upregulation of HER receptors at transcriptional and protein 
levels as demonstrated in the previous chapters suggests that NRF2 may be 
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directly involved in regulating HER receptor expression and as such might have a 
role in responses to targeted chemotherapies involving HER receptor family. The 
cellular cytotoxicity of HER targeting lapatinib and/or erlotinib culminates with the 
engagement of AR pathway and the concomitant inhibition of NRF2 function 
during drug action. 
To answer this important question, PEO1, OVCAR3 and SKOV3 cells either with 
lapatinib and erlotinib alone or by co-treatment with retinoid/rexinoid (bexarotene) 
were investigated to examine the consequences of NRF2 inhibition on drug 
effects and cellular responses. Treatment with lapatinib alone or erlotinib alone 
represses both pNRF2, pHER1 pHER2 pHER3 and pHER4 levels in the cell lines 
(Figure 6.7A and B). There was also similar concomitant marked repression of 
pAKT levels in cell lines by either drugs and in combination with bexarotene. 
These results are consistent with lapatinib or erlotinib inhibiting NRF2 activity and 
repressing HER receptor family. Moreover, co-treatment with an NRF2 inhibitor 
(bexarotene) can further repress the HER signalling pathway and might sensitize 
the ovarian cancer cells to the killing effects of lapatinib and/or erlotinib. 
Furthermore, results in (Figure 6.2) appears to lend support to these assertions, 
as significant increased cytotoxicity of lapatinib or erlotinib following the 
pharmacological inhibition of NRF2 with bexarotene was observed.  
These findings illustrated the important role of NRF2 in influencing outcomes to 
targeted therapies involving HER receptor inhibition. These results indicate the 
effectiveness of anti-cancer therapy involving lapatinib and erlotinib could be 
enhanced by incorporating bexarotene to inhibit the NRF2 dependent antioxidant 
response pathway. As such, this represents a novel mechanism and role for 
NRF2 inhibition by bexarotene in sensitising cancer cells to the killing effect of 
lapatinib and erlotinib. It also highlights the possibility of using the combination of 
lapatinib and bexarotene or erlotinib with bexarotene to overcome drug 
resistance. 
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Figure 6.7: NRF2 inhibition with bexarotene sensitises HER signalling pathway to RTK inhibitors: (A) 
Lapatinib and (B) Erlotinib. Immunoblot analysis showing bexarotene dependent repression of HER 
signalling following its combination with lapatinib and erlotinib. Exponentially growing cells were either left 
untreated in media containing 1 nM Heregulin (UT) or treated with treated with same media containing in the 
presence of 1 nM Heregulin with lapatinib (Lap) alone or erlotinib (Erl) alone, each at 5 µM, or with co-
treatment of 2.5 μM bexarotene (Lap+Bex) or (Erl+Bex) for 24 h before and processed for immunoblotting 
using relevant antibodies and β-actin was used as loading control. Images are representative of at least two 
independent experiments performed. 
6.5. Key findings 
This chapter aims to explore signalling pathways that might explain the 
mechanism of action and efficacy of HER family targeted chemotherapies that 
are critical to use or avoid in order to overcome therapeutic resistance. 
Specifically, it seeks to determine the action mechanism of targeted 
chemotherapeutic agents (lapatinib and erlotinib) and in particular, to understand 
enhanced cytotoxic response, ROS accumulation, NRF2 inhibition and GSH 
depletion triggered uniquely by a combination of either one or two 
chemotherapeutics, with the addition of bexarotene (NRF2 inhibitor) rather than 
individual agents in ovarian cancer cells. It was found that at least part of the 
mechanism of action of these chemotherapeutic agents involved NRF2 inhibition 
(Figure 6.4A) and generation of ROS (Figure 6.3), which contributed to the 
cytotoxic effects and killing of the ovarian cancer cells (Figure 6.2). The cell lines 
exhibited cytotoxicity to lapatinib and erlotinib alone, or their combination with 
bexarotene (Figure 6.2). However, there was inhibition of HER signalling (Figure 
6.7) following lapatinib or erlotinib alone or their combination with bexarotene in 
ovarian cancer cells. 
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7.1. Discussion 
This research work was carried out to further the knowledge of the functional 
regulation of the HER receptor family and NRF2 in different conditions and cell 
lines. It was intended to help gain an overall understanding of how the function of 
NRF2 could have a role in regulating the HER receptor family in ovarian cancer 
cells. This, in turn, may enable the improvement of the efficacy of RTK targeting 
cancer chemotherapeutic agents in order to overcome chemoresistance in 
ovarian cancer. This was achieved by firstly cloning the proximal promoter 
regions HER1 and HER4, and then using the already cloned (Khalil et al., 2016b) 
promoter regions of HER2 and HER3 to examine and re-examine their 
functionality and transcriptional regulation. The basal and inducible expression 
levels of the four genes were evaluated using both the NRF2 inducer (tBHQ) and 
inhibitors (siRNA and RA) with a panel of ovarian cancer cells. The tBHQ 
treatments lead to up-regulation of the transcription of all the HER receptors 
whilst inhibiting NRF2 function leads to their down-regulation, suggesting that 
NRF2 regulates the expression of HER receptors in ovarian cancer cells. 
Following the screening of a panel of compounds expected to be potent NRF2 
modulators, bexarotene was found be one of the most potent NRF2 inhibitors as 
well as the most suitable to include in further studies because it is already a 
clinical and anticancer drug.  
Next, the study looked at the protein levels of both NRF2 and HER receptors in 
order to examine their responses, following different treatments and perturbations 
of NRF2 function. This initial part of the research provided some insight into the 
molecular basis for regulation of the expression of these HER family receptor 
genes by NRF2. The research also found a novel mechanism and role for NRF2 
inhibition by bexarotene in sensitising ovarian cancer cells to the killing effect of 
RTK inhibitors, lapatinib and erlotinib. It also highlighted the possibility of using a 
combination of lapatinib and bexarotene, or erlotinib with bexarotene, to sensitize 
and overcome drug resistance. 
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7.1.1 Cloning of the proximal promoter regions of human HER1 and HER4 
genes 
This section of the study reports on cloning of the promoter regions of human 
HER1 and HER4 genes and examines their transcriptional activity in human 
ovarian cancer cell lines (PEO1, OVCAR3 and SKOV3). The HER family 
receptors are one of the regulators of cellular proliferation and survival and are 
also, in part, the ones that determine the initiation and progression of cancer 
(Kang et al., 2014b, Schlessinger, 2000, Roskoski Jr, 2014, Yarden, 2001, 
Prenzel et al., 2001). Using the computer-based analysis known as bioinformatics 
(Sandelin et al., 2004), it was found that the promoters of HER1 and HER4 
contained putative binding sites of NRF2 (Figure 3.2), this being a transcription 
factor that steers the expression of many genes including cytoprotective and 
detoxifying genes (Hayes, 2000, Hayes et al., 2016, Hayes and McMahon, 2009).  
Recent studies have identified HER family as a target in cancer (Burgess, 2008, 
Downward, 2003, Khalil et al., 2016a, Khalil et al., 2016b, Goltsov et al., 2014a, 
Zwick et al., 2001, Gschwind et al., 2004, Mendelsohn and Baselga, 2000, 
Shende et al., 2017, Koustas et al., 2017, Guo et al., 2016) and showed that the 
expression of HER family could be regulated both at the transcriptional and 
translational level (Khalil et al., 2016b, Khalil et al., 2016a). However, little is 
known about the gene promoter and cognate transcription factors that mediate 
HER family gene expression. So far, only a few studies were undertaken to find 
potential cis-regulatory elements and investigate their influence on HER family 
gene transcription (Khalil et al., 2015, Khalil et al., 2016b, Khalil et al., 2016a). A 
study reported by Khalil et al., (2016) characterised the HER2 and HER3 
promoter genes. The genes contain the putative NRF2 binding sites at the 
proximal promoter level. Further, it has demonstrated crosstalk between the 
transcription factor NRF2 and HER2/HER3 transcription (Khalil et al., 2016b). 
The presence of a putative binding site of NRF2 in the promoters of these genes 
and other previous studies (Khalil et al., 2016b) enables the hypothesis of a 
possible link between HER receptors and NRF2, and is why it was decided to 
clone the promoter regions of HER1 and HER4. 
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One of the aims of this study was to clone and then test basal activities HER1 
and HER4 promoters. 1.5 kb and 1.3 kb DNA fragments encompassing the HER1 
and HER4 gene proximal promoters were each placed upstream of the luciferase 
reporter gene in the pGL3 vector. Following this, the clones were confirmed via 
sequencing before being transiently transfected into three different panels of 
ovarian cell lines, namely PEO1, OVCAR3 and SKOV3. The luciferase reporter 
system assay indicated that both prHER1 and prHER4 showed a high and 
differential basal level of expressions in all the cell lines tested when compared to 
the control pGL3 vector (Figure 3.8). This study found that the transcriptional 
activity of HER1 and HER4 suggested the functionality of the promoter 
constructs, and this, therefore, provided the tools to study the regulation of HER1 
and HER4 receptors. 
The generation basal levels of luciferase activity suggest that the regulation of 
HER1 and HER4 gene expression occur at the transcriptional level. As shown in 
this study, the identification of the putative binding sites of NRF2 in the promoter 
regions of genes may enhance the promoter activity, thereby suggesting a 
possible role of NRF2 in HER1 and HER4 regulation. These findings suggest that 
the 1.5 kb and 1.3 kb fragments upstream of the transcription start site could be a 
core functional promoter, essential for the study of the transcriptional regulation of 
HER1 and HER4 in cancer cells. Recently, a study by Khalil et al. reported the 
cloning of promoter regions of HER2 and HER3, and so provided the importance 
of generating transcriptional reporter assays for both HER2 and HER3 receptors 
in the context of studying transcriptional regulations in cancer therapy (Khalil et 
al., 2016b). Another study by Horikawa et al. (1999) is similar to this study, and 
this provides credence and support for the importance of cloning promoter 
regions of a gene for the study of its regulation. Horikawa et al. (1999) reported 
the cloning and characterisation of human telomerase reverse transcriptase 
(hTERT) gene promoter providing transcriptional regulation of the hTERT gene, 
with this suggesting that investigation of the molecular mechanisms that regulate 
hTERT gene expression could lead to a better understanding of telomerase 
regulation, cellular senescence and immortalization, and human carcinogenesis 
(Horikawa et al., 1999). The expression of telomerase activity is strongly 
associated with human cell immortalization and carcinogenesis (Chiu and Harley, 
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1997, Kim et al., 1994); therefore identification of the NRF2 putative binding sites 
in the promoter sequence of HER1 and HER4 is essential in understanding their 
regulation. 
Studies have reported the roles of several other transcription factors other than 
NRF2, such as specificity protein 1 (sp1), EGFR-specific transcription factor 
(ETF) and activator protein 1 (AP-1) (Kitadai et al., 1992, Johnson, 1996, 
Kageyama et al., 1988) in the transcriptional initiation. These transcription factors 
might thus be one of the critical factors promoting the initiation of HER receptor 
transcription. Thus, the interaction between the relevant transcription factors and 
their possible roles in the transcription of HER1 and HER4 could be investigated 
further. 
7.1.2 Regulation of HER1 and HER4 by NRF2 in ovarian cancer cells 
Previous evidence has implicated NRF2, ROS and HER receptors in cell growth, 
cell survival, cancer initiation and progression and therapeutic resistance in 
cancer cells (Khalil et al., 2016a, Khalil et al., 2016b), therefore highlighting the 
possibility of direct linkage between ROS, HER family and NRF2 pathways.  
This section demonstrates that NRF2 may regulate cancer cell proliferation, 
susceptibility and resistance to chemotherapeutic drugs via transcriptional 
regulation of HER family receptors. In order to demonstrate the role of NRF2 in 
regulating the HER family receptors and subsequently determining the responses 
to targeted therapies, ovarian cancer cell lines, PEO1, OVCAR3, and SKOV3 
with different HER family and NRF2 expressions were used (Langdon et al., 
1988, Mullen et al., 2007, Khalil et al., 2016b), and pharmacological activation 
and pharmacological inhibition and genetic inhibition of NRF2-ARE pathway were 
employed. The mechanisms by which tBHQ induce NRF2 and RA inhibits NRF2 
and its function are known (Khalil et al., 2016a, Khalil et al., 2016b, Wang et al., 
2007), and in this research the basis for using RA was to modulate cellular NRF2 
status and ARE-dependent transcriptional power, as well as to implicate NRF2 in 
regulating cellular susceptibility to RTK targeted drugs. 
First, pharmacological activation of NRF2 with tBHQ up-regulated the 
transcriptional levels of all the HER receptors with a concomitant induction of 
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HER1, HER4, NFR2 and pAkt proteins (Figures 4.1 and 4.2). This is consistent 
with current emerging concepts of transcriptional control and gene expression 
(Khalil et al., 2016b). It is clear that tBHQ treatment leads to induction of NRF2, 
its associated antioxidant transcriptional programme and transcriptional and 
signalling activation of HER1 and HER4, and that this tBHQ response was 
evidently dependent on NRF2. 
Second, to further investigate and confirm the involvement of NRF2 in the 
regulation of HER1 and HER4, both pharmacological and genetic approaches to 
deplete NRF2 level and function using RA and siRNA were employed. This 
strategic approach caused increased transcriptional repression of HER1 and 
HER4 (Figures 4.3 and 4.5) leading to repression of HER1, HER4, total and 
pNRF2 and HO-1 levels (Figures 4.4 and 4.6), while tBHQ dependent induction of 
ARE disrupted the knocking down effect of siRNA (Figures 4.7 and 4.8). 
Moreover, NRF2 depletion by RA and siRNA caused an increase in ROS (Figure 
4.9) and depletion of total GSH (Figure 4.10) in all the ovarian cell lines tested.  
tBHQ is widely known as an NRF2 activator and can upregulate ARE response 
driven genes (Arlt et al., 2013, Wang and Jaiswal, 2006, Li et al., 2014). On the 
other hand, retinoids like RA are chemopreventive and chemotherapeutic agents. 
One source of RA is vitamin A, derived from dietary β-carotene. RA regulates cell 
proliferation, differentiation, and morphogenesis. It inhibits tumorigenesis through 
suppression of cell growth and stimulation of cellular differentiation. Also, RA 
promotes apoptosis, and this property may contribute to its antitumor properties 
(Wang et al., 2007, Tan et al., 2008). siRNA, however, is a class of double-
stranded RNA molecules, 20-25 base pairs in length. siRNA is similar to miRNA 
and operates within the RNA interference (RNAi) pathway, where it interferes with 
the expression of specific genes with complementary nucleotide sequences by 
degrading mRNA after transcription, resulting in no translation (Persengiev et al., 
2004, Elbashir et al., 2001, Tiscornia et al., 2003, Caplen et al., 2001, Xia et al., 
2002, Hannon, 2002). Previous studies have shown the inhibitory nature of 
siRNA and RA in on ARE (Khalil and Deeni, 2015, Wang et al., 2007, McMahon 
et al., 2014, Khalil et al., 2016b, Khalil et al., 2016a). For example, the paper 
published earlier in 2016 by Khalil et al (2016b) has reported that NRF2 regulates 
HER2 and HER3 following the use of widely used NRF2 activator (tBHQ) and 
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repressor (siRNA) which in turn upregulated and downregulated HER2 and HER3 
respectively. Here, the study demonstrates that NRF2 regulates HER1 and HER4 
following the same approach used in the case of HER2 and HER3. 
Pharmacological activation, pharmacological inhibition and genetic inhibition of 
both NRF2-ARE and HER1 and HER4 were studied.  
Several possible NRF2 binding sites were identified in the HER1and HER4 
promoter regions (Figure 3.1). The regulatory role of NRF2 on HER1 and HER4 
expressions is supported by the observed higher induction levels of HER1 and 
HER4 following NRF2 activation and inhibition/knockdown in all the cell lines 
(Figures 4.1, 4.2, 4.3, 4.4, 4.5 and 4.6). The NRF2 activation and inhibition-
dependent regulation of the HER1 and HER4 receptors and their signalling 
pathway were governed and executed by NRF2 at both the transcriptional and 
translational levels. The results from both the receptor gene reporter assays and 
western blotting of HER1 and HER4 expressions indicated that activation or 
inhibition of NRF2 also upregulated or downregulated HER1 and HER4, 
respectively. It is clear that tBHQ treatment led to activation of NRF2, its 
associated antioxidant signalling and transcriptional program, which led to the 
transcriptional upregulation of HER1 and HER4. Moreover, this tBHQ response 
was evidently dependent on NRF2. Also, RA treatment and knockdown of NRF2 
with siRNA led to depletion of NRF2, its associated antioxidant signalling and 
transcriptional program, with subsequent transcriptional and translational 
downregulation of HER1 and HER4, RA or siRNA dependent responses were 
evidently dependent on NRF2. 
In support of the finding that NRF2 depletion by siRNA causes transcriptional 
down-regulation of HER1 and HER4 leading to repression of HER1, HER4 and 
pAkt proteins, a study by Khalil et al (2016a) showed a similar approach and 
outcome. Moreover, it demonstrated that while inhibition of NRF2 significantly 
sensitised ovarian cancer cells to targeted immunotherapy, the parallel approach 
of knockdown of KEAP1 reversed this sensitisation (Khalil et al 2016a). These 
results support and confirm the earlier hypothesis of the regulatory role of NRF2 
in the transcription of HER1 and HER4 receptors, as well as its possible 
involvement of alteration of HER1 and HER4 protein levels. Another study by 
(Kang et al., 2014a), reported a similar role for NRF2 in regulating the expression 
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of one of the members of HER family receptors, but did not show the evidence of 
direct transcriptional regulation as shown in (Khalil et al., 2016b) and this study.  
The direct interaction of NRF2 and HER2 in regulating the expression of NRF2 
target genes, including HO-1 through binding of the complex to the ARE of the 
target genes, has been demonstrated (Kang et al., 2014b). Moreover, the down-
regulation of HER2, HER3 and pAKT as well as HO-1 and pNRF2 levels following 
siRNA-mediated depletion of NRF2, has been reported (Khalil et al., 2016b). This 
adds credence to observed down-regulation of HER1, HER4 and pAkt as well as 
NRF2 and HO-1 levels, following the siRNA-mediated knockdown of NRF2 in this 
study.  
Since NRF2 overexpression has been reported in cancers (Kang et al., 2014b, 
Chian et al., 2014b, Chio et al., 2016, Choi and Kwak, 2016), NRF2 silencing 
using siRNAs as a means of therapy may be a reliable alternative approach for 
treating NRF2 overexpressing cancers (Kanninen et al., 2015), including ovarian. 
Such findings could give insight to further understanding the molecular genetic 
aspect of ovarian cancer and its treatment. Furthermore, understanding that there 
is a limitation of compounds to decrease NRF2 activity could give insight into the 
molecular genetic aspects of ovarian cancer and its treatment, in the context of 
NRF2 targeted gene therapy. To date, over 2,000 clinical trials in gene therapy 
have already been conducted, with cancer being the basis of the majority of these 
trials. Various regulated vectors have been designed so that gene transfer is 
specific, regulated, effective and safe in the same way that conventional drugs 
are. This would prevent the occurrence of unwanted side effects of long-term 
transgene expression, as reported by (Springer et al., 1998). Although NRF2 
silencing using siRNA strategy has been shown to enhance chemo- and 
radiotherapy (Singh, 2006, Singh et al., 2010), there are many problems including 
difficulties in intracellular delivery and trafficking and clearance by the immune 
system, as well as the occurrence of off-target effects associated with this 
approach. These should be talked about further before considering this strategy 
in the clinic (Pecot et al., 2011). Gene therapy may well provide a more specific 
approach than small molecular weight inhibitor in targeting NRF2 in cancer. This 
is due to the fact that general systemic NRF2 inhibition is not desirable, as NRF2 
serves important protective functions in healthy normal cells.  
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In conclusion, these results support and confirm the earlier identified role of NRF2 
in the regulation of HER2 and HER3 reported by Khalil et al. (2016) (Khalil et al., 
2016b). A recent study by Khalil et al. (2016) reported that NRF2 regulates HER2 
and HER3, thereby adding credence to present findings on HER1 and HER4, 
with this further confirming the role of NRF2 as a regulator of all four members of 
the HER family receptors. It also gives further insight into the future possibility of 
using gene therapy in silencing NFR2 hyperactivation in ovarian cancer patients.  
7.1.3 Screening for inhibitors of the NRF2-ARE signalling pathway and their 
potential applications in ovarian cancer therapy 
In this section of the research, a panel of compounds anticipated to be potent 
NRF2-ARE modulators were screened to uncover the most potent compound. 
NRF2 is a transcription factor that mediates protection against electrophiles and 
oxidants. It regulates the expression of many genes such as cytoprotective and 
detoxifying genes. ROS, however, are involved in the physiological aspects of the 
cell, including signal transduction cascades and calcium signalling (Liou and 
Storz, 2010, McMahon et al., 2014). Both NRF2 activation and elevation of ROS 
have been detected in almost all cancers, and these promote tumour 
development and progression (McMahon et al., 2014, Liou and Storz, 2010). 
The panels of potent NRF2 modulators and in particular NRF2 inhibitors, were 
investigated using the MCF7-AREc32 reporter cell line (Wang et al., 2007). Three 
lowest different concentrations (2.5 µM, 5.0 µM and 10 µM) of the compounds 
were used to evaluate their ability to inhibit NRF2 and to elevate ROS. The 
investigation indicated that compounds such as bexarotene, RA, 9-cis RA, 
luteolin and brusatol were able to inhibit the NRF2-ARE in MCF7-AREc32 cell 
line (Figures 5.2 and 5.3) and also elevate ROS (Figure 5.4), even at the lowest 
concentration of 2.5 µM. Interestingly, bexarotene, which is a clinically used anti-
cancer drug, appeared to be one the most potent inhibitors of NRF2-ARE 
dependent activity.  
The compounds that were more promising in their ability to inhibit NRF2 and 
elevate ROS were used at the lowest concentration (2.5 µM), to examine their 
effect on the level of NRF2 and its substrate gene target at a protein level in the 
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MCF7-AREc32 cell line. As expected, all the compounds were able to cause 
repression of total NRF2, pNRF2 and HO-1, with bexarotene still proving to be 
the most potent (Figure 5.3). The ability of bexarotene to inhibit NRF2 levels 
suggests that it can be used in targeting NRF2 to modulate HER receptor 
expression in ovarian cancer cells. The effect of bexarotene, lapatinib and 
erlotinib on MCF7-AREC32, was examined, the results shown that low 
concentrations (2.5 µM and 5 µM) of lapatinib, erlotinib and bexarotene have 
induced the cytotoxicity, increased ROS and inhibit NRF2 dependent ARE 
pathways (Figure 5.5).  
Following cell viability assay to estimate the required concentrations of lapatinib, 
erlotinib and bexarotene for the further treatment of ovarian cancer cell lines, 
PEO1, OVCAR3 and SKOV3 (Figure 5.6), The effect of these drugs was 
examined when the ovarian cancer cells were transiently transfected with 
prHER1, prHER2, prHER3 and prHER4. Interestingly, the results indicated that 
bexarotene as well lapatinib and erlotinib, down-regulated the transcriptional level 
of HER1, HER2, HER3 and HER4 in all the ovarian cancer cell lines (Figures 5.7, 
5.8 and 5.9). These findings suggest bexarotene, has the ability to inhibit NRF2 
dependent ARE pathways, to elevate cellular ROS levels in MCF7-AREc32 cell 
lines and to down-regulate HER1 and HER4 transcriptionally in PEO1, OVCAR3 
and SKOV3 ovarian cancer cell lines.  
NRF2 is increasingly being recognised as a crucial transcription factor which 
mediates protection against electrophiles and oxidants by regulating the 
expression of many cytoprotective and detoxifying genes (Hayes, 2000, Hayes et 
al., 2016, Hayes and McMahon, 2009). Elevated rates of ROS have been 
detected in almost all cancers, where they promote many aspects of cellular 
proliferation, tumour development and progression (Khalil et al., 2016b, Khalil et 
al., 2016a, Khalil and Deeni, 2015, Liou and Storz, 2010, Leone et al., 2015, Park 
et al., 2010, Poillet-Perez et al., 2015, Trachootham et al., 2009, Prasad et al., 
2017). Tumour cells also express increased levels of antioxidant proteins to 
detoxify ROS, suggesting that a delicate balance of intracellular ROS levels is 
required for cancer cell function. To effectively target cancer cells, specific ROS-
sensing signalling pathways that mediate the diverse stress-regulated cellular 
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functions need to be identified (McMahon et al., 2014, Liou and Storz, 2010, 
Tebay et al., 2015). 
The compounds screened in this section were able to induce NRF2-KEAP1 either 
by positive or negative feedback to stimulate NRF2 activity. These compounds 
included an RXR agonist (bexarotene), which possesses anti-cancer activity and 
is reported to inhibit NRF2-ARE pathway (McMahon et al., 2014). These effects 
may be either indirect or due to the modulation of pathways directly involved in 
the regulation of NRF2 function. In the case of bexarotene, an RXR agonist, for 
example, the findings that this compound reduced NRF2 signalling (Figure 5.3) 
are consistent with an earlier finding that RXR acts as a negative regulator of 
NRF2-ARE signalling (McMahon et al., 2014, Qi et al., 2016, Wu et al., 2014). 
The negative regulation occurs when a rexinoid such as bexarotene specifically 
binds to RXR which in turn forms a complex with NRF2 and blocks it from binding 
to ARE, leading to NRF2 repression (Farol and Hymes, 2004, Qi et al., 2016, Wu 
et al., 2014). This provides further evidence supporting the interaction of RXR 
with NRF2 to inhibit NRF2-ARE function that now extends to ovarian cancer cells. 
Thus, bexarotene could be used as a potent inhibitor of NRF2 as part of the drug 
development process to sensitize and overcome cancer chemoresistance. 
Developments in treatment approaches together with the earlier diagnosis have 
considerably increased the average survival of cancer patients. Nevertheless, 
recent reports of the involvement of NRF2 in increasing cancer cell survival 
leading to chemoresistance, have made researchers focus on the screening and 
identification of novel inhibitors of NRF2 that would be recommended for clinical 
trials in treating cancer patients. Drug discovery and development often employs 
high-throughput screening (HTS) of libraries that may contain a huge number of 
compounds typically covering the commercially available chemical diversity. The 
study in this section has revealed a new way for researchers to consider the HTS 
of potent inhibitors of NRF2, so as to increase the number of those that have 
been discovered for improved cancer treatment (Varbanov et al., 2017). 
So far, a number of studies have conducted screenings for NRF2 inhibitors and 
compared to the number of NRF2 activators known, the number of inhibitors is 
quite small (Zhu et al., 2016).  One of the aims of screening for NRF2 inhibitors is 
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to find inhibitors with efficiency and safety profiles for application in clinical cancer 
therapies. Furthermore, applying these inhibitors in clinical settings would be 
more successful if these agents blocked the NRF2 signalling pathway in cancer 
cells, whilst leaving normal cells unaffected or with very low cytotoxicity to normal 
cells (Zhu et al., 2016). Specifically, among the inhibitors studied, ochratoxin A is 
reported to have nephrotoxicity and carcinogenicity (Limonciel and Jennings, 
2014). Triptolide causes oxidative injuries in many cells and tissues (Liu et al., 
2013) and brusatol is reported to cause loss of body weight in nude mice (Ren, 
2011), with the adverse effects of other compounds remaining unexamined. More 
accurate and detailed preclinical studies and clinical trials need to be conducted 
to elucidate dose-dependent, cell-type-dependent and even stage-dependent 
effects (Zhu et al., 2016). In addition, as well as experiments in vitro as per this 
study, long-term animal model experiments are needed. 
7.1.4 NRF2 co-regulates HER family receptors to modulate the efficacy of 
lapatinib and erlotinib as RTK targeting chemotherapeutics in ovarian 
cancer 
The transition from cytotoxic chemotherapy to molecularly targeted cancer drugs 
has resulted in an increasing number of successful therapies that have impacted 
positively on the lives of a large number of cancer patients.  
In this section, all of the HER receptor family were investigated following 
treatments with either bexarotene alone or in combination with lapatinib or 
erlotinib. A series of experiments such as cytotoxicity assays, immunoblotting, 
ROS level detection and total GSH were performed. The HER family receptors 
and NRF2 have already been implicated in numerous reports as key contributors 
to resistance towards anti-cancer drugs (Khalil et al., 2016a, Khalil et al., 2016b, 
Goltsov et al., 2014a, Kobayashi and Yamamoto, 2005, Ercan et al., 2012, Xu et 
al., 2013). However, the majority of these studies have reported the role of NRF2 
in resistance to chemotherapeutic drugs (Namani et al., 2014, Gupta et al., 2012, 
Kundu and Surh, 2010, Singh et al., 2013, Ramos-Gomez et al., 2001, Wang, 
2008, Singh et al., 2010, Ohta et al., 2008). One of the major challenges for 
cancer treatment is to identify and target key survival pathways in cancerous cells 
that can provide selectivity against them that will lead to improved cancer 
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treatment. This is a challenging task owing to the complexity of responses 
generated by different types of cancers, age and different settings (Khalil, 2012). 
Experimental and clinical studies have shown enhanced efficacy and safe 
tolerability of HER targeting drugs such as trastuzumab, pertuzumab, lapatinib 
and erlotinib (Arora and Scholar, 2005, Madhusudan and Ganesan, 2004, 
Haouala et al., 2009, Polli et al., 2009, Leveque, 2008, Arlt et al., 2013, Goltsov et 
al., 2014a, Khalil et al., 2016a, Khalil et al., 2016b, Slamon et al., 2001, Kuang et 
al., 2010). The small molecule cancer drugs, lapatinib and erlotinib have been 
recognized as promising therapeutics targeting the increased EGFR expression 
in triple-negative breast cancer (TNBC), specifically through their use with other 
chemotherapies (Hoelder et al., 2012, Kuang et al., 2010, Roskoski Jr, 2014, 
Haouala et al., 2009, Ryan et al., 2008).  However, outcomes of treatments with 
HER targeting drugs either used singly or in combination, remains unpredictable. 
This could be due to tumour type specificity and tumour biology-dependency, 
especially expression levels of cell surface receptors, their dimerization 
preferences, recycling kinetics and ligand abundance (Khalil et al., 2015, Khalil et 
al., 2016a, Ryan et al., 2008, Slamon et al., 2001). Thus, the efficacy of these 
drugs is potentially reduced due to limited therapeutic efficacy and frequent 
emergence of resistance. 
There are many reasons to be optimistic about cancer drug discovery and 
development because of the novel and improved recent scientific and 
technological breakthroughs. Novel concepts such as ‘non-oncogene addiction’ 
(Luo et al., 2009) and ‘synthetic lethality’ (Kaelin, 2005, Ashworth et al., 2011) 
have widened the scope beyond the exploration of oncogenic pathway 
addictions, and have helped guide the identification of novel targets either 
through hypothesis-driven research or large-scale screening campaigns. 
Enormous genome sequencing and molecular pathology efforts, coupled with 
bioinformatics and system biology approaches, are allowing continuous 
refinement of the understanding of how cancer cells are wired, and how they can 
be targeted through single agents or on several fronts through drug combinations 
(Hoelder et al., 2012, Heller, 2002, Loman et al., 2012, Karp et al., 2002, Weston 
and Hood, 2004, Voelkerding et al., 2009, Subramaniam et al., 2011, Cronin and 
Ross, 2011, Stratton, 2011, MacConaill and Garraway, 2010, Kitano, 2003). 
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This present study demonstrates that NRF2 regulates cancer cell proliferation, 
susceptibility and resistance to targeted therapy via transcriptional regulation and 
alteration of HER family receptors. This study sought to determine the 
mechanism of action of targeted chemotherapeutic agents, lapatinib and erlotinib, 
and in particular to understand their ability to inhibit NRF2, elevate ROS and 
enhance cytotoxic response triggered either by their combination with bexarotene 
or as single chemotherapeutics agents. This research used ovarian cancer cell 
lines PEO1, OVCAR3 and SKOV3 with different degrees of HER family and 
NRF2 expression status (Mullen et al., 2007, Khalil et al., 2016a, Khalil et al., 
2015). The study found that the mechanism of action of lapatinib, erlotinib and 
retinoids used in this research involved generation of ROS and GSH depletion, 
which contributed to killing effects and cancer growth retardation. This is 
consistent with the conventional adage that depletion of GSH can cause oxidative 
stress and sensitise tumours to the killing effects of the therapeutic agents 
(Gorrini et al., 2013, Khalil et al., 2016a, Goltsov et al., 2014a). To demonstrate 
the role of NRF2 in HER signalling pathways and thus determine responses to 
targeted therapies, ovarian cancer cell lines with different expressions of both 
HER receptors and NRF2 (Khalil et al., 2015, Khalil et al., 2016a, Mullen et al., 
2007) were grown in HER receptor ligand HRG, in association with 
pharmacological activation or inhibition of both NRF2-ARE and HER signalling 
pathways. 
Firstly, pharmacological activation of NRF2 with tBHQ enhanced ovarian cancer 
cell growth and protected cells from cytotoxicity caused by combined RTK 
targeting chemotherapeutic agents, lapatinib and erlotinib took place (Figure 6.1). 
The pharmacological inhibition of NRF2 with bexarotene did the opposite and 
increased cytotoxicity caused by the agents (Figure 6.2).  
It is clear that tBHQ treatment led to the induction of NRF2, its associated 
antioxidant transcriptional programme and transcriptional and signalling activation 
of HER1 and HER4, and that this tBHQ response was evidently dependent on 
NRF2. Thus, NRF2 activation by tBHQ desensitised the RTK signalling pathway 
to the inhibitory action of the HER targeting chemotherapeutic agents, lapatinib 
and erlotinib, whilst the inhibition of NRF2 with bexarotene did the opposite. 
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Furthermore, it was observed that treatments with lapatinib, erlotinib, their 
combination with each other or their combination with bexarotene, led to ROS 
generation in all the ovarian cancer cell line models (Figure 6.3). This approach 
also led to the repression of NRF2 and HO-1 (Figure 6.4) and disruption of the 
antioxidant response programme of NRF2 transcription (Figure 4.5), as well as 
depletion of total GSH (Figure 6.6), which confirms the crosslink between NRF2 
and ROS. These results support and confirm an earlier study by Khalil et al. 
(2016b), which reported that treatments with pertuzumab, trastuzumab, their 
combination with each other or with RA, led to ROS generation in cancer cell line 
models, depletion of total GSH, and disruption of the antioxidant response 
programme as well as suppression of NRF2.  
The observation that lapatinib and erlotinib alone or as co-treatment with 
bexarotene caused down-regulation of HER family receptor protein levels as well 
NRF2, suggests that NRF2 may be directly involved in regulating HER receptor 
expression and as such, might have a role in responses to RTK targeted 
chemotherapies, involving the HER receptor family. The action of lapatinib, 
erlotinib and bexarotene culminates with the engagement of the AR pathway and 
the concomitant inhibition of NRF2 function during drug action. 
The fact that treatments with combinations of lapatinib with bexarotene or 
erlotinib with bexarotene repress pNRF2, pHER1 pHER2 pHER3, pHER4 as well 
as pAKT levels in the cell lines (Figure 6.7 A and B), suggests that this might 
sensitize ovarian cancer cells to the killing effects of lapatinib and/or erlotinib. 
Moreover, data in Figure 6.2 appear to support these assertions, as significantly 
increased cytotoxicity of lapatinib or erlotinib following the pharmacological 
inhibition of NRF2 with bexarotene were evident. This demonstrates that 
bexarotene causes repression of NRF2 dependent antioxidant pathway, which 
may contribute to the enhanced cytotoxicity of lapatinib and erlotinib. 
The role of bexarotene as an effective anticancer drug is under active 
examination in various clinical trials (Qi et al., 2016, Saito-Hakoda et al., 2015, 
Heo et al., 2016, Farol and Hymes, 2004). The selective NRF2 inhibition and high 
toxicity to cancer cells and not normal cells may be the major advantage of 
bexarotene, which is already known to be generally safe and well tolerated (Duvic 
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et al., 2001, Papadavid et al., 2008, Rigas and Dragnev, 2005, Abbott et al., 
2009, Whittaker et al., 2012, Yen et al., 2004b, Mehta et al., 2012, VäkEvä et al., 
2012, Quéreux et al., 2013, Talpur et al., 2014). However, NRF2 inhibitory 
therapy combined with bexarotene will be cautiously examined in a pre-clinical 
setting because NRF2 has a protective effect against oxidative damage to normal 
tissue. This study will lead to better molecular and therapeutic understanding of 
NRF2 inhibition using certain compounds including bexarotene, which may lead 
to the sensitization and elimination of resistant cancer cells (Wu et al., 2014, Qi et 
al., 2016, Garattini et al., 2014, Saito-Hakoda et al., 2015). The work here has 
demonstrated that the effectiveness of anti-HER receptors therapies such as 
lapatinib and erlotinib can be reduced even in the presence of HRG, which can 
bind the receptors and activate alternative signalling pathways (in this case 
NRF2-ARE). This leads to subsequent modulation of dimerization profiles and 
activation of associated downstream signalling, thereby overcoming the inhibitory 
effects of the RTK drugs. Importantly, this research has shown an improved 
efficacy of lapatinib and erlotinib when combined with bexarotene against ovarian 
cancer cells, by repressing the HER family receptors NRF2 and AKT. 
Overall, this research is in agreement with the in vitro and in vivo data reported by 
Khalil et al., (2016a and 2016b), which illustrate the important role of NRF2 in 
influencing outcomes to targeted therapies involving HER2 receptor inhibition 
(Khalil et al., 2016a), and on the regulation of HER2 and HER3 by NRF2 to 
oppose HER2 targeted immunotherapy (Khalil et al., 2016b). The study in this 
section opens up a new potential opportunity for improving the effectiveness of 
lapatinib and erlotinib via inhibition of NRF2, as well as a novel strategy of cancer 
cell sensitization during the course of targeted therapy for cancer employing 
chemotherapeutics. 
7.2. Conclusions 
This current PhD research study involved designing novel tools for evaluating the 
regulation of the HER receptor family and NRF2 pathways to ovarian cancer 
treatment and outcome. A number of assays involving cloning, luciferase assay, 
cytotoxicity assay, ROS assay, western blotting and total glutathione assay were 
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employed in the investigation. The research discovered regulatory mechanisms 
of HER family receptor function involving HER1 and HER4 receptors and 
NRF2/ARE-dependent transcriptional modulation through their promoter activity. 
The second means of regulation is via the mechanism of their NRF2 mediated 
modulation and their concomitant alteration at a protein level.  
The novel findings in the current research work extend current knowledge 
regarding the mechanism of HER receptors and NRF2 expression. This research 
provides further insight into the molecular basis for regulation of the expression of 
the HER genes by NRF2, as well as the clinical potential of using siRNA via gene 
therapy to improve cancer treatment. It also highlights a novel mechanism and 
role for NRF2 inhibition by bexarotene in sensitising ovarian cancer cells to the 
killing effect of RTK inhibitors, lapatinib and erlotinib. Finally, it highlights the 
possibility of using the combination of lapatinib and bexarotene, or erlotinib with 
bexarotene, to overcome RTK-associated drug resistance. 
7.3 Recommendations 
The study presented here, albeit being generally successful, was not without 
limitations. In this section, the main recommendations and suggestions of how to 
extend the aforementioned hypothesis in future research are hereby discussed. 
This study has reported on the modulation of HER receptor family and NRF2 in 
improving ovarian cancer therapy. Further experiments such as gel shift assay 
and ChIP assay should be employed to investigate the interaction between other 
relevant transcription factors such AP-1, sp1 and ETF and their possible roles in 
the transcription of HER1 and HER4. The study has shown that NRF2 regulates 
HER1 and HER4, and further experiments are needed to confirm the role of 
NRF2 as a transcription factor for HER receptors. The clinical potential of 
appropriately designed siRNAs in various diseases including cancer has been 
demonstrated (Guo et al., 2013, Huang et al., 2008, Xia et al., 2002, Kanninen et 
al., 2015, Esmaeili, 2016). Many simple questions need to be answered to 
uncover the full therapeutic benefit of this mechanism. These include details of 
the components and function of various enzymes involved in the formation of 
siRNA, the role of siRNA in DNA methylation and chromatin modelling, as well as 
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other epigenetic mechanisms used by cells to control gene expression. Since 
these agents are in clinical trials, issues related to bioavailability and safety need 
to be critically evaluated. Furthermore, the clinical potential of using NRF2 
inhibitors such as brusatol, luteolin and bexarotene has been reported (Ren, 
2011, Chian et al., 2014a, Chian et al., 2014b, Wu et al., 2014). These inhibitors 
have been demonstrated to sensitize cancer cells to chemotherapeutic and 
immunotherapeutic agents, as well as to radiotherapy. Generally, the purpose of 
screening for these inhibitors is to find inhibitors with sufficient potency that are 
safer for application within clinical cancer therapies. To better recommend the 
use of these agents in clinical settings, there is a need for more collective 
research to explore whether these inhibitors can reliably be used in future either 
alone or as efficient sensitizing agents in combination with chemotherapy and 
radiotherapy to improve not only ovarian cancer treatment, but also other cancer 
treatments. 
Most current therapies against cancer consist of empirically combined strategies 
as a way of improving cancer treatment and overcoming drug resistance. Drug 
combinations are widely used because multiple drugs affect multiple targets and 
cell populations, and so enhance their therapeutic effects (Bijnsdorp et al., 2011). 
It is important to test the potency of a combination and its synergic and/or 
antagonistic effects before evaluation in the clinic. A combination can be 
examined by combining two agents in various different ways such as 
simultaneous or sequential combination schedules (Bijnsdorp et al., 2011). One 
of the most widely used ways to evaluate whether a combination is effective is 
the median-drug effect analysis method (Bijnsdorp et al., 2011). Using this 
method, a combination index (CI) is calculated from drug cytotoxicity or growth 
inhibition curves (Bijnsdorp et al., 2011, Ashton, 2015). To calculate a CI, the 
computer software Calcusyn can be used, taking the entire shape of the growth 
inhibition curve into account for calculating whether a combination is synergistic, 
additive or antagonistic (Bijnsdorp et al., 2011, Jia et al., 2009, Ashton, 2015). It 
is recommended that future studies consider how combinations can be designed 
in vitro and then analysed using Calcusyn or Compusyn so as to identify 
limitations and advantages of using such combinations. Thus, future studies 
might expand the role of NRF2 as a key element in driving drug resistance and 
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opens up additional strategies of sensitising cancer cells to HER family targeted 
therapy, as well as overcoming the resistance of cancer cells to such drugs. 
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9.1 Appendix I 
Table: 9.1.1: List of cell lines sources, nature and media used 





Breast cell line 
pGL-8xARE, along 
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96-well 2.5 x 103 0.2 
Cytotoxicity assays (Cell viability), Total 
Gluthathione and ROS assays 
24-well 5 x 104 0.5 Promoter transfection for luciferase assay 
12-well 1 x 105 1 
Immunofluorescence studies: For drug 
treatments of cells grown on Poly-L lysine 
coated coverslips 
60mm 8 x 105 3 
For liposome mediated cell transfections by 
harvesting protein lysates of cells treated with 
different drugs. 
100mm 2 x 106 10 
For liposome mediated cell transfections by 




7 x 105 5 For cell propagation and maintenance 
75 cm2 
flask 
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HER1- EP38Y Rabbit ab52894 Abcam 
pHER1 Rabbit ab40815 Abcam 
HER2 Rabbit 2165S 
Cell 
signalling 
pHER2-Try877 Rabbit 2241S 
Cell 
signalling 
HER3 Rabbit 4754S 
Cell 
signalling 
pHER3-Tyr1289 Rabbit mAb #4791 
Cell 
signalling 
HER4 Rabbit ab32375 Abcam 
pHER4- Y1284 Rabbit ab61059 Abcam 
NRF2 Rabbit ab89443 Abcam 
pNRF2- EP1809Y Rabbit ab76026 Abcam 
HO-1 Rabbit 5853S 
Cell 
signalling 
pAkt- Ser473 Rabbit ab9271 
Cell 
signalling 
Akt Rabbit ab 9272 
Cell 
signalling 






β-actiin Rabbit 1801 Abcam 
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           9.1.4:  Bradford assay 
The standard protein concentration curve for Bradford assay was established 
by using a standard protein Bovine Serum Albumin (BSA). The stock was at a 
concentration of 2mg/mL and was diluted to produce varying concentrations, 
carrying out Bradford assay and plotting the standard graph. The dilutions 
were made as shown in the Table 9.1. 
 


















Each of the 20μL mix was transferred to wells in 96-well plate and 180μL of 
1x Bradford reagent was introduced and the contents mixed together. After 
10min of incubation, absorbance from each well was measured at 595nm 




2mg/mL Water Final 
BSA (μL) (μL) concentration 
  (mg/mL) 
0 20 0 
   
1 19 0.1 
   
2.5 17.5 0.25 
   
5 15 0.5 
   
7.5 12.5 0.75 
   
10 10 1.0 
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                      Table 9.1.4.2: Absorbance of standard protein 
 

















The absorbance value of the blank (0mg/mL) was subtracted from the 
absorbance values of the samples and the resulting values were plotted on a 
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Figure 9.2: Protein standard curve for Bradford assay. To provide a 
protein standard curve for Bradford assay different dilutions of a known 
standard (2mg/mL BSA) were made as set out in table A1.6 and their 
absorbance measured at 595nm. The data was plotted in a graph using the 
x,y scatter and its trend line shown. Using the equation shown in the figure, 
protein concentrations of the experimental protein lysates were determined 
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           9.2 Appendix-II:  
        Buffers and chemicals 
9.2.1 50x TAE buffer 
 
121gm Tris Base 
 
28.5mL Glacial acetic acid 
 
100mL 0.25M EDTA 
 
Contents mixed together and water added to the final volume of 500mL. The 
pH of the buffer is around 8.5. 
 
To make 0.25M EDTA stock, 46.5 gm of EDTA disodium salt was added to 
400mL of water, pH adjusted to 8 with NaOH, and the contents dissolved until 
clear. The final volume was taken up to 500mL with water. 
 
 
9.2.2 Poly L-lysine coating 
 
For immunostaining procedures, cells were seeded on sterile cover-slips 
which were first coated with Poly L-lysine. All the procedure was performed in 
tissue culture hood under sterile condition in the following way: 
 
Cover-slips to be coated were first autoclaved and placed in tissue culture 
hood. 1% Poly L-lysine solution was made in sterile water by taking 9.9mL of 
sterile water and 100μL of Poly  
L-lysine solution. The cover-slips to be coated were then put in 50mL 
eppendorf tube and the solution was poured in it so that all the cover-slips are 
covered in the liquid. The eppendorf was capped tightly and the tube was 
placed on a gyro shaker and shaken gently at 30rpm for 2 hr. After that, the 
tube was placed back into the hood, the solution poured off and the coverslips 
washed three times with sterile water in the same tube. After the last wash, 
the water was decanted, the coated cover-slips placed flat on a sterile paper 
towel placed in the hood for to dry them for 30min. Cover-slips were stored in 
a sterile jar ready to use. 
 
 




100mL Phosphate buffered saline 
 
100μL 0.1M NaOH 
 
Heated to 70°C and dissolved. Allowed to cool to room temperature and pH 
adjusted to 7.2 with concentrated HCL. 
 
To make 0.1M NaOH, 40mg of NaOH was dissolved in 10mL of water. 
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9.2.4 Terrific Broth (TB) 
 
12 gm Tryptone 
 




Distilled water added to 900mL 
 






Distilled water added to 100mL 
 
Both bottles autoclaved and the contents of each mixed together in a sterile 
environment to make a litre of TB. 
 
 










Water was added to the volume of 800mL. pH was set at 7.4 and again water 
was added until the final volume of 1 L. 1x PBS was made from the stock with 
water and usually autoclaved before using. 
 
 
9.2.6 Preparation of Luciferase Assay Reagent II (LAR-II): 
 
All the reagents used were provided in the Dual Luciferase Assay kit 
(Promega, UK). The lyophilized Luciferase Assay Substrate was resuspended 
in the 10ml of the supplied Luciferase Assay Buffer II. Once the substrates 
and buffer were mixed, the vial was labelled “LAR II” and stored at -80°C. At 
the time of use, the frozen LAR-II was thawed in water bath set at 37°C. 
 
 
9.2.7 Preparation of Passive Lysis buffer: 
 
The passive lysis buffer was provided as 5x concentrate (Dual Luciferase 
Assay kit, Promega, UK). 5mL of this concentrate was mixed with 20mL of 
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9.2.8 Preparation of Stop and Glo® reagent:  
The Stop and Glo® reagent was provided as 50x concentrate (Dual Luciferase 
Assay kit,  
Promega, UK). It was always prepared on the day of use by transferring 10μL 
of this reagent with 490μL of distilled water. The working stock was protected 
from light and stored at - 80°C until used. At the time of use, the frozen stock 
was thawed in water bath set at 37°C. 
 
 
9.2.9: Running buffer for immunoblotting: 
 
50mL 20x Nupage® MOPS SDS running buffer (Invitrogen, UK) 
 
1mL Nupage® Sample reducing agent (Invitrogen, UK) 
 
Distilled water was added to the final volume of 1 Litre. Mixed and stored at 
4°C until used. 
 
9.2.10 Transfer Buffer for immunoblotting: 
 




1mL Nupage® Sample reducing agent (Invitrogen, UK) 
 
Distilled water was added to the final volume of 1 Litre. Mixed and stored at 
4°C until used. 
 
 
9.2.11: Washing buffer for Immunoblotting: 
 
A 10x concentrated washing buffer provided with WesternDOTTM625 Goat 
anti rabbit/mouse western blot kit (Invitrogen, UK) was diluted to 1x with 
distilled water. Alternatively, a 0.1% solution of Tween20 in PBS was used in 
the same manner. 
 
9.2.12:  Blocking buffer for Immunoblotting: 
 






TBS or PBS added to 50mL and mixed well until all contents were dissolved. 
 
Also, milk based blocking buffer was used by replacing BSA above with 
2.5gm milk keeping everything else the same. 
 
 
9.2.13 SDS sample buffer for western blot: 
  
A 4x concentrated Nupage® LDS sample buffer was used by diluting it to 1x 
with the RIPA extracted protein lysates. 
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Dissolved in 800mL distilled water. 
 
10mL 0.25M KCl 
 
pH adjusted to 7. Water added to the final volume of 1 Litre. The media was 
autoclaved. Before use, 5mL of sterile 2M MgCl2 added.0.25M KCl made by 
dissolving 0.93gm of KCl in water to the final volume of 50mL. 2M MgCl2 
made by dissolving 9.52gm of MgCl2 in water to the final volume of 50mL. 
 
 
9.2.15 Freezing Medium for mammalian cell storage: 
 
Freezing medium was made in tissue culture hood using sterile reagents. 
10mL of freezing medium was made in a 15mL falcon tube in the following 
way: 
 
7mL Cell culture media 
 




These contents were mixed together and stored at -20°C. During use, the 
freezing medium was thawed in water bath set at 37°C. 1mL of the medium 
was usually used to store 100% confluent cells from a T75 flask in cryotubes. 
 
 








The solution was applied to the immunoblot and incubated usually for 1 h at 
37°C. 
 
9.2.29 Drug solutions used in this study: 
 
All solutions were filter sterilized before using. 
 
 
9.2.29.1 tBHQ (Sigma-Aldrich, UK): 
 
20mM stock solution of tBHQ was prepared by dissolving 34mg tBHQ powder 
in sterile DMSO to a final volume of 10mL. The vial was protected from light 
and stored at -20°C. The final concentration of the drug (usually 100μM) was 
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9.2.29.2 9-CIS-RETINOIC ACID (Carbosynth, UK): 
 
6.7mM stock of 9-Cis retinoic acid was prepared by dissolving 2mg 9-Cis 
retinoic acid powder in DMSO to a final volume of 1mL. The vial was 
protected from light and stored at -80°C. The final concentrations of drug 
(usually 2.5, 5.0, 10μM) were obtained by diluting the stock in cell culture 
media during treatment. 
 
 
9.2.29.3 RETINOIC ACID (Carbosynth, UK): 
 
20mM stock of retinoic acid was prepared by dissolving 60mg retinoic acid 
powder in sterile DMSO to a final volume of 10mL. The vial was protected 
from light and stored at -80°C. The final concentrations of the drug (usually 




9.2.29.4 PROCYANIDIN B2 (Carbosynth, UK): 
 
3.5mM stock of Procyanidin B2 was prepared by dissolving 2mg Procyanidin 
B2 powder in sterile DMSO to a final volume of 1mL. The vial was stored at -
20°C. The final concentrations of the drug (usually 2.5, 5.0, 10μM) were 
obtained by diluting the stock in cell culture media during treatment. 
 
 
9.2.29.5 BRUSATOL (Carbosynth, UK):  
 
3.85mM stock of Brusatol was prepared by dissolving 2mg cisplatin in sterile 
distilled water to a final volume of 1mL. The vial was protected from light and 
stored at -20°C. The final concentrations of the drug (usually 2.5, 5.0, 10Μm) 
were obtained by diluting it in cell culture media during treatment. 
 
 
9.2.29.6 NALIXIDIC ACID (Sigma-Aldrich, UK): 
 
20mM stock of Nalixidic acid was prepared by dissolving 23.8mg of Nalixidic 
acid powder in sterile DMSO to a final volume of 5ml. The vial was protected 
from light and stored at  
-20°C. The final concentrations of the drug (usually 2.5, 5.0, 10μM) were 
obtained by diluting it in cell culture media during drug treatment.  
 
9.2.29.7 QUERCETIN (Carbosynth, UK): 
 
20mM stock of Quercetin was prepared by dissolving 61mg of Quercetin 
powder in sterile DMSO to a final volume of 1ml. The vial was carefully 
wrapped and stored at  
-20°C. The final concentrations of the drug (usually 2.5, 5.0,10μM) were 
obtained by diluting it in cell culture media during drug treatment.  
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9.2.29.8 BEXAROTENE (Carbosynth, UK): 
 
20mM stock of Bexarotene acid was prepared by dissolving 35mg of 
Bexarotene powder in sterile DMSO to a final volume of 5ml. The vial was 
protected from light and stored at  
-20°C. The final concentrations of the drug (usually 2.5, 5.0, 10μM) were 
obtained by diluting it in cell culture media during drug treatment.  
 
9.2.29.9 LUTEOLIN (Carbosynth, UK): 
 
35mM stock of Nalixidic acid was prepared by dissolving 100mg of Luteolin 
powder in sterile DMSO to a final volume of 10ml. The vial was protected from 
light and stored at  
-20°C. The final concentrations of the drug (usually 2.5, 5.0, 10μM) were 
obtained by diluting it in cell culture media during drug treatment.  
 
9.2.29.10 ASCORBIC ACID (Carbosynth, UK): 
 
20mM stock of Ascorbic acid was prepared by dissolving 35.2mg of Ascorbic 
acid powder in sterile DMSO to a final volume of 10ml. The vial was protected 
from light and stored at  
-20°C. The final concentrations of the drug (usually 2.5, 5.0, 10μM were 
obtained by diluting it in cell culture media during drug treatment.  
 
9.2.29.11 GLYCETEIN (Carbosynth, UK): 
 
35mM stock of Glycetein was prepared by dissolving 100mg of Glycetein 
powder in sterile DMSO to a final volume of 10ml. The vial was protected from 
light and stored at  
-20°C. The final concentrations of the drug (usually 2.5, 5.0, 10μM) were 
obtained by diluting it in cell culture media during drug treatment.  
 
9.2.29.12 XANTHOHUMOL (Carbosynth, UK): 
 
20mM stock of Xanthohumol acid prepared by dissolving 72mg of 
Xanthohumol powder in sterile DMSO to a final volume of 10ml. The vial was 
protected from light and stored at  
-20°C. The final concentrations of the drug (usually 2.5, 5.0, 10μM) were 
obtained by diluting it in cell culture media during drug treatment.  
 
9.2.29.13 p-COUMARIC ACID (Carbosynth, UK): 
 
20mM stock of p-Coumaric acid prepared by dissolving 33mg of p-Coumaric 
acid powder in sterile DMSO to a final volume of 1ml. The vial was protected 
from light and stored at  
-20°C. The final concentrations of the drug (usually 2.5, 5.0, 10μM) were 
obtained by diluting it in cell culture media during drug treatment.  
 
9.2.29.14 LAPATINIB (Cell Signaling, UK): 
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10mM stock of lapatinib prepared by dissolving 14gm of lapatinib powder in 
sterile DMSO to a final volume of 1ml. The vial was protected from light and 
stored at  
-20°C. The final concentrations of the drug (usually 5.0Μm) was obtained by 
diluting it in cell culture media during drug treatment.  
 
9.2.29.13 ERLOTINB (Cell Signaling, UK): 
 
10mM stock of Erlotinib prepared by dissolving 14gm of Erlotinib in sterile 
DMSO to a final volume of 1ml. The vial was protected from light and stored 
at  
-20°C. The final concentrations of the drug (usually 5.0Μm) was obtained by 
diluting it in cell culture media during drug treatment.  
          9.3 Appendix-III 
 
Purchased reagents, chemicals and kits 
 
 
           Table 9.3. 1: Chemicals, reagents and kits used  
Chemical/Reagent/Kits Company and catalogue number 
Agar A5306-250G Sigma-Aldrich 
Agarose BIO-41025 Bioline 
Bovine serum albumin A2153-100G Sigma Aldrich 
Bradford reagent 23200 Pierce Biotechnology 
DMEM cell culture media 12491-015 Invitrogen 
Lipofectamine™ Invitrogen 
Dual luciferase assay 
reagent E1910 Promega 
Gel pilot DNA loading dye 239901 Qiagen 
Gel pilot DNA loading 
ladders 239045 Qiagen 
Glycerol G5516 Sigma Aldrich 
GoTaq® Flexi DNA 
polymerase M8305 Promega 
HaltTM Protease 
phosphatase Inhibitor 
Cocktail 78440 Pierce Biotechnology 
HRP linked anti mouse 
antibody 7076 Cell signalling 
Ibrahim Hamza Kankia Regulation of HER family and NRF2 in ovarian cancer  
PhD THESIS Page 214 
 
HRP linked anti rabbit 
antibody 7074 Cell signalling 
Hybond ECL nitrocellulose 
membrane NP0322BOX Invitrogen 
 
 
Cont. Chemicals, reagents and kits used 
 
Novex®sharp prestained 
protein standard LC5800 Invitrogen 
Nupage® LDS sample 
buffer NP0007 Invitrogen 
Nupage® MOPS SDS 
running buffer NP0001 Invitrogen 
Nupage® Sample reducing 
agent NP0009 Invitrogen 
Nupage® Transfer buffer NP0006 Invitrogen 
I Blot dry blotting system Thermofisher 
Omni swab pack WHA-WB100035 Whatman 
OPTIMEM serum reduced 
media 31985070 Invitrogen 
PBS 20012-027 Invitrogen 
Poly L lysine solution P4707-50ML Cell signalling 
QIAprep spin miniprep kit 27104 Qiagen 
QIAquick gel extraction kit 28704 Qiagen 
plasmid plus Maxi kit 12963 Qiagen 
Restriction endonucleases R6161 Promega 
RIPA buffer 89901 Pierce biotechnology 
GelRed DNA stain NBS-SV NBs biological 
Sodium chloride S3014-1KG Sigma Aldrich 
T4 DNA ligase M1801 Promega 
  M1801 Promega 
Trypsin 25300054 Invitrogen 
Tryptone T7293-1KG Sigma Aldrich 
Shield mounting medium 
with DAPI 
H-1200 Vectashield 
  H-1200 Vectashield 
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Xcell Surelock® mincell 
system 
E10007 Invitrogen 
Yeast Extract Y1625 Sigma Aldrich 
 
 


























Ultra violet transillumation box UVP Upland USA 
  
Gel documentation machine Alpha-innotech, USA 
  
PCR amplification machine Techgene, UK 
  
96 well plate reader for absorption Rosys anthos HTIII 
  
96 well Luminometer and Modulus microplate, Turner biosystems, 
fluorometer UK. 
  
Autoclave machine Priorclave, UK 
  
Nanopure water Barnsted Nanopure DiamondTM, USA 
  
Microscope Lieca DM-IRE2 inverted fluorescence 
 microscope 
Syngene G:BOX 
Chemi-XX6 Gel Documentation System 
(Synoptics, UK) 
  
Spectrophotometer Thermospectronic, USA 
  
Thermomixer comfort Eppendorf, UK 
